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I. Introduction 
1.1  The Immune System  
The immune system evolved to protect the body against potentially harmful substances. Antigen-
recognition and subsequent immune responses towards pathogens are the main functions of the 
immune system, which comprises various tissues, cells, and proteins. The immune system can be 
roughly subdivided into the innate and the adaptive immune system. The innate immune system 
provides the first line of defense and consists of cellular components (monocytes/macrophages, 
granulocytes, dendritic cells, mast cells and natural killer cells) as well as countless soluble 
proteins (complement proteins, acute phase proteins, cytokines, and chemokines). Cells of the 
innate immune system perform non-specific immune responses based on the recognition of 
pathogen-associated molecular patterns (PAMPs) via pattern-recognition receptors (PRR). Thus 
triggered immune responses are fast while lacking immunological memory. Moreover, they build 
the most important host defense, found in most organisms (Litman et al. 2005). Since cells and 
soluble components of the innate immune system activate and participate in adaptive immune 
responses, they form an intricate association between the innate and the adaptive immune 
systems. 
The adaptive immune system comprises the two main lymphocyte subsets, B and T cells, which 
in contrast to innate immune cells, express specific receptors directed against certain target 
structures, and establish immunological memory. The diversity of these antigen-specific receptors 
originates in their development that include random recombination of variable receptor gene 
segments and pairing of different variable chains (Janeway 2008). This diversity, as consequence 
of more rapid and specific recognition and elimination of upcoming antigens, warrants efficient 
immune responses and long-lasting protection. Upon specific antigen-recognition, clonal 
expansion of a small subset of selectively activated lymphocytes initiates the subsequent adaptive 
immune response. Activated B cells differentiate into Ig-secreting plasma cells, contributing to 
the humoral immunity. Activated T cells affect other cells, either by regulating the activity of 
immune cells or by killing transformed or infected cells. Based on their co-receptor expression, 
mature T cells can be divided into different subgroups: CD8
+
 cytotoxic T lymphocytes (CTLs) 
mediate cell-death of virus-infected and tumor cells via direct cell-cell interaction. CD4
+ 
T helper 
cells (Th) modulate the activation of further immune cells. Naïve Th cells can differentiate into at 
least four effector subtypes: Th1, Th2, Th17, and regulatory T cells (Tregs). Th1 cell-secreted 
cytokines, such as interferon (IFN)- and interleukin (IL)-2 are mainly involved in the activation 
of macrophages and CTLs (cell-mediated responses). Th2 cytokines, in contrast, including IL-4 
and IL-5, are generally known to promote antibody production by stimulating B cell (humoral) 
responses. Th17 cells produce several pro-inflammatory cytokines, particularly IL-17A. Tregs, 
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conversely, suppress immune reactions via cytokine production and cell-cell contact-dependent 
suppression mechanisms, thus, maintaining tolerance. Dysregulation of immune functions causes 
inadequate, excessive, or absent immune responses, leading to immune disorders. Disturbed 
immune responses provoke manifestation of allergic diseases, hypersensitivity, autoimmune 
diseases, graft-versus-host disease (GVHD), and immunodeficiency (Parkin and Cohen 2001). 
Consequently, several control mechanisms have evolved to control immune homeostasis.  
1.2  Regulatory T Cells 
One major problem concerning the body’s immune defense involves the discrimination between 
“self” and “non-self” or foreign antigens. Mechanisms have evolved that allow for effective 
immune responses against microbial antigens, while preventing autoimmune responses. Strategies 
for immunological self-tolerance include physical elimination of autoreactive immune cells 
(known as “clonal deletion”) or their functional inactivation (known as “anergy”) (Ramsdell and 
Fowlkes 1990). In addition, a subpopulation of T cells emerged with the capacity to suppress 
CD4
+
 effector T cells, CD8
+
 T cells, antigen presenting cells (APCs), natural killer cells (NKs) 
and B cells. Based on their function they were named regulatory T cells (Tregs). In 1995, 
Sakaguchi and colleagues were the first to observe the existence of Tregs by illustrating that the 
transfer of purified CD4
+
CD25
+
 cells inhibited naïve CD4 T cell-mediated autoimmunity in 
lymphopenic mice (Sakaguchi et al. 1995). The significance of Tregs for proper immune function 
becomes evident when Tregs are dysfunctional and/or deficient as this is associated with high 
incidences of autoimmune diseases, inflammatory bowel disease (IBD), allergies and alleviated 
GVHD (Robinson 2004; Dejaco et al. 2006; Pilat et al. 2010).  
In both, humans and mice, CD4
+
 Tregs are defined by their expression of Treg marker molecules, 
including CD25 (the IL-2 receptor -chain), the transcription factor Foxp3 (forkhead box p3), 
CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4, also known as CD152), and GITR (glucocorticoid-
induced TNFR-related protein). Furthermore, Tregs are characterized by their scarce production 
of the cytokines IL-2, IFN-, IL-4 and IL-17, as well as their hypoproliferative condition upon T 
cell receptor (TCR)-activation (Sakaguchi 2005). Two main groups of Tregs can be distinguished; 
naturally occurring CD4
+
CD25
hi
Foxp3
+
 Tregs (nTregs) arise intrathymically from CD4 single 
positive precursor cells and account for approximately 10% of all peripheral CD4
+
 T cells 
(Baecher-Allan et al. 2002). Induced Tregs (iTregs) on the other hand derive extrathymically 
from CD4
+
CD25
-
 naïve T cells following antigen exposure and TCR activation in adequate 
environments. Induction of the transcription factor Foxp3 provides a crucial step in the 
progression of iTreg conversion. An interaction between both, nTregs and iTregs, is crucial to the 
mediation of dominant tolerance toward “self”, and for controlling ongoing immune reactions, as 
their distinct origins reveal divergent Tregs functions (Haribhai et al. 2011). Due to their 
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intrathymically development, nTregs express specific TCR against self-antigens, whereas 
iTregs are specific for self- and foreign antigens encountered in the periphery.  
The differentiation of peripheral iTregs depends on successful antigen presentation via APCs in 
the presence of IL-2 and transforming growth factorTGF) - which was demonstrated in 
various in vivo scenarios (Zheng et al. 2007). While TGF- is crucial for Treg induction, IL-2 is 
indispensable for Treg survival and expansion. Furthermore, TCR signals and Foxp3 need to 
synergize in order to generate functional Tregs (Marson et al. 2007). Suboptimal antigen 
stimulation (e.g. constant ingestion of proteins in the gut) results in iTreg induction, leading to 
oral tolerance. Furthermore, proceeding inflammatory diseases induce the generation of iTregs, 
which in turn hamper exacerbated immune responses to prevent fatal acute inflammation (Curotto 
de Lafaille et al. 2008). Proceeding inflammatory diseases include autoimmune diseases such as 
multiple sclerosis and allergic diseases such as allergic rhinitis. In addition, induction of iTregs 
was also observed following allogeneic transplantations, and enhanced amounts of iTregs may 
ameliorate transplantation outcomes by preventing allograft rejection (see mixed lymphocyte 
culture (MLC)) (Neto et al. 2000). In these scenarios, activated effector T cells (Teffs) are 
generated concomitantly with iTregs and the balance between Teffs and Tregs determines the 
clinical outcome. Therefore, generation and increase of iTregs is a promising step in the ablation 
of various adverse immune responses.  
1.3  Mechanisms of Treg-Mediated Suppression 
Overall, two types of suppression can be defined: Treg-dependent deprivation of Teff activation 
signals, and direct Treg-mediated inactivation and killing of Teffs and APCs. Incorporated in the 
first group is a CTLA-4-dependent suppression mechanism, revealed by the development of fatal 
lymphoproliferation and autoimmune diseases in Treg-specific CTLA-4-deficient mice 
(Waterhouse et al. 1995). The co-inhibitory molecule CTLA-4 is constitutively expressed by 
Tregs, contrary to its activation-induced upregulation by Teffs. CTLA-4 presents higher affinity 
towards CD80/86 than its co-stimulatory homologue CD28. Thus, CD28 signaling, which is 
indispensable for T cell activation, is inhibited by CTLA-4 expression. This is because Treg-
CTLA-4 prevents Teff-CD28-mediated co-stimulation by outcompeting CD28 for CD80/86 in the 
immunological synapse. The deprivation of CD28 signaling is further supported by down-
regulation of CD80/86 on APCs in a CTLA-4-dependent manner (Qureshi et al. 2011). 
Additionally, CTLA-4 interaction with DCs induces expression of the tryptophan catabolizing 
enzyme indoleamine 2,3-dioxygenase (IDO) which contributes to T cell suppression (Mellor et al. 
2004).  
Moreover, an IL-2-dependent mechanism of suppression was discovered that depends on both, 
the unique Treg-associated features including IL-2 hypoproduction and the constitutive 
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expression of the IL-2 high affinity receptor. These conditions result in strong exogenous IL-2-
dependence for Treg cell survival, as demonstrated by reduced Treg numbers and 
lymphoproliferative/autoimmune diseases in IL-2- or IL-2 receptor-deficient animals (Nelson 
2004). Increased IL-2 high-affinity receptor expression on Tregs results in local IL-2 absorption. 
In turn, antigen-reactive Teffs are inhibited or eliminated by undergoing apoptosis. Activation 
and expansion of Tregs and Teffs can be modulated by IL-2 supplementation, because the 
survival of Tregs firmly relies on IL-2, whereas concomitantly Tregs abrogate IL-2 production in 
Teffs. Additionally, Treg-mediated suppression is achieved by cytokine production (e.g. IL-10 
and TGF-) and the expression of cytotoxic and immunmodulatory molecules.  
As “master control gene” responsible for these suppressive functions foxp was validated 
(Fontenot et al. 2003). 
1.4  Foxp3          
The transcription factor Foxp3 belongs to the forkhead/winged-helix family of transcriptional 
regulators. Foxp3 is considered as the Treg key transcription factor relevant for Treg function, 
stability, and differentiation. Foxp3 regulates the expression of various genes through the 
formation of oligomeric complexes with other proteins. Among the regulated genes are the 
Foxp3-repressed genes il-2, il-17 and the Foxp3-activated genes ctla-4, cd25, as well as foxp3 
itself (Hu et al. 2007). Its importance is best illustrated in Foxp3- deficient mice (scurfy mice) and 
humans suffering from IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked 
syndrome) with mutations or deletions in the foxp3 gene (Bennett et al. 2001). Consequently 
missing Treg formation results in fatal autoimmune diseases, inflammatory bowel disease, severe 
allergies, and infections. In addition, the relevance of Foxp3 for Treg function is also 
demonstrated by Foxp3 transfection studies, which demonstrate induction of Treg phenotypes in 
conventional T cells, including the upregulation of Treg-associated molecules like CD25, CTLA-
4 and GITR (Hori et al. 2003). Additionally, the adoptive transfer of polyclonal wild-type T cells 
transduced with an inducible form of Foxp3 was shown to suppress immune responses (Andersen 
et al. 2008). Correspondingly, mixed bone-marrow chimeras consisting of both wild-type and 
Foxp3
-/-
 cells demonstrated that Foxp3
-/-
 cells are incapable of generating suppressive 
CD4
+
CD25
+
 T cells (Fontenot et al. 2003). Therefore, Foxp3 establishes Tregs as a functionally 
distinct T cell lineage.  
1.5  Epigenetic Regulation of Foxp3 Expression 
The Foxp3 locus is located on the p-arm of the X chromosome and comprises a conserved 
promoter sequence upstream of the transcription start site. This promoter sequence includes 
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common eukaryotic promoter features, such as GC, TATA and CAAT boxes, known to bind the 
transcription-factors AP1, NF-AT, Sp1 and Sp3 (Mantel et al. 2006).  
Foxp3 expression levels are regulated by transcriptional and post-transcriptional mechanisms. 
Epigenetic modifications play a key role in the control of Foxp3 expression. Epigenetics is 
defined by heritable changes in phenotype or gene expression without altering the DNA sequence 
of the genome (Slatkin 2009). These gene modifications involve methylation of DNA-included 
CpG dinucleotides, or covalent posttranslational modification of histones, since specific amino 
acids of histone N-tails form targets for enzyme-mediated modifications. Several epigenetic 
markers, such as histone acetylation and cytosine residue methylation in CpG islands, were 
described for the Foxp3 locus, which contains three conserved intrinsic non-coding sequences 
(CNS) with discrete function in Treg differentiation and maintenance. These cis-regulatory 
elements, CNS1 and CNS2, are located upstream of exon 1, whereas CNS3 resides in intron 1 
(Zheng et al. 2010). CNS1 contributes to peripheral Foxp3 induction. CNS3 is considered to play 
an essential role in de novo induction of Foxp3 expression in the thymus and in the periphery 
making it indispensable for nTreg and iTreg generation. CNS2, also referred to as Treg-specific 
demethylated region (TSDR), contains a CpG island. In nTregs this TSDR is demethylated 
resulting in stable Foxp3 expression. In contrast, this site shows residual methylation in iTregs, 
concomitantly with instable Foxp3 expression. Hence, CNS2, which recruits the Foxp3-
Runx/CBF complex in a CpG demethylation-dependent manner, controls Treg lineage 
commitment by controlling the heritable maintenance of Foxp3 expression (Zheng et al. 2010). In 
addition to CNS2, another TSDR resides in the first intron of Foxp3. This TSDR is fully 
demethylated in nTregs, but is methylated in naïve CD4
+
 T cells (Polansky et al. 2008). 
Moreover, the methylation pattern influences the commitment to Treg lineage; as iTregs with 
transient Foxp3 expression, induced by TCR activation, can be converted into nTregs by 
demethylating agents, which induce high stable Foxp3 expression required for the induction of a 
functional Treg suppressor phenotype.   
1.6  Interaction of Histone-Deacetylase (HDAC) Sirt-1 and Foxp3 
Enzymes of the group HDACs catalyze deacetylation from-amino-acetylated lysine residues of 
histones and non-histone proteins. Four classes of HDACs are distinguished. Classes I, II and IV 
are zinc-dependent enzymes, whereas class III members, named Sirtuins (silent mating type 
information regulation 2 homolog) require NAD
+
 (nicotinamide adenine dinucleotide) as a 
cofactor. In mammals, seven closely related Sirtuin enzymes (Sirt-1 – Sirt-7) were described, all 
sharing a characteristic ~30 kDa core deacetylase domain. During Sirtuin-mediated deacetylation, 
the hydrolysis of every molecule of NAD
+
 produces one molecule of nicotinamide, the 
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deacetylated substrate, and one molecule of 2’3’-O-acetyl-ADP-ribose (O-AADPr) (Landry et al. 
2000). 
Among the Sirtuins, Sirt-1 is the most extensively studied enzyme, revealing important roles in 
many aspects of physiological processes ranging from aging, to metabolism, to neurological 
development (Kong et al. 2009). Sirt-1 possesses two nuclear localization signals at the N-
terminus supporting its presence in the nucleus and a coiled-coil domain C-terminus of the core 
domain (Frye 1999). Endogenous substrates for Sirt-1 are plentiful and include p53, p65, c-Jun, 
and c-Myc.  
Notably, Sirt1 is also expressed in T cells following TCR-mediated signaling (Beier et al. 2011). 
Interaction of Sirt-1 with various transcription factors involved in the production of inflammatory 
cytokines and leucocyte activation was demonstrated and suggests a modulating role of Sirt-1 in 
innate and adaptive immune responses. By repressing the proinflammatory activity of NFkB and 
AP-1, Sirt1 functions as a negative regulator of CD4
+
 T cells (Zhang et al. 2009). Conversely, 
CD4-specific deletion of Sirt-1 was demonstrated to reduce cardiac allograft rejection, which was 
likewise achieved by treatment with Sirt-1 inhibitors (Beier et al. 2011). The mechanism enabling 
prolonged allograft survival was verified to include increased Treg function, as Sirt-1 targeting in 
Tregs promotes Foxp3 expression. Alongside, van Loosgdregt et al. proved Foxp3 as Sirt-1 
substrate because cotransfection of Foxp3 and Sirt-1 into HEK 293 cancer cells resulted in Foxp3 
deacetylation (van Loosdregt et al. 2010).  
Whereas deacetylated Foxp3 proteins possess a short life-time, Foxp3-acetylation prevents its 
own proteasomal degradation, thus inducing increased Foxp3 levels. Accordingly, inhibition of 
Sirt-1-activity enhances Foxp3 levels in murine and human primary T cells, revealing an 
increased amount of Tregs with improved suppressive capacity. As molecular mechanism, an 
acetylation/ubiquitinylation switch in Foxp3 was proposed, where lysine acetylation and 
polyubiquitination are mutually exclusive (see Fig. 1) (van Loosdregt et al. 2011). Acetylation 
out-competes polyubiquitination hence prevents protein degradation. Recently, three Foxp3 
acetylation sites were identified which regulate suppressive capacity of Tregs. In mice these 
include K31, K262, and K267. The corresponding sites in human Foxp3 are K31, K263, and 
K268 (Kwon et al. 2012). Foxp3 acetylation is mainly regulated by the histone acetyl transferase 
(HAT) p300 (van Loosdregt et al. 2010).                          
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Fig. 1 Influence of Sirt-1 on Foxp3-stabilization. Foxp3 protein is acetylated by the 
acetyltransferase p300 and deacetylated by the HDAC Sirt-1. Deacetylated lysine residues are vacant to 
be ubiquitinylated by the E1, E2/E3 complex leading to proteasomal degradation of Foxp3 protein. 
Inhibition of Sirt-1 therefore results in decreased Foxp3 degradation and increased amounts of Tregs. In 
human, the Foxp3 lysine acetylation sites K31, K263, and K268 were discovered. Foxp3-deacetylation 
by Sirt-1 consumes NAD
+
 and produces 2’3’-O-acetyl-ADP-ribose (O-AADPr) (Landry et al. 2000; van 
Loosdregt et al. 2010; Beier et al. 2011; Kwon et al. 2012).  
 
1.7  The Allergic Immune Response 
Allergies occur as a consequence of hypersensitive immune reactions towards harmless 
environmental antigens and precede under the control of IL-4 and IL-5 producing Th2 cells. Th2 
cytokines and co-stimulatory signals stimulate B cells to produce IgE antibodies, which bind to 
high affinity FcRI receptors on the surface of mast cells, basophils, and activated basophils. 
Antigen cross-linking of FcRI-bound IgE activates the release of inflammatory mediators. Once 
IgE is produced in response to allergen exposure, reexposure to the same allergen triggers an 
allergic response. 
Two classes of mediators released by activated mast cells are distinguished. The first class 
comprises pre-formed mediators such as histamine, which are stored in granules and secreted 
rapidly after mast cell activation. The second class of mediators includes cytokines and 
chemokines, which become newly synthesized upon mast cell activation and are therefore 
secreted with a delay. The immediate allergic reaction caused by mast cell degranulation is 
followed by the late-phase response, which involves the recruitment of other effector cells, 
including eosinophils, basophils, and Th2 cells. Since mast cell activation occurs at the site of 
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allergen exposure the immunopathology of allergic IgE-mediated reactions depends on the 
allergens route of entry.  
Seasonal allergic rhinoconjunctivitis, also commonly known as hay fever, is induced by the 
inhalation of pollen and is associated with intense nasal itching, sneezing, and rhinorrhea (excess 
nasal secretion) (Zuberbier et al. 2010). In addition, the airborne pollen induce allergic 
conjunctivitis in the majority of hay fever patients (Katelaris and Bielory 2008). Hay fever is the 
most common allergic disease affecting approximately 400 million people worldwide (Pawankar 
et al. 2011) and is generally caused by environmental antigens with seasonal prevalence. These 
allergens comprise specific weed, tree, and grass pollen, e.g. timothy grass (Phleum pretense)-
derived pollen. Grass pollen exposure is one of the major causes of allergic rhinitis in many parts 
of the world (D'Amato et al. 2007; Burbach et al. 2009). 
T lymphocytes are among the principal factors that regulate and co-ordinate immune responses in 
allergic diseases. Studies reported decreased expression of Foxp3 in asthma and allergic rhinitis 
(Provoost et al. 2009). Clinical improvement after allergen immunotherapy in allergic diseases 
such as rhinitis and asthma is associated with the induction of IL-10 and TGF- producing Tr-1 
cells, a Treg subpopulation, as well as Foxp3 (Nouri-Aria 2009). 
1.8  Graft-Versus-Host-Disease (GVHD) 
Following allogeneic hematopoietic cell transplantation (HCT) about 35-50% of patients develop 
acute graft-versus-host disease (GVHD) (Jacobsohn and Vogelsang 2007). This systemic 
inflammatory disorder represents a significant threat of morbidity and mortality and is based on 
the presence of graft-derived immunocompetent cells, which are not eliminated by the 
immunocompromised recipient. These alloreactive donor-derived T cells consider recipient-
derived tissue as foreign, due to disparities within alloantigens, namely minor histocompatibility 
molecules, and major histocompatibility molecules (MHC). In humans, MHC antigens are 
encoded in the human leucocyte antigen (HLA) loci, reaching nearly 1600 alleles due to 
polymorphism and polygenesis (Tinckam and Chandraker 2006). Therefore, the likelihood for 
MHC mismatches between unrelated individuals is immense. In addition, the non-MHC proteins 
mHAgs, first described by Barth and colleagues in 1956, are polymorphic expressed molecules 
(Barth et al. 1956). In fact, every polymorphic protein can function as mHAg and induce GVHD, 
even in the presence of identical MHC molecules. Until today the role of mHAgs is not entirely 
elucidate.  
Alloantigen recognition by donor-derived lymphocytes induces excessive immune activation 
resulting in tissue damage, including skin, gastrointestinal tract and liver destruction. The 
occurrence of acute GVHD was historically limited to 100 days following HCT (Pidala 2011). 
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Moreover, chronic GVHD arises in up to 60%-80% of patients, who survived the first 100 days. 
related clinical observations suggest that alloreactive T cells play a substantial role in the 
pathobiology of chronic GVHD (Group. 2005).  
1.8.1 The Mixed Lymphocyte Culture as In Vitro Model for GVHD 
As early as 1964, independent studies from Bain et al. and Bach and Hirschhorn reported 
development of blastoid cells in a multiple-day mixed culture of PBMC (peripheral blood 
mononuclear cells) from unrelated donors (Bach and Hirschhorn 1964; Bain et al. 1964). 
Likewise, a mixed culture of PBMC derived from monocygotic twins showed no blastoid cells. 
Nowadays, mixed lymphocyte cultures (MLC) comprising PBMC from a potential donor, mixed 
with irradiated lymphocytes from the potential recipient, are primarily generated to detect the 
presence of alloreactive T cells by measuring proliferation of activated donor cells. The described 
procedure is named one-way MLC and provides insight into which potential donor shows the 
least alloreactivity towards the recipient. 
Concomitantly, in a two-way MLC untreated PBMC of two persons are mixed. In this MLC 
lymphocyte proliferation and cytokine production cannot be assigned to the respective 
individuals. However, this is of no importance when MLC generation serves as in vitro research 
model for GVHD (Maclaurin 1965; Segall and Bach 1976). Alongside, the Th1 cytokine IFN- 
production was identified as a sensitive lymphocyte activation parameter, revealing IFN- as a 
marker for direct T cell activation (Danzer et al. 1996). Faber et al. used IFN- detection in two-
way MLCs to investigate the specificity of MHC mismatches. Interestingly, permissive 
mismatches did not induce an allogeneic immune response in the MLC (Faber 2004).  
Notably, Treg number and chronic GVHD are inversely associated (Miura et al. 2004), 
supporting the assumption that Treg therapy may be beneficial to patients with GVHD. Two 
broad strategies for Treg therapy are applied in humans: firstly, induction of Tregs from naïve 
precursors in vivo using targeted delivery of alloantigen under appropriate tolerizing conditions 
(Dhodapkar et al. 2001). The second approach is the infusion of ex vivo expanded autologous 
Tregs derived from peripheral blood (Hoffmann et al. 2004). Preclinical models show that the 
adoptive transfer of Tregs ameliorated GVHD, but the clinical approach has been challenging 
(Cohen et al. 2002).     
1.9  Autoimmune Diseases 
The loss of self-tolerance and expansion of auto-reactive lymphocytes results in autoimmune 
disorders, in which the body’s tissues are attacked by its own immune system. Until now, 
research on autoimmune diseases has not completely unraveled the mechanism underlying 
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autoimmune responses. One important aspect is the genetic predisposition of certain individuals 
to develop autoimmune diseases (Thorsby and Lie 2005). The combination with other risk factors 
including drugs or microorganisms, triggers the immune system to be directed against itself.  
Autoimmune diseases affect various body tissues. Prevalent autoimmune diseases include 
systemic lupus erythematosus (SLE), Diabetes mellitus type 1 (IDDM) (endocrinological), 
Crohn's Disease (gastrointestinal), and multiple sclerosis (MS) (neurological). 
1.9.1 Multiple Sclerosis (MS) 
MS is an inflammatory autoimmune disorder affecting the central nervous system (CNS).  This 
disease results from myelin-reactive T lymphocytes and their mediators, which initiate 
inflammation, demyelation of axons, and neurodegeneration, leading to sensory deficits, 
cerebellar or brainstem dysfunction, and cognitive impairment. Active MS lesions reveal 
pronounced inflammatory infiltrate, composed mainly of lymphocytes, macrophages, and 
activated microglia. Autoantigen-specific T cells belong to the key players in the induction of 
CNS-concentrated autoimmunity. CD8
+ 
T lymphocytes predominate in MS lesions and are 
supposed to directly attack neurons (Babbe et al. 2000). In addition, a role of CD4
+
 T helper cells 
is well recognized in the pathogenic T cell response, including prominent roles for IFN--
producing Th1 cells and IL-17 producing Th17 cells (Chu et al. 2000; Hofstetter et al. 2009). In 
accordance with these findings, Tregs of patients with MS exhibit impaired function and reduced 
Foxp3 expression, implying Tregs as a promising therapeutical target (Venken et al. 2008). 
Around 120,000 - 140,000 patients are diagnosed with MS worldwide, making it the most 
common chronic-inflammatory disease of the CNS (Friedrich 2008; Sellner et al. 2011). In order 
to gain a better understanding of MS, various animal models have been established. In particular 
the model of experimental autoimmune encephalomyelitis (EAE) has become widely accepted as 
an MS animal model.  
1.9.2 EAE as Animal Model for MS 
The experimental autoimmune encephalomyelitis is induced by injecting animals with various 
CNS-derived protein-antigens such as myelin-antigens. The administered proteins are emulsified 
in an adjuvant to generate an enhanced immune response. In addition, the animals are injected 
with pertussis toxin, which allows the crossing of the blood-brain barrier. That way, the animal’s 
immune system becomes sensitized towards its own myelin tissue, resulting in spontaneous CNS 
inflammation closely resembling MS in man. Symptoms involve sensory loss, muscle weakness, 
ataxia, and spasms. Comparable to MS, Th1 and Th17 T cells were established as the key 
immunopathogenetic mediators in EAE. The immense production of IL-17A promotes 
inflammatory cell infiltration, the formation of extensive spinal cord lesions, and clinical 
11 
 
dysfunction (Aranami and Yamamura 2008). Counteracting Tregs were found to ameliorate EAE 
progression (McGeachy et al. 2005). 
Two types of EAE were identified, which can be specifically induced by certain auto-antigens: 
chronic EAE and relapsing-remitting EAE. Whereas chronic EAE shows progressive pathogenic 
lesions in the CNS and increasing paralysis of the nervous system, the symptoms of relapsing-
remitting EAE animals display a disease peak about 2 weeks after EAE induction followed by a 
relapse-remitting course (Zhang et al. 2004). It has to be taken into account that although the EAE 
model is useful for studying specific aspects of MS pathology and pathogenesis, it does not 
mirror the complex pathology of human MS. 
1.10 Zinc and the Human Body 
Zinc is an essential trace element with various functions in all cell and organ systems (Prasad 
2009). The human body contains a total amount of 2-3g zinc (Haase and Rink 2010) and its 
distribution differs considerably between the various tissues, spanning from 10 µg/g dry weight in 
the brain (1.5% of the total body zinc) up to 100 µg/g in the bone (29% of the total body zinc). In 
contrast, plasma zinc concentrations merely reaches 10-18 µM, equaling to around 1 µg/g (0.1 % 
of the total body zinc) (Mills 1989). Plasma zinc is abundantly bound to albumin (60%) with low 
affinity; to 2-macroglobulin (30%), and with high affinity to transferrin (10%) (Rink and 
Gabriel 2000). Cellular zinc is distributed between nucleus (30-40%), cytoplasm, organelles, and 
vesicles (50%) (Vallee and Falchuk 1993), including zinc-specific vesicles called “zincosomes” 
(Beyersmann and Haase 2001). The remaining zinc is associated with the cell membrane. Like 
serum zinc, the vast majority of cellular zinc is bound to proteins leaving only a minor loosely-
bound or unbound part of intracellular zinc, which is referred to as “free zinc” and contributes to 
the regulation of cellular processes. The intracellular protein methallothionein (MT) contains over 
20 cysteine residues, representing nearly 30% of its amino acid residues (Sutherland and Stillman 
2011) and binds 5-20% of cellular zinc (Andrews 2001). Thus, MT protects against metal-toxicity 
and oxidative stress. Its expression is regulated in a zinc-dependent way by the transcription-
factor MTF-1 (metal-response element-binding transcription-factor). In addition, MTF-1 induces 
expression of further regulatory genes involved in the complex control of zinc homeostasis 
(Andrews 2001). Zinc uptake into cells and its intracellular homeostasis are regulated by 
members of the zinc transporter family, including 14 Zip proteins (Zrt- and Irt-like protein, 
SLC39), responsible for zinc transport into the cytosol, and 10 zinc transporter (ZnT, solute 
linked carrier, SLC30) family proteins that export zinc from the cytosol (Lichten and Cousins 
2009). 
The importance of zinc is apparent in its function as a cofactor in more than 300 enzymes and an 
even higher amount of proteins attaching zinc (Vallee and Falchuk 1993). Based on a search for 
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known zinc-binding sequences, it was estimated that up to 10% of the proteins encoded in the 
human genome may contain zinc (Andreini et al. 2006). Based on this estimate, zinc influences 
the regulation of virtually all cellular processes, including signal transduction (Haase et al. 2008), 
transcription (Vallee and Falchuk 1993), DNA replication (Wu and Wu 1987), enzymatic 
catalysis (Auld 2001), redox regulation (Maret 2006), cell proliferation (MacDonald 2000), cell 
differentiation (Chesters and Petrie 1999) and apoptosis (Sunderman, 1995; Truong-Tran et al., 
2001b).  
The recommended daily allowance (RDA) suggested by the World Health Organization (WHO) 
recommends a supply of 11 mg for men and 8 mg for women. Since the body has only limited 
zinc storage capacity, frequent zinc intake is necessary to replenish the total body zinc. Dietary 
zinc refills about 0.1 % of the total body zinc-content in humans (Maret and Sandstead 2006). 
This is accomplished by two well-balanced systems: the absorption from the intestine on the one 
hand, and the endogenous loss via pancreatic and other intestinal secretion systems on the other 
hand (Liuzzi et al. 2004).  
Zinc deficiency poses an immense risk factor for human health and accounts for one of the life-
threatening factors especially in developing countries (World Health Organization. The World 
Health Report, 2002). Zinc deficiency manifests itself on different levels and can be subdivided 
into either severe zinc deficiency or into marginal zinc deficiency. Severe zinc deficiency is 
provoked by the zinc uptake-affecting metabolic disorder Acrodermatitis enteropathica as well as 
by other causes such as total parenteral nutrition without zinc, excessive use of alcohol, or 
following penicillamine therapy (Prasad 2008). Marginal zinc deficiency may be caused by 
nutritional zinc deficiency due to high consumption levels of zinc-chelating phosphates, lignins, 
and phytates which counteract zinc absorption; by the malabsorption syndrome, or by sickle cell 
anemia (Lonnerdal 2000; Prasad 2002). It also occurs frequently in the elderly, during pregnancy 
and lactation, due to rapid growth, in vegetarians, or persons with renal insufficiency (Brieger and 
Rink 2010; Haase and Rink 2010). In comparison, increased zinc levels may result in low copper 
status, altered iron function, and metabolism disorders (Fosmire 1990). However, only extremely 
high zinc levels as obtained by excessive use of denture fixative with high zinc content (17-32 
mg/g) were observed to act poisonous, leading to hematologic and neurologic abnormalities 
linked to copper deficiency (Barton et al. 2011). Overall, when moderately supplied (≤50 
mg/day), zinc is a comparatively nontoxic nutrient. 
1.11 Zinc and the Immune System 
The importance of zinc for proper immune function is most obvious in zinc-deficient individuals. 
Disturbances in the zinc homeostasis affect multiple aspects of the immune system, including 
hematopoiesis, the innate immunity, the adaptive immune response, and immune-regulating 
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molecules. Regarding innate immunity, increased basal production of proinflammatory cytokines 
and ROS (reactive oxygen species) is observed in zinc-deficient individuals (Fagiolo et al. 1993; 
Kahmann et al. 2008), resulting from modulated signal transduction via NFB or p38 MAPK 
signaling (Haase et al. 2008; Prasad 2008). The influence of zinc on T cell immunobiology is 
prominent, because zinc deficiency results in various T cell defects manifested in thymus atrophy 
and lymphopenia (King et al. 2005). Additionally, altered T cell function and disturbed 
polarization of mature T cells occur. Zinc deprivation inhibits the polarization into Th1 cells and 
hence changes the Th1/Th2 ratio towards Th2 cells, leading to unbalanced cell-mediated immune 
responses (Prasad 2000). Accordingly, the risk for infections and Th2-driven allergies is 
increased. Furthermore, the functional impairment of T cell-mediated responses, during zinc-
deficiency, favors the development of autoimmune diseases (Honscheid et al. 2009).  
Consistently, both zinc deficiency, and also increasing zinc levels influence T cell function. 
Increasing zinc levels during T cell activation were postulated to calibrate TCR signaling, leading 
to T cell responses following suboptimal stimuli (Yu et al. 2011). In contrast, physiological zinc-
level-exceeding zinc concentrations (50-100 µM) inhibit T cells as demonstrated by suppressed 
IL-1-stimulated IFN- expression (Wellinghausen et al. 1997), and reduced IFN- production in 
zinc supplemented MLCs (Campo et al. 2001). Therefore, a concentration-conditioned zinc  
effect promotes T cell activation in lower concentration while hampering T cell activity in higher 
concentration, notably without affecting cell viability. 
Important molecular zinc targets responsible for the above mentioned zinc effects comprise 
receptor proteins, kinases, phosphatases, caspases, and transcription factors, which can be 
activated or inactivated by zinc (Haase and Rink 2009). Furthermore, its function as a second 
messenger involved in signal transduction contributes to its immunomodulating capacity (Haase 
et al. 2008).   
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II. Scope of the Study 
Although zinc supplementation already has been reported to suppress immune function the 
mechanism underneath has not been revealed sufficiently, yet. The importance of 
immunosuppression becomes obvious in the context of various adverse immune reactions, which 
are aimed to be attenuated. These adverse reactions comprise widespread allergic reactions, 
frequently appearing autoimmune diseases, and transplantation-associated allogeneic immune 
reactions. Until now, a major medical goal is the induction of tolerance against allergens, 
autoantigens, and alloantigens. Concomitantly, the immune response towards hazardous antigens 
must persist in a protective manner. Therefore, complete immunosuppression as generally applied 
in transplanted patients is important for the prevention of acute and chronic transplant rejection, 
but concurrently compromises the patient’s health. An interesting target for modulating adverse 
immune reactions is the induction or the enrichment of regulatory T cells, due to their 
immunosuppressive function. Enhanced amounts of Tregs directed against allergens, auto-, or 
alloantigens suppress these adverse immune reactions, but allows for a sustained immune-
mediated protection. 
Among other various functions, the essential micronutrient zinc is involved in immune regulation. 
Pharmacological zinc doses inhibit allogeneic immune reactions effectively. As molecular 
mechanism behind the immunosuppressive effect a zinc-induced upregulation of Tregs is 
reasonable. The scope of this thesis is to reveal the capacity of zinc to enhance protective Tregs 
and its possible attenuating effect regarding the allergic-, auto-, and allogeneic immune reaction. 
In this study, the allergic reaction is represented by timothy grass allergen supplementation to 
isolated PBMCs. The autoimmune disease MS is simulated by induction of experimental 
autoimmune encephalomyelitis in mice, and the allogeneic immune response is induced in the 
mixed lymphocyte culture. The impact of zinc regarding diverse parameters is investigated. 
Moreover, it is of interest to further analyse the probable induction of Tregs by zinc. Since zinc 
plays an important role in various enzymes, a potential molecular target for zinc involved in the 
induction of Tregs is explored in this work. By revealing a molecular mechanism of the zinc-
induced immunosuppressive effect, the role of zinc in modulating the adverse immune responses 
achieves further importance. The relevance of this study is provided in the fact that zinc 
administered in physiological concentrations lacks toxic effects for the human body. In addition, 
although the enrichment of Tregs is a major goal in transplantation medicine, until today there is 
no applicable method reported to reach adequate tolerance by Treg-induction. Therefore, it is of 
great interest to investigate the immunomodulatory role of zinc. This is even reinforced by the 
ubiquity and inexpensiveness of zinc, which makes it a favourable candidate for the treatment of 
adverse immune reactions. 
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III. Materials and Methods 
3.1 Materials 
3.1.1 Equipment 
 
 Analytical scales, 770/GS/GJ (Kern, Balingen-Frommern) 
 Blot transfer chamber, Mini-trans (Bio-Rad, München) 
 Cell Counter, Casy 1 TT (Scharfe System, Reutlingen) 
 CO2 incubator, MCO-17AIC (Sanyo, Gunma, Japan) 
 Electrophoresis chamber for polyacrylamide gels, Mini-Protean 3 Electrophoresis  
Module Assembly (Bio-Rad, München) 
 Electrophoresis chamber for polyacrylamide gels, Protean II xi (Bio-Rad, München) 
 Electrophoresis net, EPS 3500 XL (Amersham Pharmacia Biotech, Uppsala, Sweden) 
 Electrophoresis power supply, Power Pac 300 (Bio-Rad, München) 
 Electrophoresis power supply, Power Pac 1000 (Bio-Rad, München) 
 ELISA Reader, Magellan (Tecan, Crailsheim) 
 ELISA Washer, Atlantis (Asys Hitech, Eugendorf) 
 Flow cytometer, FACScan and FACSCalibur (Becton Dickinson, Heidelberg) 
 Floor centrifuge, Varifuge 3.0 RS (Heraeus Christ, Osterode) 
 Floor centrifuge, Z 400 K (Hermle, Wehingen) 
 Freezer, -20°C (Bosch, München) 
 Freezer, -80°C, MDF-U71V (Sanyo, Gunma, Japan) 
 Heat sealer, Polystar 100 (Rische and Herfurth, Hamburg) 
 Laboratory scales, 1265 MP (Sartorius, Göttingen) 
 Liquid Scintillation  Counter 1219 Rackbeta (LBK, Wallace, Freiburg)  
 Luminescent image analyzer, LAS-3000 (Fujifilm, Düsseldorf) 
 Magnet stirring bar retriever, MR3001 (Heidolph, Schwabach) 
 Microscope, SM-LUX (Leitz, Wetzlar) 
 Multipipetter, Multipette plus (Eppendorf, Hamburg) 
 Multiplate Reader, Ultra 384 (Tecan, Crailsheim) 
 pH measuring device, HI 9321 (Hanna Instruments, Kehl am Rhein) 
 Photometer, BioPhotometer (Eppendorf, Hamburg) 
 Pipetter, pipetus-akku (Hirschmann, Eberstadt) 
 Pipettes, 0.5-10 μl, 10-100 μl an 100-1000 μl, Research (Eppendorf, Hamburg) 
 Refrigerator (Bosch, München) 
 Shaker, HS 250 basic (IKA Labortechnik, Staufen) 
 Sonicator, Vibra Cell (Sonics & Materials, Danbury, CT, USA) 
 Sterile working station, KR-130 and KR-210 (Kojair, Vilppula, Finland) 
 Table top centrifuge, 5417 (Eppendorf, Hamburg) 
 Table top centrifuge, Biofuge A (Heraeus, Osterode) 
 Taqman PCR-Gerat, Sequence Detection System ABI Prism 7000 (Life Technologies 
         Corporation, Carlsbad, CA, USA) 
 Thermomixer, comfort and compact (Eppendorf, Hamburg) 
 Video Graphik Printer, UP-895CE (Sony, Tokyo, Japan) 
 Vortexer, Reax (Heidolph, Schwabach) 
 Weighing scales, 1265 MP (Sartorius, Göttingen) 
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 Western Blot chamber, Mini-Protean 3 Electrophoresis Module Assembly (Bio-Rad, 
München) 
 
3.1.2 Laboratory Supplies 
 
 Bürker counting chamber (Brand, Wertheim) 
 Casy-Cups (Scharfe System, Reutlingen) 
 Cell culture flasks, T25 and T75 (Nunc, Roskilde, Denmark) 
 Cell culture 6-well, 12-well, 24-well plates (Becton Dickinson, Heidelberg) 
 Centrifuge tubes, Sorvall GS3 (Kendro, Langenselbold) 
 Centrifuge tubes, Sorvall SA-600 (Kendro, Langenselbold) 
 FACS tubes (Sarstedt, Nümbrecht) 
 Film cassette, 20 x 25 cm (Bio-Rad, München) 
 Gel blotting paper GB003 (Schleicher and Schuell, Dassel) 
 Glass pipettes (Brand, Wertheim) 
 Glass plates, outer glass PLT W/1.5 mm, M-P 3 (Bio-Rad, München) 
 Glass plates, short plates, M-P 3 (Bio-Rad, München) 
 Glass plates, outer plates 16 x 20 cm (Bio-Rad, München) 
 Latex gloves (Kimberly-Clark, Zaventem, Belgium) 
 Microcentrifuge tubes, 1.5 ml (Sarstedt, Nümbrecht) 
 Nitrocellulose membrane Trans-blot transfer medium, pure (Bio-Rad, München) 
 One-way pipettes, 5 ml, 10 ml and 25 ml (Grenier, Nürtingen) 
 Optical Tubes 8er Stripes ABI PRISM (Applied Biosystems, Foster City, USA) 
 Optical Caps 8er Stripes ABI PRISM (Appield Biosystems, Foster City, USA) 
 Pipette Combitips, 1 ml, 2.5 ml, 5 ml and 10 ml (Eppendorf, Hamburg) 
 Pipette tips, 1-10 μl and 10-1000 μl (Sarstedt, Nümbrecht) 
 Pipette tips, 100-1000 μl (Eppendorf, Hamburg) 
 Plastic tubes with tops, 15 ml and 50 ml (Falcon, Heidelberg) 
 Plastic wrap (RUF, Bremen) 
 Polystyrene tubes with tops, 13 ml (Sarstedt, Nümbrecht) 
 Sponges, 8 x 11 cm (BioRad Laboratories, München) 
 Szintillation tubes (PerkinElmer, Rodgau) 
 Syringes, 1 ml, 10 ml and 20 ml (Braun, Melsungen) 
 UV-cuvette, UVette (Eppendorf Hamburg) 
 Vacuum filter, Stericup 0.22 μm GP ExpressPlus (Millipore, Schwalbach) 
 
3.1.3 Cell Culture Media and Additives 
 
 Culture medium RPMI 1640 (Lonza, Verviers, Belgium) 
 Fetal calf serum (PAA, Cölbe) 
 L-glutamine, 200 mM (Lonza, Verviers, Belgium) 
 Non-essential amino acids (Lonza, Verviers, Belgium) 
 Penicillin/Streptomycin, 10,000 U/ml + 10,0000 μg/ml (Lonza, Verviers, Belgium) 
 Phophate Buffered Saline (PBS) without Ca2+ and Mg2+ (Lonza, Verviers, Belgium) 
 Sodium chloride (KMF, Leipzig) 
 Sodium pyruvate (Lonza, Verviers, Belgium) 
 Ultra Doma (Lonza, Verviers, Belgium) 
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3.1.4 Immunological Reagents 
 
3.1.4.1 Antibodies used for Immunoprecipitation/Western-blot 
 
 Goat anti-biotin conjugated HRP (Cell Signaling, Beverly, MA, USA) 
 Goat anti-rabbit conjugated HRP (Cell Signaling, Beverly, MA, USA) 
 Horse anti-mouse conjugated HRP (Cell Signaling, Beverly, MA, USA) 
 Mouse anti-human Foxp3 (Abcam, Cambridge, UK) 
 Rabbit anti-human -Actin (Cell Signaling, Beverly, MA, USA) 
 Goat anti-Foxp3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
 Rabbit anti-human AcK31-Foxp3 (kindly provided by Dr. Melanie Ott (J. David 
Gladstone Institute of Virology and Immunology, San Francisco, CA, USA) 
 
3.1.4.2 Antibodies used for Flow-Cytometry 
 
 Mouse anti-human CD4 conjungated FITC (Becton Dickinson, Heidelberg) 
 Mouse anti-human CD25 conjungated FITC (Becton Dickinson, Heidelberg) 
 Mouse anti-human CD25 conjungated PE (Becton Dickinson, Heidelberg) 
 Mouse anti-human CD69 conjungated PE (Becton Dickinson, Heidelberg) 
 Mouse anti-human CD152 conjungated PE (Becton Dickinson, Heidelberg) 
 Mouse anti-human CD152 conjungated PE-Cy5 (Becton Dickinson, Heidelberg) 
 Mouse anti-human Foxp3 conjugated PE (Becton Dickinson, Heidelberg) 
 Mouse anti-human/mouse RORT/RORC2 conjungated PE (R&D Systems, 
Minneapolis, MN, USA) 
 Rat anti-mouse CD4 conjungated APC (eBiosciences, San Diego, CA, USA) 
 Rat anti-mouse Foxp3 conjungated PE (Becton Dickinson, Heidelberg) 
 
3.1.4.3 Isotype-control Antibodies used for Flow-Cytometry 
 
 Mouse IgG1, k conjugated FITC isotype (Becton Dickinson, Heidelberg) 
 Mouse IgG2a, k conjugated FITC isotype (Becton Dickinson, Heidelberg) 
 Mouse IgG1, k conjugated PE isotype (Becton Dickinson, Heidelberg) 
 Mouse IgG2a, k conjugated PE isotype (Becton Dickinson, Heidelberg) 
 Mouse IgG2a, k conjungated PE-Cy5 isotype (Becton Dickinson, Heidelberg) 
 Mouse IgG2b, k conjungated PE isotype (Becton Dickinson, Heidelberg) 
 Rat IgG2b conjungated APC isotype (eBiosciences, San Diego, CA, USA) 
 Rat IgG2b, k conjungated PE isotype (Becton Dickinson, Heidelberg) 
 
3.1.4.4 Antibodies used for Immunehistochemistry 
 
 Rabbit anti-mouse CD3 (Abcam, Cambridge, UK) 
 Rabbit anti-mouse Foxp3 (Abcam, Cambridge, UK) 
 Horse anti-rabbit biotinylated secondary antibody (Vector Labs BA 2000, Burlingame, 
CA, USA) 
 
3.1.5 Miscellaneous Reagents 
 
 Acetic acid, 100 % (Merck, Darmstadt) 
 Acylamide/bisacrylamide, 30 % (Serva, Heidelberg) 
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 Agarose (Gibco, Karlsruhe) 
 Aqua ad iniectabilia (Braun, Melsungen) 
 Aqua irrigation solution (Delta Select, Pfulingen) 
 5-Aza-2-deoxycytidine (Sigma-Aldrich, Steinheim) 
 Ammonium persulfate (BioRad Laboratories, München) 
 Aminoethyl carbazole (Invitrogen, Germany) 
 Biocoll, Ficoll 1.077 g/ml (Biochrom, Berlin) 
 Brilliant SYBR Green QPCR Mastermix (Life Technologies Corporation, Carlsbad, 
CA, USA) 
 Bromphenol blue (Riedel-de-Haën, Hannover) 
 Bovine serum albumin (Fluka, Buchs, Switzerland) 
 Calcium aspartate, capsule (RWTH University Hospital, Aachen) 
 Casy-Ton (Scharfe System, Reutlingen) 
 Chloroform (RWTH University Hospital, Aachen) 
 Clexane (Sanofi-aventis, Frankfurt) 
 Cyclosporin A (Alexis Corporation, Lausen, Switzerland) 
 Dimethylsulfoxide (DMSO) (Carl-Roth, Karsruhe) 
 Di-Natriumhydrogenphosphat-Dodecahydrat (Carl-Roth, Karlsruhe) 
 Dithiothreitol (DTT) (Sigma-Aldrich, Steinheim) 
 Ethanol, absolut (RWTH University Hospital, Aachen) 
 Ethanol, 70 %, denatured (RWTH University Hospital, Aachen) 
 Ethylenediaminetetraacetic acid (Carl-Roth, Karlsruhe) 
 EX-527 (Sigma-Aldrich, Steinheim) 
 Fat-free milk powder Sucofin (Trade Service International, Zeven) 
 Fluozin-3 (Life-Technologies, Darmstadt) 
 Glycerine (Merck, Darmstadt) 
 Glycine (Sigma-Aldrich, Steinheim) 
 H-89 (Sigma-Aldrich, Steinheim) 
 Heparin sodium, 5000 (Ratiopharm, Ulm) 
 Hha I (New England Biolabs, Ipswich, MA, USA) 
 Histo-Clear (Biozym, Hessisch-Oldendorf) 
 IBMX, Isobutyl-1-methylxanthin (Sigma-Aldrich, Steinheim) 
 Hydrochloric acid, 32 % (Merck, Darmstadt) 
 Hydrogen peroxide (Carl-Roth, Karlsruhe) 
 Lipoluma Plus (Lumac LSC B.V., Groningen, Niederlande) 
 Loading dye solution, O`Range 6x (MBI Fermentas, St. Leon-Rot) 
 LumiGLO reagent and peroxide (Cell Signaling, Beverly, MA, USA) 
 N, N, N’, N’ – Tetermethylethylenediamine (Sigma-Aldrich, Steinheim) 
 Na3VO4 Protease Inhibtor Cocktail (Sigma-Aldrich, Steinheim) 
 McrBC (500U) (New England Biolabs, Ipswich, MA, USA) 
 Methanol (RWTH University Hospital, Aachen) 
 Methyl-[3H]-Thymidine (Amersham Biosciences, Buckinghamshire, UK) 
 Natriumdihydrogenphosphat-Monohydrat (Carl-Roth, Karlsruhe) 
 -Mercaptoethanol (Merck, Darmstadt) 
 Paraformaldehyde (Sigma-Aldrich, Steinheim) 
 Phytohemagglutinin (PHA) (Becton Dickinson, Heidelberg) 
 Ponceau S (Fluka, Buchs, Schweiz) 
 Propidium Iodide, Minimum 95% (HPLC) (Sigma-Aldrich, Steinheim) 
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 Protein A/G agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
 Protein marker, biotinylated (Cell Signaling, Beverly, MA, USA) 
 Recombinant human IL-2 (Peprotech Inc., NY, USA) 
 Sodium azide (Merck, Darmstadt) 
 Sodium chloride (Merck, Darmstadt) 
 Sodium chloride 0,9% solution (Braun, Melsungen) 
 Sodium citrate dehydrate (Sigma-Aldrich, Steinheim) 
 Sodium dodecyl sulfate (Merck, Darmstadt) 
 Sulphuric acid 95-97% (Merck, Darmstadt) 
 Timothy grass pollen-extract (Artu biological, Hamburg; provided by Prof. Dr. Petersen 
from the Leibnitz-Center for Medicine and Biosciences, Borstel) 
 Tris-(hydroxymethyl)-aminomethane (Tris Base) (Merck, Darmstadt) 
 Trizol Reagent (Ambion, Austin, TX, USA) 
 TSST superantigen (produced as described in (Gross et al. 2006) 
 Tween-20 (Merck, Darmstadt) 
 Zinc apartate, solution (Unizink®) (Köhler Pharma GmbH, Alsbach-Hähnlein) 
 Zinc aspartate, capsule (Unizink®) (Köhler Pharma GmbH, Alsbach-Hähnlein) 
 ZinPyr-1 (NeuroBioTex, ) 
 ZnSO4 x 7 H2O (Merck, Darmstadt) 
 
3.1.6 Commercially Available Kits 
 
 Fluorogenic SIRT1 (Sir2) Assay Kit (BPS Biosciences, San Diego, CA, USA) 
 Human ELISA Component-Set for IL-2, IL-10, IFN- and TNF- detection (BD 
Biosciences Pharmingen, Heidelberg ) 
 Hooke kits for induction of EAE (Hooke Laboratories, Lawrence, MA, USA) 
 Human Foxp3 buffer set (Becton Dickinson, Heidelberg) 
 Mouse Foxp3 buffer set  (Becton Dickinson, Heidelberg) 
 NucleoSpin RNA® II Kit (Macherey-Nagel, Dueren) 
 Qia Amp DNA Mini Kit (Qiagen, Hilden) 
 Q-Script cDNA Synthesis Kit (Quanta, Gaithersberg, MD, USA) 
 VECTASTAIN® ABC (peroxidase) system (Vector Labs, Burlingame, CA, USA) 
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3.2 Methods 
3.2.1 Preparation of Zinc Solutions 
Zinc sulphate was dissolved in Aqua ad iniectabilia to a stock solution of 100mM. The zinc 
solution was sterile filtered with bacteria filters (pore size 0.2µm). Subsequently, the stock 
solution was diluted in Aqua ad iniectabilia and further in protein-free medium (Ultradoma) 
providing a 2mM zinc sulphate solution.  
Zinc-aspartate (Unizink®, 0.6mg/ml) was diluted in NaCl (0.9%) to concentrations of either 0.03 
mg/ml or 0.006 mg/ml, respectively. 
 
3.2.2 Cell Cultures 
The different cell lines listed in table 1 were cultured in CO2-incubators maintained at 37°C, 5% 
CO2, and saturated air humidity. The cells were examined under a microscope twice a week and 
transferred into fresh medium (1ml cells + 10ml medium). Fetal calf serum (FCS) was inactivated 
at 56°C for 30 min. Freshly isolated primary cells were used depending on the respective 
experiment settings.  
                    Table 1. Cell lines and corresponding culture medium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                    1
 from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen) 
                    2
 from American Type Culture Collection (Manassas, USA) 
             
3 
kindly provided from Prof. B. Fleischer, Bernhard-Nocht-Institut Hamburg 
 
 
Cell line Media Supplements 
Jurkat
1
 RPMI 
1640 
10 %  heat-inactivated FCS 
1 % L-Glutamin 
1 % Penicillin/Streptomycin 
1 % Natriumpyruvat 
1 % NEAA 
Molt-4
1
, Hut-78
1
, 
Raji
1
, 
RAW264.7
2
 
RPMI 
1640 
10 %  heat-inactivated FCS 
1 % L-Glutamin 
1 % Penicillin/Streptomycin 
primary cells RPMI 
1640 
10 %  heat-inactivated FCS 
1 % L-Glutamin 
1 % Penicillin/Streptomycin 
V3 IMDM 10 %  heat-inactivated FCS 
1 % L-Glutamin 
1 % Penicillin/Streptomycin 
1 ml G418 
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3.2.3 Peripheral Blood Mononuclear Cell (PBMC) Isolation 
Background: 
Peripheral blood mononuclear cells (PBMC) comprise blood leukocytes carrying a round shaped 
nucleus, including lymphocytes, monocytes, and NK cells. Compared to granulocytes and 
erythrocytes they maintain a lower density, which simplifies their isolation by Ficoll-density-
gradient. Ficoll is composed of high molecular polysaccharides and epichlorohydrin, a reactive 
organic compound. After centrifugation, erythrocytes and granulocytes settle to the bottom of the 
gradient, whereas low density cells like thrombocytes remain in the upper phase. Due to their 
density, PBMCs accumulate in an interphase above the Ficoll solution and can be removed 
selectively. Isolated PBMCs are washed twice with PBS before culturing in medium. 
Reagents: 
 Heparin (25,000 U/ml) 
 PBS 1x 
 Ficoll with densitiy 1.077 g/ml 
 Whole blood 
Procedure: 
1. 50ml whole blood containing 2500U heparin was diluted 1:1 with PBS 
2. 25ml of the blood/PBS mixture was slowly pipetted onto 25ml Ficoll (4x50ml tubes) 
3. The Ficoll gradient was centrifuged for 20 min at 600g and RmT 
4. The PBMC-containing interphase was carefully removed and placed in a new 50 ml Falcon 
tube, which was then filled to the top with PBS 
5. The PBMCs were centrifuged for 10 min at 300g and RmT 
6. The pellets were washed twice with PBS 
 
3.2.4 Lysis of Erythrocytes  
Background: 
Contaminating erythrocytes, which occur during the isolation of PBMC, are removed through 
hypotonic lysis. This procedure comprises the brief resuspension of PBMC in sterile water to 
induce erythrocyte lysis. Subsequently, the addition of the same volume of 2 times concentrated 
PBS recreates isotonic conditions. Acaryotic erythrocytes respond more sensitive to hypotonic 
solutions and can therefore be eliminated specifically.       
Reagents: 
 Aqua irrigation solution 
 PBS (2x und 1x) 
 RPMI medium containing 10% heat-inactivated FCS, 1% L-glutamine and 1% 
penicillin/streptomycin 
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Procedure: 
1. The PBMCs were washed with PBS 
2. The pellets were briefly resuspended in 10ml Aqua irrigation solution and rapidly 10ml 
2xPBS was added 
3. The PBMCs were centrifuged for 10 min at 300g and RmT 
4. The pellets were resuspended in 50ml 1xPBS  and centrifuged for 10 min at 300g and RmT 
5. The cell concentration was adjusted with RPMI medium 
The isolated PBMC were used for further stimulation as indicated, the generation of MLCs (see 
3.2.5) and in the allergy assay (see 3.2.7) 
 
3.2.5 Generation and Stimulation of Two-Way Mixed Lymphocyte Cultures (MLC) 
In the MLC equal amounts of different donors’ PBMCs are mixed and incubated. After 
incubation over an experiment-dependent time-period, various parameters, such as protein 
expression or proliferation, were analyzed.   
Reagents: 
 RPMI medium containing 10% heat-inactivated FCS, 1% L-glutamine and 1% 
penicillin/streptomycin 
 ZnSO4 (2mM)  
 CsA (1 mg/ml) 
Procedure: 
1. The PBMCs were adjusted to a concentration of 2x106/ml  
2. The PBMCs were incubated in T25 cell-culture flasks with either RPMI medium, or ZnSO4 
(50µM), or CsA (1 µg/ml), for 15 min at 37°C and 5% CO2.  
3. The same volume of PBMC of two donors (with the same stimulation) were mixed and 
dispersed into a 24-well plate (1 ml/well) 
4. The MLCs were incubated at 37°C and 5% CO2. Supernatants were collected for the analysis 
of cytokine expression by ELISA (3.2.17); pellets were used for FACS analysis (3.2.18), 
western blot (3.2.23) and real-time PCR (3.2.30). FACS analysis included the detection of 
surface molecule expression (3.2.18.1), and the expression of intracellular proteins 
(3.2.18.2). Furthermore, the MLC was analyzed in the [3H]-thymidine proliferation assay 
(see 3.2.31). 
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3.2.6 Human Zinc-Supplementation Study  
A group of 9 healthy male subjects were orally administered with 10 mg/day zinc in form of Zn-
DL-Aspartate for a time period of 10 days. Prior to the first zinc intake, peripheral blood samples 
were obtained (t=0d). The serum zinc-concentration was determined by Atomic Absorption 
Spectrophotometry (AAS). Furthermore, peripheral blood mononuclear cells (PBMC) were 
isolated (compare 3.2.3) and MLCs were generated (compare 3.2.5). The MLCs were incubated 
for 8 days at 37°C and 5% CO2 and supernatants along with cells were used for the analysis of 
different parameters. After 10 days of zinc-intake (t=10), peripheral blood samples were 
repeatedly taken and processed as described above (t=0). As control group a group of 7 healthy 
male subjects were supplemented with placebo for 10 days and samples were analyzed 
equivalently. Placebo capsules contained filling material likewise used in the zinc-containing 
capsules. Both were produced under pharmacological law in the hospital pharmacy in the RWTH 
hospital pharmacy. The study was approved by the local ethical committee Nr. AZ 016/09 
„Vergleich der Bioverfügbarkeit verschiedener Präparate zur Nahrungsergänzung mit Zink 
(BioVZn)“. (Comparing the bioavailibilty of diverse compounds used for nutritional zinc 
supplementation) 
 
3.2.7 Allergy Assay 
In the allergy assay, PBMCs were incubated with timothy-grass pollen extract prior to the 
investigation of various relevant parameters. PBMCs were obtained from allergic donors 
immunoreacting to the exposure of timothy grass (responder). Timothy grass allergen-insensitive 
donor-derived PBMCs served as control (non-responder). The experiments were conducted 
during hay fever season to guarantee pre-activation and high-responsiveness of allergen-
responsive immune cells in the timothy-grass allergic subjects.  
Reagents: 
 RPMI medium containing 10 % heat-inactivated  FCS, 1 % L-glutamine and 1 % 
penicillin/streptomycin 
 ZnSO4 (2mM)  
 Timothy-grass pollen extract dissolved in PBS (1 mg/ml)  
Procedure: 
1. The PBMCs were adjusted to a concentration of 2x106/ml  
2. The PBMCs were incubated in T25 cell-culture flasks with either PBS or ZnSO4 (50µM) for 
15 min at 37°C and 5% CO2 
3. 1 ml of pre-incubated PBMCs was dispersed in each well of a 48 well plate prior to addition 
of either PBS or timothy grass pollen extract (2.5 µg/ml) 
4. The cells were incubated at 37°C and 5% CO2 for 5 days at the most. Supernatants were 
collected for the analysis of cytokine expression by ELISA (3.2.17); pellets were used for 
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analysis by FACS (3.2.18), western blot (3.2.23) and real-time PCR (3.2.30). FACS 
analysis included the detection of surface molecule expression (3.2.18.1) and the expression 
of intracellular proteins (3.2.18.2). Furthermore, the proliferation was measured by [3H]-
thymidine proliferation assay (3.2.31).  
 
       3.2.8 V-Assay 
Background: 
The Vassay serves as a stimulation assay for murine T cells, which were transfected with either 
a human V2 element or with a V6.5 element of the T cell receptor. In the presence of antigen 
presenting cells (Raji B cell line) V T cells can be activated by the addition of the superantigens 
TSST-1 (toxic shock syndrome toxin 1) or SEA (staphylococcal enterotoxin A).  
Reagents: 
 IMDM-Medium containing 10% heat-inactivated FCS, 100 U/ml Penicillin, 100 µg/ml 
Streptomycin, 2mM L-Glutamine, and 1ml G418 
 V cells 
 Raji cells 
 PFA (3%) 
 TSST-1 (20 µg/ml) 
 ZnSO4 (2mM) 
 PHA (1 mg/ml) 
Procedure: 
1. The Raji cells were adjusted to 2.5x105 cells per ml and fixated with PFA for 10 min at 37°C. 
2. The V cells were adjusted to 5x105 cells/ml 
3. 500µl of both cell lines were then mixed in a 24 well plate and preincubated with or without 
zinc (50µM) for 15 min at 37°C and 5% CO2 
4. The preincubated cells were stimulated with PHA (10 µg/ml) or TSST-1 (250 ng/ml) for 24h 
at 37°C and 5% CO2 
5. The supernatants were collected and analyzed by mIL-2 ELISA (3.2.17) 
 
3.2.9 Murine Splenocyte Isolation 
Reagents: 
 RPMI medium containing 10% heat-inactivated FCS, 1% L-glutamine and 1% 
penicillin/streptomycin 
 70% ethanol 
 Sterile H2O 
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 PBS (1x) 
 PBS (2x) 
Procedure: 
1. 5 ml RPMI medium were added to a petri dish 
2. Double-layered gauze was mounted on a 50 ml centrifuge tube 
3. The sacrificed mouse was washed with 70% ethanol 
4. The spleen was removed: 
a. The fur along the left side of the mouse was cut away, about half-way between the 
front and back legs 
b. The body cavity was cut open 
c. The spleen was removed using sterile forceps 
5. The spleen was homogenized with the plunger end of the syringe 
6. The cells were transferred through the gauze into the 50 ml tube (the gauze served as a cell 
strainer) 
7. 5 ml RPMI medium were used to wash the petri dish and transfer of the remaining 
splenocytes through the gauze into the tube 
8. The cells were centrifuged at 300g for 10 min 
9. The supernatant was discarded and the pellet was resuspended in 5 ml H20, followed by rapid 
administration of 5 ml PBS (2x) (lysis of erythrocytes) 
10. The tubes were filled up with PBS (1x) and centrifuged at 300g for 10 min 
11. The supernatant was discarded and the pellet was resuspended in 25ml RPMI medium and 
centrifuged at 300g for 10 min 
12. The pellet was resuspended in 20 ml RPMI medium and the cells were counted 
13. The splenocyte concentration was adjusted to 1x106/ml  
 
3.2.10 Generation and Stimulation of Murine MLCs 
Background: 
Isolated murine splenocytes were allogeneic stimulated with cells of the murine leukemic 
monocyte macrophage cell-line RAW264.7. The splenocytes were obtained from wild-type 
C57BL/6 mice, carrying the H2
b
 haplotype, whereas the Balb/c strain-derived RAW264.7 cells 
express the H2
d
 haplotype. Due to different MHC haplotypes, the splenocytes are activated by the 
MHC-expressing RAW264.7 cells, resulting in allogeneic immune reaction.   
Reagents: 
 ZnSO4 (2mM)  
 RPMI medium containing 10% heat-inactivated FCS, 1% L-glutamine and 1% 
penicillin/streptomycin 
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Procedure: 
1. The RAW cells were adjusted to a concentration of 2.5x105 cells/ml and seeded into a 24 well 
plate 24 h prior to MLC generation 
2. 1x106 splenocytes/ml were preincubated with or without 50µM zinc for 15 min at 37°C and 
5% CO2    
3. 1 ml of the splenocyte suspension was added to each well of the adherent RAW cells in the 
24 well plate 
4. The MLCs were incubated for 5 and 8 days, the cells were used for FACS analysis (3.2.18), 
western blot (3.2.23) and the supernatant was collected 
 
3.2.11 Animal Treatment and Induction of Experimental Autoimmune 
Encephalomyelitis (EAE) 
Female C 57BL/6 mice 10 weeks old were obtained from JANVIER (le Genest-St-Isle, France) 
and maintained in the animal facilities of the Medical Faculty of the RWTH Aachen University. 
Animals underwent routine cage maintenance once a week and microbiological monitoring 
according to the Federation of European Laboratory Animal Science Associations 
recommendations. All procedures were in accordance with the Review Board for the Care of 
Animal Subjects of the district government (North Rhine-Westfalia, Germany) and performed 
according to international guidelines on the use of laboratory animals. The animal testing number 
was 10612G1. 
Mice were immunized subcutaneously (s.c.) on the upper back and at the lower back with 200µg 
of myelin oligodendrocyte glycoprotein peptide (MOG)35-55 emulsified in Complete Freund`s 
Adjuvant (CFA) containing 2 mg/ml of Mycobacterium tuberculosis H37Ra. Pertussis toxin 
(1µg), a potent ancillary adjuvant necessary for EAE induction, was injected intraperitoneally 
(i.p.) at day 0 and 2. 
The animals were divided into the 5 different groups I-V (compare Table 2). Groups I and II did 
not receive EAE induction, but either NaCl or high dose zinc treatment, respectively. Groups IV-
V were injected (i.p.) daily with 6 µg/day (100 µl of 0.006 mg/ml solution) or 30 µg/day (100µl 
of 0.03 mg/ml solution) zinc aspartate, respectively, starting two days before EAE immunization. 
Group III was injected with 100µl NaCl (0.9%) serving as control.  
Mice were sacrificed after 19 days following EAE induction. Animal scarification was performed 
two days after the mice reached the peak of disease (acute EAE).  
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   Table 2. Experimental set-up 
 
 
 
 
 
 
 
 
       * one animal died before start of experiment 
 
3.2.12 Clinical Evaluation of EAE  
Mice were monitored daily for clinical signs of EAE and neurological impairment was scored 
according to the following increasing severity scale:  
0.  no disease 
1.  limp tail (tail plegia) 
2.  limp tail and weakness of hind legs 
3.  limp tail and complete paralysis of hind legs or paralysis of one front and one hind leg 
4.  complete hind leg and partial front leg paralysis 
5.  complete hind and complete front leg paralysis or mouse is found dead due to paralysis 
Mice scoring level 4 for 2 days were euthanized and then listed as score 5. 
 
3.2.13 Tissue Sample Harvesting 
For FACS analysis, blood and spleen were collected from the animals. After animal anaesthesia, 
blood was taken from the Orbital Sinus by using small glass capillaries. The blood was 
immediately filled into 1.5ml reaction tubes containing 2µl heparin (25,000 U/ml).  
Subsequently, the spleen was removed and processed for FACS analysis as described in 3.2.18.  
For histological/immunohistochemical analysis, mice were transcardially perfused with 2% 
paraformaldehyde containing 1.5% saturated picric acid as described in 3.2.14. 
 
3.2.14 Transcardial Perfusion of Mice 
Background: 
Transcardial perfusion accomplishes the fixation of whole animals, which enables 
histological/immunhistochemical tissue analysis.  
 
 
Group Treatment Number of mice 
I NaCl only 4 
II Zn-Aspartate only (30 µg/day) 4 
III NaCl and EAE 11 (12)* 
IV Zn-Aspartate and EAE (6 µg/day) 12 
V 
Zn-Aspartate and EAE (30 µg/day) 12 
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Reagents: 
 RPMI medium containing 10% heat-inactivated FCS, 1% L-glutamine and 1% 
penicillin/streptomycin 
 Perfusion solution (NaH2PO4 3g, Na2HPO4 45g, paraformaldehyde 20g, saturated picric acid 
100ml, in 1000ml,  pH 7.4) 
 Clexane (40mg) 
 PBS 
 Isofluran (5%) 
Procedure: 
1. 10µl Clexane (40mg) was applied 30 min prior to the start by intraperitoneal injection 
2. Animals were deeply anaesthetized with Isofluran (5%) 
3. Animals were fixed, the thorax was opened by using forceps and scissors, and a small 
opening was cut into the right heart atrium 
4. A small needle was inserted into the left heart ventricle prior to perfusion of 50 ml ice-cold 
perfusion solution 
5. The head and the trunk were cut 
6. The brain/spinal cord was dissected and stored in 1:5 diluted (in PBS) perfusion solution at 
4°C until used 
 
3.2.15 Paraffin-Embedding of Mice Tissue Samples 
Background: 
Paraffin is immiscible with water, which necessitates tissue dehydration by ethanol baths 
with progressively increasing ethanol concentration. This is followed by a clearing agent, 
usually xylene or Histo-clear. Finally, tissue samples are put into molten paraffin wax 
(60°C). The wax is changed 3 times eliminate xylene residues. 
Reagents:   
 Ethanol (abs., 96%, 70%)  
 Histo-Clear  
 Paraffin 
Procedure: 
1. The tissue samples were embedded in paraffin by immersing them under gentle 
agitation as described in Table 3 
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                              Table 3. Treatment of tissue samples   
70% ethanol 3x30 min 
96% ethanol 3x30 min 
100% ethanol 3x30 min 
Histo-Clear 3 x 60 min 
paraffin 3 x 120 min and then 
overnight at 60°C 
 
 
3.2.16 Immunhistochemistry (IHC) 
Background: 
After transcardial perfusion (3.2.14) and overnight postfixation in the same fixative, spinal cords 
were dissected for further analysis by IHC. IHC comprises detection of antigens expressed in 
cells of tissue sections. Antibodies directed against the target protein are used and visualising of 
the antigen-antibody complex is achieved by conjugation of antibody to an enzyme, which can 
catalyse a colour-producing reaction.  
Reagents:   
 Blocking solution: PBS containing 2% normal horse serum 
 Antibodies 
 PBS 
 Biotinylated secondary antibody 
 Peroxidase-coupled avidin-biotincomplex 
 Kaiser's glycerine gelatin 
 Aminoethyl carbazole  
 Soduim citrate buffer (10mM citric acid,  0.05% Tween 20, pH 6.0) 
 Tris/EDTA buffer (10mM Tris Base, 1mM EDTA Solution, 0.05% Tween 20, pH 9.0) 
 Xylol 
 Hydrogen peroxide 0.3% 
 Ethanol (absolute, 96%, 70%) 
 H20 dest. 
Procedure: 
1. 5 μm-thick sections were placed on superfrost glass and deparaffinised in 4 x 5 min xylol, 
rinsed in 3 x 5 min 100% ethanol and 2 x 5 min 96% ethanol and 1 x 5 min 70% ethanol and 
1 x 5 min in PBS 
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2. Heat-mediated antigen retrieval was performed by boiling slides in the desired buffer, sodium 
citrate buffer for 20 min, followed by cooling-down of the slides  
3. The slides were washed 3x in PBS (5 min) 
4. Unspecific binding of the secondary antibodies was blocked by incubating the slides in PBS 
containing 2% normal horse serum for 1 h at RmT 
5. The blocking solution was decanted and primary antibody was applied diluted 1:1000 
(Foxp3) or 1:500 (CD3) in blocking solution and incubated overnight at 4°C 
6. The primary antibody was decanted and the slides were washed 2x with PBS (2 min) 
7. The endogenous peroxidase activity was blocked by incubating slides for 30 min in 0.3% 
hydrogen peroxide diluted in PBS in the dark 
8. The slides were washed 2x in PBS (2 min) 
9. VECTASTAIN® ABC (peroxidase) system was used to label primary antibody-antigen 
conjugates following the manufacturer`s recommendation. 
10. The slides were washed 2x in PBS (2 min) 
11. The slides were incubated in aminoethyl carbazole for up to 30 min at RmT to visualize 
antibody-antigen conjugates 
12. The slides were counterstained with the nuclear dye hematoxylin for 5 min and then 
rinsed with water 
13. The the slides were mounted in Kaiser’s glycerine gelatine 
14. CD3
+
 and Foxp3
+
 cells were counted by 3 blinded independent individuals  
 
3.2.17 Enzymed-Linked Immunosorbent Assay (ELISA) 
Background: 
Sandwich ELISAs are commonly used for determining the amount of secreted molecules such as 
cytokines. The sandwich ELISA starts with the immobilization of an antigen-specific antibody 
(“capture antibody”) in a 96-well plate. The plate is then blocked with BSA to prevent unspecific 
binding. Subsequently, titrated standard and diluted samples, most commonly cell supernatant, 
are added to the appropriate wells. After incubation of the samples/standards, excess cytokines 
are aspirated and a biotinylated antibody specific for a different epitope of the investigated 
cytokine (detection antibody) is provided. Finally, the enzyme reagent consisting of avidin-
horseradish peroxidase conjugate is added. After further wash steps to remove excessive 
antibodies, the substrate (p-Nitrophenyl phosphate) is added and a chemical reaction proceeds, 
which induces a change in colour corresponding to the amount of present antibody. This reaction 
is stopped by sulphuric acid, which induces a further change of the developed colour. The 
adsorption can now be measured by a well-plate reader.   
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Reagents: 
 Carbonate buffer: 29mM sodium carbonate, 22mM sodium hydrogen carbonate, pH 9.6 
 Coating buffer: Carbonate buffer + 1% BSA 
 Assay diluent: PBS + 10% FCS 
 Wash buffer: 2000mL PBS + 1ml Tween 20 
 Capture antibodies (monoclonal anti-human IFN-, IL-10, IL-2, TNF-)  
 Biotinylated detection antibodies (monoclonal anti-human IFN-, IL-10, IL-2, TNF-) 
 Standard solutions (Recombinant human IFN-, IL-10, IL-2, TNF- 
 Substrate solution: Tetramethylbenzidine (TMB) and Hydrogen Peroxide (1:1) 
 Stop solution (1M H2SO4) 
Procedure: 
1. Coating of the micro titre plates and assay procedure were performed in accordance with the 
producers’ instructions 
 
3.2.18 Fluorescence-Activated Cell Sorting (FACS) 
Background: 
Due to its multifunctionality, the technique of flow cytometry is of increasing relevance for 
various research issues. Among other functions it allows the accession of cell surface marker 
expression, sorting of cells according to particular characteristics, performance of intracellular 
staining, visualizing of apoptotic cells, and determination of cell cycle progression. Despite its 
name not every FACS machine is capable of cell sorting and they are often used for cell analysis 
only. 
Through a nozzle the cell suspension flows into a stream of sheath fluid leading to cell scattering 
before entering into a laser path. At an interrogation point the cells are then analyzed for 
reflection, diffraction, or refraction of light or fluorescence. A photodiode measures forward-
angle scatter (FSC) light whilst photodetectors sense emitted side scatter light (SSC). 
Combination of both detectors reports the size and granularity of the investigated cells. 
Fluorescence-labelled cells emit light, which is separated into characteristic wavelength and 
whose intensity is measured by photodetectors equipped with coloured filters. As light passes 
through the photodetectors, the light signals are transformed into electrical signals. Each 
photodetector can be adjusted by changing its voltage and amplifier gain.  
Specific binding of fluorochrome-conjugated antibodies is controlled by using isotype controls. 
Isotype controls are antibodies bearing the identical isotype but lacking specificity towards 
antigens in the investigated organism. Herewith, unspecific binding as, for example arising by 
antibody-binding to Fc-receptors, can be distinguished from specific binding to the desired 
antigen.    
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Flow-cytometry was applied for the following procedures and methods: 
- cell-surface marker analysis  MLC, allergy assay, EAE, PBMC 
- intracellular staining MLC, allergy assay, EAE 
- detection of intracellular zinc levels  (see 3.2.33)  PBMC 
 
3.2.18.1 Cell-Surface Marker Analysis 
Immune cells express cell-specific surface marker. By using antibodies directed against these 
molecules, the molecule’s expression level per cell can be analyzed as well as the total and 
relative amount of cells expressing the molecule. 
Reagents: 
 PBS 1x 
 PBS/FCS (1%) 
 Lysing solution 10x: magnesium chloride (1.5M ammonium chloride, 100mM sodium 
bicarbonate, H2O, pH 7.4) 
 antibodies 
Procedure: 
1. The cells were adjusted to a concentration of 1 x 106/ml in PBS/1 % FCS  
2. 100 µl whole blood or 1 ml of  1 x 106/ml cells were transferred into each FACS tube  
3. The tubes were centrifuged for 10 min at 300g and RmT, and the supernatants were discarded 
4. For erythrocyte-lysis in murine whole blood (3.2.4)  the cells were incubated for 10 min at 
4°C in the dark with 2 ml lysing solution (1x) and washed twice in 2 ml PBS 
5. The pellets were resuspended and 100µl PBS/1%FCS was added to each tube 
6. Direct fluorescent-labelled antibodies were added and incubated with cells for 20 min at RmT 
in the dark 
7. Step 3 was repeated  
8. The supernatants were discarded, and the pellets were resuspended in 500μl PBS/1% FCS  
9. The samples were analyzed by using FACS-Calibur or FACS-Scan 
 
FACS analysis was performed with CellQuest software (Becton Dickinson, Heidelberg). 
 
3.2.18.2 Intracellular Staining 
Intracellular staining is applied if the desired antigen is present within the cell. This is the case for 
molecules such as transcription factors or cytokines. In order to stain intracellular antigens with 
the fluorescence-associated antibodies, cells need to be permeabilized and fixated.  
Reagents: 
 PBS 1x 
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 Stainig buffer: PBS 1x, heat-inactivated FCS (2%), sodium azide (0.1%) 
 Fixation solution  
 Permeabilization solution  
 Antibodies 
Procedure: 
       Steps 1-7 were performed analogous to cell surface marker analysis 
Intracellular staining was performed as instructed by the manufacturer and analyzed by using 
FACS-Calibur or FACS-Scan. 
 
3.2.18.3 PI (Propidium Iodine) Staining 
The fluorochrome propidium iodine (PI) is not capable of entering living cells through the intact 
plasma membrane. Therefore, it is used for the staining of dead cells.  
Reagents: 
 Propidium iodine (1 mg/ml) 
 PBS/FCS (1%) 
Procedure: 
1. Cells were adjusted to 1x106/ml in 1ml PBS/1% FCS 
2. 10 µg/ml PI was added and the cells were incubated at 4°C in the dark for 10 min 
3. Flow cytometric analysis was performed by using FACS-Scan or FACS-Calibur 
 
3.2.19 Calculating the Protein Concentration 
Background: 
The Bradford protein assay functions as protein concentration determination assay. Bradford 
reagent is a solution based on the acidic dye called Coomassie Brilliant Blue G, which complexes 
with proteins. Proteins in the presence of an acidic milieu alter the absorption maximum of this 
dye from 465 nm to 595 nm. The Coomassie dye binds to basic and aromatic amino acid residues, 
particularly arginine. A protein standard curve, using BSA, is established before the actual 
samples are measured. Its variation coefficient should not exceed 10%. The micro-Bradford assay 
was performed detecting proteins in a concentration range from 1 to 25μg/ml. 
Reagents: 
 Bradford reagent  
 Bovine serum albumin (BSA) (1 mg/ml) dissolved in Aqua ad iniectabilia 
 Aqua irrigation solution 
Procedure: 
1. The standards were generated according to Table 4 
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                       Table 4. Standards for the Micro Bradford Assay 
CONCENTRATION AQUA BSA 
1 µg/ml 799 µl 1 µl 
2.5 µg/ml 797.5 µl 2.5 µl 
5 µg/ml 795 µl 5 µl 
10 µg/ml 790 µl 10 µl 
15 µg/ml 785 µl 15 µl 
25 µg/ml 775 µl 25 µl 
 
2. 200μl Bradford reagent was added to blank, standards, and samples 
3. Standards, blank, and samples were incubated for at least 5 min 
4. The absorption was measured at 595 nm with a photometer 
 
3.2.20 Generation of Cell Lysates 
Background: 
For the detection of non-secreted intracellular proteins, the cells need to be disrupted prior to 
SDS-PAGE procedure and western blot analysis (3.2.23). Cell lysates are generated in sample 
buffer containing sodium-orthovanadate in order to inhibit protein tyrosine phosphatases and 
alkaline phosphatases from removing phosphate groups. This is important when phosphorylated 
proteins are investigated.   
Reagents: 
 Sample buffer: 65mM Tris-HCl, 25% glycerine, 10% SDS, 1mM sodium orthovanadate, pH 
6.8  
Procedure: 
1. Samples were centrifuged in microcentrifuge tubes for 1 minute at 20,000g 
2. The supernatants were removed, and the pellets were resuspended in 100μl sample buffer 
3. The samples were sonificated on ice (Intensity 3, Output control 5, duty cycle 50%, 10 sec) 
4. The sonificated samples were boiled at 95°C for 5 min 
5. The samples were stored at -20°C 
 
3.2.21 Immunoprecipitation 
Background: 
In order to concentrate distinct proteins from whole cell lysates immunoprecipitation is 
performed. Whole cell lysates are incubated with an antibody directed against the desired protein 
in the presence of agarose-beads coupled to protein A/G. Incubation allows binding of the 
antibody to its target antigen and binding of the Fc fragment to protein A/G-coupled beads. 
Isolation of the protein/antibody/beads complex is achieved by centrifugation, resuspension in 2x 
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sample buffer and 5 min boiling. Immunoprecipitation-efficiency is detected by the collection of 
supernatant before the addition of the antibody and after incubation with the beads. Sample 
analysis is performed by SDS-PAGE (3.2.22) and western blot (3.2.23).  
Reagents: 
 RIPA-lysis buffer: 20mM Tris HCl, pH 7.5, 150mM NaCl, 10mM EDTA, 1% (vol/vol) 
Triton X-100, 1% (wt/vol) Desoxycholate 
 Phenylmethylsulfonylfluorid (PMSF) 100mM 
 Aprotinin (1000 Kallikrein-inhibitor units/ml) 
 Sodiumbutyrate 0.9M (deacetylase inhibitor) 
 Anti-Foxp3 antibody (Santa Cruz) 
 Protein A/G agarose beads 
 2 x Sample buffer (130 mM Tris-HCl, 50% glycerine, 20% SDS, 200 mM sodium 
orthovanadate, 2% -mercaptoethanol, 5% bromphenol blue, pH 6.8) 
Procedure: 
1. 1x107 cells were lysed in 500µl RIPA-lysis buffer provided with freshly added protease 
inhibitors: PMSF (1mM), aprotinin (100 KIU/ml) and sodiumbutyrate (20mM) 
2. The lysates were incubated on ice for 10 min and sonificated on ice (Intensity 3, Output 
control 5, duty cycle 50%, 10 sec) 
3. The lysate was incubated on ice for 30 min and centrifuged at 4°C for 10 min at 10000g  
4. The supernatants were transferred into a new reaction tube and the protein concentration was 
determined by Bradford protein assay (3.2.19)  
5. 100-500µg total protein per sample was incubated with 1.5µl anti-Foxp3 antibody at 4°C for 
1 h with constant agitation  
6. 20µl Protein A/G agarose beads per sample were washed in PBS, resuspended in RIPA buffer 
and added to the lysate/antibody mixture 
7. The lysates were incubated over night at 4°C with constant agitation 
8. Immunoprecipitates were collected by centrifugation at 4°C, 3000rpm for 5 min  
9. The supernatants were removed carefully and the beads were washed four times with 1ml 
RIPA buffer to diminish unspecific bound proteins 
10. The supernatants were removed and the pellets resuspended in 40µl 2x sample buffer and 
boiled at 95°C for 5 min to ensure antibody-complex destruction 
11. SDS-Page was loaded with 6-10µl per sample and western blots were performed 
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3.2.22 Sodium Dodecyl Sulfate Discontinuous Polyacrylamid Gelelectrophoresis 
(SDS-PAGE) 
Background: 
The SDS-PAGE functions to separate proteins according to their electrophoretic mobility. The 
anionic detergent sodium dodecyl sulfate (SDS) covers protein charges, providing uniformly 
negatively charged proteins. Addition of -mercaptoethanol-containing sample buffer disrupts 
disulfide bridges within polypeptides. Furthermore, secondary and tertiary structures are 
dislocated by 5 minutes of protein-boiling. Thus, the polypeptides are present in their primary, 
linear structure and negatively charged, which allows for fractionation by approximate size during 
electrophoresis.  
By using discontinuous SDS-PAGEs more concentrated bands develop that simplify the 
identification of the investigated protein. For this purpose two different buffer sets are used. The 
stacking gel concentrates the proteins, which are then separated according to their molecular 
weight by the resolving gel.  
Reagents: 
 Sample buffer (65mM Tris-HCl, 25% glycerine, 10% SDS, 100mM sodium orthovanadate, 
pH 6.8) 
 Distilled water 
 Ammonium persulfate (APS) (10%) 
 Bromphenol blue 
 β-mercaptoethanol 
 Stacking gel buffer: Tris-HCl (1.5M, pH 8.8) 
 Resolving gel buffer: Tris-HCl (0.5M, pH 6.8) 
 Electrophoresis buffer (5x): 0.12M Tris base, 0.96M glycine, 30 ml 10% SDS, 600ml, pH 8.3 
 Acrylamide:Bisacrylamide 29:1 (30%) 
 N,N,N’,N’-tetramethylethylenediamine (TEMED) 
 Biotinylated molecular marker  
Procedure: 
1. The glass gel plates were rinsed with 70% ethanol, wiped clean with tissues, and then placed 
in the gel holders 
2. The reagents for the 10% resolving gel were mixed according to Table 5, pipetted between 
the glass plates, layered with distilled water, and left for 20 min of polymerization 
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Table 5. Gel Reagents for SDS-PAGE 
SUBSTANCES 8,5% RESOLVING 
GEL 
SUBSTANCES 4% STACKING GEL 
H2O 4.11 ml H2O 2.08 ml 
1.5 M TrisHCL 
pH 8.8 
2.34 ml 0.5 M TrisHCL 
pH 6.8 
910 µl 
Acrylamide/ 
bisacrylamide, 30% 
2.55 ml Acrylamide/ 
bisacrylamide, 30% 
467 µl 
APS, 10% 90 µl APS, 10% 35 µl 
TEMED 20 µl TEMED 7.8 µl 
Total volume 9 ml Total volume 3.5 ml 
 
3. The water was removed, the 4% stacking gel was prepared as shown in Table 5, the combs 
were placed in the gel, and the stacking gel was allowed to polymerize for 20 minutes 
4. The gel comb was removed and the glass plates containing the polymerized gel were placed 
into the electrophoresis chamber 
5. The chamber was filled with 1x electrophoresis buffer 
6. The samples and the molecular weight marker were mixed with bromphenol blue and 1% β- 
mercaptoethanol and were heated at 95°C for 5 minutes prior to pipetting into the gel slots 
7. The electrophoresis was conducted at 150V for 90 min on ice 
 
3.2.23 Western Blot 
Background: 
Western Blot includes the transfer of by SDS-PAGE separated proteins from polyacrylamide 
matrices onto nitrocellulose membranes utilizing electrical fields. The protein pattern remains 
conserved during protein transfer. Protein-bound SDS is washed out in this procedure so that the 
proteins regain their original secondary, and to some extent tertiary structure. Proteins can hence 
be recognized by epitope-directed antibodies, enabling the detection of specific target proteins 
within a homogenized culture sample.  
In order to prevent non-specific antibody-binding to the nitrocellulose membrane, potential 
binding sites are blocked with protein solutions containing BSA or fat-free milk powder. 
Detection of high-affinity antibodies bound to protein epitopes is achieved by using species-
specific secondary antibodies conjugated to the horseradish peroxidase enzyme (HRP). This 
enzyme converts substrate (LumiGLO solution) into its oxidized form, which then emits light 
detected by a digital biomolecular imager.   
Reagents: 
 Transfer buffer: 25mM Tris base, 0.2M glycine, 20 % methanol, pH 8.5 
 Ponceau S-solution 
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 TBS-buffer (10x): 0.2M Tris base, 2.28M NaCl, pH 7.6 
 TBS/T buffer (1x): TBS, 0.1% Tween 20 
 Blocking buffer: 2.5g fat-free milk powder dissolved in 50ml TBS/T buffer 
 Primary antibody: 10ml TBS-T, 5% fat-free milk powder, and primary antibody (diluted 
1:1000) 
 Secondary antibody: 10ml TBS-T, 5% fat-free milk powder, secondary antibody (diluted 
1:2000), and HRP-conjugated anti-biotin antibody (diluted 1:1000) 
 Detection solution: 250μl LumiGLO reagent (20 x), 250μl LumiGLO peroxide (20 x), and 
4.5ml distilled water for each gel 
Procedure: 
1. The nitrocellulose membrane and gel blotting paper were cut to fit the size of the gel 
2. The membrane, gel blotting paper, and sponges were equilibrated in transfer buffer 
3. The blot sandwich was assembled and then placed in the blot module with the gel facing the 
cathode side and the membrane facing the anode side 
4. The cooling element was placed next to the blot module and the module was filled with 
transfer buffer 
5. The blotting process was performed for about 90 min at 100 V 
6. The proteins were visualized by placing the membrane in Ponceau S solution and then 
washed with distilled water to ensure proper blotting 
7. The Ponceau S solution was completely removed by transfer buffer and the membrane was 
rinsed with distilled water 
8. The membrane was incubated with 25 ml blocking buffer for 1 h at RmT followed by 
incubation with the primary antibody at 4°C overnight 
9. The membrane was washed 3 x with TBS/T buffer 
10. The membrane was incubated with the secondary antibody for 1 h at RmT 
11. Step 10 was repeated 
12. The membrane was covered with 5 ml detection solution for 1 minute 
13. Chemiluminescence was detected by LAS-3000 imager 
 
3.2.24 Membrane Reprobing 
Background: 
Membrane stripping is useful when more than one protein is investigated on the same membrane. 
Previously antibody-incubated nitrocellulose membranes derived from western blot analysis 
(3.2.23) can be reused for further analysis by using a β-mercaptoethanol-containing buffer. The 
stripped nitrocellulose membrane is reusable following blocking in fat-free milk powder for 
incubation with further antibodies.   
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Reagents: 
 Stripping buffer (0.06M Tris base, 0.7% β-mercaptoethanol, 0.07M SDS, pH 6.8) 
 TBS/T buffer (1 x): TBS, 0.1% Tween 20 
Procedure: 
1. The membrane was washed 4 x with TBS/T buffer  
2. The membrane was incubated with stripping buffer for 30 min at 70°C 
3. The membrane was washed 6 x with TBS/T buffer  
4. The washed membrane entered the western blot procedure at step 8 (3.2.23)  
 
3.2.25 RNA Isolation from PBMCs 
Background: 
RNA isolation was performed using the NucleoSpin RNA® II Kit (Macherey-Nagel), which 
allows RNA isolation of fragments larger than about 200 bp thereby preventing the isolation of 
small RNA molecules such as 5.8S rRNA, 5S rRNA und tRNA. First, cells are lysed by a solution 
containing large amounts of chaotropic ions that inactivate interfering RNases. In the presence of 
ethanol intact RNA binds to a silica membrane. Washing steps with different buffers remove 
salts, metabolites and macromolecular cellular components. Finally, pure RNA is eluted under 
low ionic strength conditions with RNase-free H2O. 
Reagents: 
 -Mercaptoethanol 
 Ethanol (70%) 
 RNase-free water 
 Lysis Buffer RA1 
 Wash Buffer RA2 
 Wash Buffer RA3 
 Membrane Desalting Buffer MDB 
 Reaction Buffer for rDNase 
 rDNase 
Procedure: 
1. RNA isolation was performed exactly as described in the manual 
2. Isolated RNA was stored at -80°C after determination of the RNA concentration   
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3.2.26 DNA Isolation of PBMCs 
Background: 
The QiaAmp DNA Mini Kit from Qiagen enables the isolation of genomic DNA. Following cell 
lysis, the genomic DNA binds to a silica membrane in the presence of ethanol. Finally, the elution 
is achieved with H2O. 
Reagents: 
 Proteinase K 
 AL-buffer 
 Ethanol, absolute 
 AW1 buffer 
 AW2 buffer 
 Aqua ad iniectabilia 
Procedure: 
1. DNA isolation was performed exactly as described in the manual 
2. Isolated DNA was stored at -20°C after determination of the DNA concentration   
 
3.2.27 Spectrophotometric Determination of RNA or DNA Concentration 
Background: 
A method for determining nucleic acid concentration and purity is spectrophotometry. 
Absorbance at wavelength of 260nm and 280nm is detected. Whereas the absorption peak of 
proteins takes place at 280nm, the absorption peak of nucleic acids is at 260nm. The ratio 
A260/A280 provides information about the purity of isolated RNA or DNA. Pure preparations of 
DNA and RNA have A260/A280 ratios of 1.8 to 2.0. Ratios significantly lower indicate protein 
or phenol contamination (high A280) while higher ratios indicate salt contamination (high A260).    
Reagents: 
 Aqua ad iniectabilia  
Procedure: 
1. RNA was diluted 1:50 and DNA was diluted 1:10 in Aqua ad iniectabilia 
2. The photometer was blanked with aqua ad iniectabilia 
3. The RNA concentration was calculated as follows: 
  Concentration (µg/ml) = dilution factor x 40 x extinction at 260nm 
  The DNA concentration was calculated as follows: 
  Concentration (µg/ml) = dilution factor x 50 x extinction at 260nm 
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3.2.28 Reverse Transcription 
Background: 
For reverse transcription of isolated RNA into cDNA (complementary DNA) the qScript cDNA-
Synthesis Kit (Quantas) was used. This kit provides oligo-dT primer (complementary to the poly-
A-tail at the 3’end of the mRNA) and random hexamer primers. Primer annealing to mRNA 
results in double-strand DNA/RNA molecules serving as a starting point for DNA synthesis by 
reverse transcriptase enzymes.  
Reagents: 
 Aqua ad iniectabilia  
 1µg RNA template 
 qScript Reaction Mix (5x) 
 qScript Reverse Transcriptase 
Procedure: 
1. 1µg RNA was diluted with 15µl Aqua ad iniectabilia in a 1.5 reaction tube 
2. 4µl Reaction Mix (5x) and 1µl Reverse transcriptase were added 
3. Tubes were mixed gently and heated in a thermomixer as described in table 6 
                              Table 6. Temperature conditions 
 
  
 
 
 
 
3.2.29 Methyl Screen Assay 
Background: 
In order to identify genomic DNA methylation patterns the methyl screen assay provides an 
efficient and sensitive alternative to the else used bisulfite-sequencing method. The Methyl screen 
assay utilizes combined restriction from both methylation-sensitive restriction enzymes (MSRE, 
e.g. Hha1) and methylation-dependent restriction enzymes (MDRE, e.g. McrBC). The proportion 
of digested DNA compared to undigested DNA is obtained by quantitative PCR, thereby allowing 
for the analysis of CpG methylation patterns in a target DNA region.    
Reagents: 
 Aqua ad iniectabilia   
 HhaI 
 McrBC 
Time Temperature 
5 min 25°C 
60 min 42°C 
5 min 85°C 
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 New England Biolabs NEB2 Digestion buffer (100 μg/ml BSA, 10mM GTP in 1x NEB2-
buffer) 
 Glycerine solution (50% in Aqua ad iniectabilia)    
Procedure: 
1. Each of four 1.5ml reaction tubes was filled with 1µg DNA and digestion buffer (1x) up to a 
total volume of  97µl 
2. The restriction enzymes or glycerine, respectively, were added as follows: 
A. + 3µl glycerine (50 %) (mock) 
B. + 3µl HhaI (60U) 
C. + 3µl McrBC (30U) 
D. + 3μl HhaI + 3μl McrBC 
3. The DNA was digested over-night at 37°C in a thermomixer 
4. Stopping of the enzymatic reaction was achieved by heating to 65°C for 20 min followed by 
cooling on ice for 5 min 
5. The samples were stored at -20°C  
6. For further analysis by real-time PCR, 3µl DNA was diluted in 2µl Aqua ad iniectabilia and 
PCR was performed as described in 3.2.30 
7. DNA methylation occupancy calculation was calculated using following formula: 
 
 
3.2.30 Quantitative Real time Polymerase Chain Reaction (Q-PCR) 
Background: 
Q-PCR is an effective molecular-biological technique developed for the amplification and 
simultaneously quantification of DNA. Primers complementary to the target region anneal to a 
template DNA. A key role in the process of amplification plays the DNA polymerase, which 
enzymatically assembles a new DNA strand by elongating the primers at their 3’end. In the 
course of PCR progression the newly-synthetized DNA serves in turn as template leading to 
exponential amplification of initial DNA templates.  
The PCR can be divided into two different forms. In the conventional PCR agarose gel 
electrophoresis is used for size-separation and visualizing of the PCR products. In contrast, real-
time PCR measures the amount of DNA product after each round of amplification by detection of 
double-strand DNA-intercalating reporter dyes such as SYBR Green. The emitted light of the dye 
(emission maximum 529nm) increases relative to the amount of PCR product. Measurement of 
the DNA-intercalated fluorescent signals after every cycle enables the detection of the 
exponential phase. The number of cycles needed to exceed a certain threshold for fluorescence 
detection is called the cycle threshold (Ct). For gene expression quantification, the Ct method is 
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applied. Herein, the Ct for the RNA/DNA of a gene of interest is normalized to the Ct of 
RNA/DNA of a housekeeping gene (porphobilinogen deaminase) of the same sample (Ct). 
Subsequently, the expression disparity among reference sample (e.g. untreated control) and 
sample is obtained by subtraction of their Ct values (Ct). The relative expression difference 
between sample and reference sample normalized to a housekeeping gene is calculated as follows 
(Livak and Schmittgen 2001): 
                                            ratio = 2
-Ct
 
In this thesis, QPCR was applied for mRNA expression analysis and the Methyl screen assay. The 
Methyl screen assay did not involve the Ct method but was evaluated as demonstrated in 
3.2.29. 
Reagents: 
 Aqua ad iniectabilia    
 Brilliant SYBR Green QPCR Master Mix 
 Primer dissolved in Aqua ad iniectabilia    
 cDNA 
Procedure: 
1. Separate mastermixes were prepared for each, the gene of interest and the housekeeping gene, 
in a sterile 1.5ml reaction tube on ice as summarized in table 7 
 
Table 7. Reagents per cDNA/DNA sample for QPCR (25µl) 
 
 
 
 
 
 
 
2.  2 µl  cDNA was added to 23µl mastermix and pipetted into a PCR reaction tube 
3. Amplification was performed as shown in table 8 
4. The Primers used in QPCR are listed in table 9 and 10 
                                 
 
 
 
 
Reagent Volume [µl] 
Aqua ad iniectabilia 10 
SYBR Green QPCR mastermix 12.5 
Primer sense (2 µM) 1.25 
Primer antisense (2 µM) 1.25 
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                              Table 8. PCR program 
 
 
 
 
 
 
 
 
           Table 9. Primer for mRNA analysis 
hCTLA-4 
58°C 
sense 5’-3’ 
TCTGCAAAGCAATGCACGTG 
 
159 bp 
antisense 5’-3’ 
CCGCACAGACTTCAGTCAC 
hPPAR
58°C 
sense 5’-3’ 
GGGATGTCTCATAATGCCATCA 
 
66 bp 
 antisense 5’-3’ 
CGCCAACAGCTTCTCCTTCT 
hZIP8 
58°C 
 
sense 5’-3’ 
CCTCGGATTGATTTTGACTCCACT 
 
258 bp 
antisense 5’-3’ 
AGCAGGATTTGCATAGCATGTCAC 
hIFN 
58°C 
sense 5’-3’ 
AGAATTGGAAAGAGGAGAGTGACAG 
 
128 bp 
antisense 5’-3’ 
GTCTTCCTTGATGGTCTCCACAC 
hIL-4 
58°C 
sense 5’-3’ 
TTGAACAGCCTCACAGAGCAGA 
 
80 bp 
antisense 5’-3’ 
GTTGTGTTCTTGGAGGCAGCA 
hPBGD 
(porphobilinogen 
deaminase) 
58°C 
sense 5’-3’ 
ACGATCCCGAGACTCTGCTTC 
 
87 bp 
antisense 5’-3’ 
GCACGGCTACTGGCACACT 
 
 
          Table 10. Primer for Methyl Screen Assay 
 
hFoxp3 “Intron” 
56°C 
sense 5’-3’ 
CATCCACCAGCACCCATGT 
 
250 bp 
12 CpGs 
antisense 5’-3’ 
GGGATGTTTCTGGGACACAGA 
 
5. Data analysis was performed with the program Abi Prism 7000 
Temperature Duration Cycles 
50°C 20 s 1x 
95°C 15 min 1x 
95°C 30 s 
45x 56°C or 58°C 
(see table 9) 
30 s 
20°C ∞  
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3.2.31 [
3
H] Thymidine Proliferation Assay  
Background: 
Proliferation of cells can be measured by determining their incorporation of [
3
H]-thymidine into 
cellular nucleic acids. For this purpose cell cultures are pulsed with [
3
H]-thymidine during the last 
16 h before harvesting. Quantification of the incorporated [
3
H]-thymidine is accomplished by cell 
lysis, accumulation and drying of released DNA on filter papers, and, finally, dissolving of filter 
papers in a liquid scintillation cocktail. The scintillation cocktail contains liquid chemical medium 
capable of converting the kinetic energy of nuclear emissions into light energy, which can then be 
measured by a scintillation counter. Thus, the -emission originating by [3H] decay serves as a 
parameter for the amount of incorporated [
3
H]-thymidine and, therefore, for DNA synthesis. The 
degree of proliferation is indicated as counts per minute (CPM) and is expressed as proliferation 
index. 
Reagents: 
 RPMI medium containing 10% heat-inactivated FCS, 1% L-glutamine and 1% 
penicillin/streptomycin 
 [3H]-thymidine solution 
 Scintillation cocktail Lipoluma 
 Aqua dest. 
 Ethanol 70% (v/v) 
The [
3
H]-thymidine was diluted 1:20 in RPMI-medium to a concentration of 1850 kBq/ml. Every 
sample of a 96 well plate received 10µl of this solution (18.5 kBq/well).   
Procedure: 
1. 200 µl/well of PBMCs (2x106/ml) were stimulated according to the experiment and incubated 
at 37°C and 5% CO2 in a 96 well plate 
2. 10 µl [3H]-thymidine solution was added to every well 
3. Incubation for 16 h at 37°C and 5% CO2 
4. The incubation was stopped (plate can be frozen -20°C for later analysis) 
5. The cells were lysed with a cell harvester machine and DNA was accumulated on a filter 
paper 
6. The filter papers were washed 5 times with Aqua dest. and one time with ethanol (70%) 
7. The filter paper were transferred into scintillation tubes and dried for 5 min at 70°C in an 
incubator 
8. Every filter paper was dissolved in 3ml Lipoluma and the scintillation tubes were sealed 
9. The CPM was detected by a liquid scintillation  counter  
10. The proliferation index was calculated by dividing the CPM measured in stimulated cells by 
the CPM detected in unstimulated cells 
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3.2.32 Sirtuin 1 (Sirt-1) Assay 
Background: 
For measuring Sirtuin 1 (Sirt-1) enzyme activity, the fluorogenic Sirt-1 Assay Kit was used. In 
this assay the fluorometric substrate containing an acetylated lysine side chain is incubated with 
the purified Sirt-1 enzyme. Sirt-1-induced deacetylation sensitizes the substrate so that 
subsequent treatment with the Lysine Developer produces a fluorophore, which can then be 
measured by a fluorescence reader. The Sirt-1-inhibitor nicotinamide serves as a control.  
Reagents: 
 ZnSO4 (10µM; 1µM, 100nM) 
 Fluorogenic Sirt-1 Assay Kit 
 
Procedure: 
1. The Sirt-1 activity assay was performed as suggested in the instructions manual. 
  
3.2.33 Detection of Labile Zinc 
Background: 
Labile zinc levels can be detected by specific fluorescent zinc-sensors. Two zinc-probes, Fluozin-
3 and ZinPyr-1, were used in this thesis.  
The lipophilic Zinpyr-1 (C46H36Cl2N6O5) is a membrane-permeant fluorescent sensor with high 
specificity and affinity for zinc (Kd = 0.7 nM). The excitation and emission wavelength are 490 
nm and 530nm, respectively. Binding of zinc ions induces altered ZinPyr-1 fluorescence 
properties, which can then be detected by a fluorescence reader or by flow-cytometry. In T cells 
ZinPyr-1 is used to detect intracellular free zinc levels. 
In addition, the chelator Fluozin3-AM (Kd = 8.9nM) is a specific zinc-selective sensor. Following 
zinc binding, Fluozin3-AM exhibits a single excitation peak at 494nm and an emission peak at 
516nm. Two forms of Fluozin-3 are available; Fluozin3-AM and Fluozin-3A. Fluozin3-AM is 
present as an acetoxymethyl (AM)-ester, which is able to permeate cell membranes and therefore 
detect intracellular zinc. Fluozin-3A, on the other hand, is the free acid of Fluozin-3 and is used to 
detect free zinc levels in buffer, medium, or cell lysates. In contrast to ZinPyr-1, Fluozin-3 is used 
in T cells for the detection of vesicular zinc levels. 
For the calculation of the free zinc concentration, 50µM of the zinc chelator TPEN (N,N,N'N'-
tetrakis(-)[2-pyridylmethyl]-ethylenediamine) and 100µM ZnSO4 are added, in order to determine 
minimal and maximal zinc concentrations, respectively. For the detection of labile intracellular 
zinc, maximal zinc levels are induced by incubation with 100µM ZnSO4 plus the ionophore 
pyrithione (50µM). The labile zinc concentration is then calculated by the formula: 
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[Zn]=Kd*((F-Fmin)/(Fmax-F)) 
 published by Grynkiewicz et al. (Grynkiewicz et al. 1985) 
 
3.2.33.1 Fluozin-3A Detection  
Reagents: 
 FluoZin-3A (1mM in DMSO) 
 ZnSO4 (10µM; 1µM, 100nM) 
 TPEN (1mM) 
Procedure (all measurements were conducted as triplicates): 
1. The investigated buffer was dispersed in a 96 well plate (90 µl/well) 
2. 5µl of diluted (1:50) Fluozin-3A was added (=1µM ) 
3. TPEN was added (50µM) and zinc concentrations were generated (0.1; 1; 2; 2.5; 3; 4; 5 µM) 
4. The plate was incubated (shaking) for 10 min in the dark  
5. The detection was performed with the fluorescence plate reader at 485nm excitation- and 
535nm emission-wavelength 
6. The zinc concentration was calculated as described in 3.2.33 
 
3.2.33.2 Intracellular Zinc Detection 
Reagents:  
 FluoZin3-AM (1mM in DMSO) or ZinPyr-1 (2.5 mM in DMSO)   
 ZnSO4 (10µM; 1µM, 100nM) 
 TPEN (1mM) 
 Pyrithione (5mM) 
 RPMI medium containing 1% L-glutamine and 1% penicillin/streptomycin 
 PBS 1x 
Procedure: 
1. 1x106 PBMCs were distributed in 1 ml in RPMI medium without FCS 
2. Fluozin3-AM or ZinPyr-1 was added at a final concentration of 1µM or 10µM, respectively 
3. The cells were incubated at 37°C for 30 min while shaking 
4. The cells were centrifuged at 300g for 5 min and the supernatant was discarded 
5. The pellets were resuspended in100µl PBS (1x106 cells/ml) 
6. 10µl of mouse anti-human CD3-PE was added and the cells were incubated for 10 min at 
RmT in the dark 
7. The cells were centrifuged at 300g for 5 min and the supernatant was discarded and the 
pellets were resuspended in 1ml PBS 
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8. 330µl of this cell suspension was added in each FACS tube: 
a. TPEN (8.25µl)  minimal zinc concentration 
b. ZnSO4 (3.3µl) + pyrithione (3.3µl)  maximal zinc concentration 
c. Cells only  detection of intracellular zinc level   
9. The cells were incubated at 37°C for 30 min 
10.  Single cell fluorescence intensity was detected by FACS analysis (FL-1 for the zinc probe 
and FL-2 for CD3-PE) and zinc concentration was calculated as described in 3.2.33 
 
3.2.34 Statistical Significance and Program Analysis 
The results derive from series of experiments (number of experiments is shown as n = x) and are 
expressed as mean values; the standard error of the mean (SEM) is presented. The statistical 
significance was calculated using GraphPad Prism (GraphPad software, La Jolla, CA, USA). 
Statistical significances calculated by Student t-test and Mann-Whitney test are represented as 
follows: *p< 0.05, **p< 0.01 and ***p<0.001. Multiple comparisons involved ANOVA 
calculation with Tukey’s post-hoc-test. Mean values with significant differences are indicated by 
diverse letters, which indicate a significance level of p<0.05. 
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IV. Results 
4.1 Zinc Attenuates the Allogeneic Immune Reaction 
In MLCs, PBMCs derived from genetically diverse and immune-competent donors get mixed and 
cultured. Expression of divergent HLA haplotypes triggers the allogeneic immune reaction 
characterized by strong lymphocyte proliferation, the formation of T cell blasts, and pronounced 
IFN-production. The trace-element zinc has been discovered to inhibit IFN- production in 
MLCs (Campo et al. 2001). Exploration of the immunomodulating zinc-effect in MLCs was the 
aim of the following study. 
4.1.1 Modulated Cytokine Production by Zinc 
Cytokine production is a crucial feature in the MLC. Especially IFN- production was reported as 
a key parameter for allogeneic activity (Danzer et al. 1994). For this reason, MLC-production of 
the Th1 cytokine IFN- was detected by ELISA in the present study to confirm inhibition by zinc. 
Moreover, levels of the Th2 cytokine IL-10 were assessed in MLCs. The ratio of IFN-/IL-10 
provides insight into the Th1/Th2 cytokine balance. 
 
Fig. 2. Zinc modulates IFN- and IL-10 cytokine levels in the MLC. 2x106/ml PBMCs were 
preincubated either with or without 50µM zinc, respectively, or with 1µg/ml CsA (A) for 15 min before 
mixing of MLCs. Supernatants were collected after 8 days of incubation (A) and at indicated time points 
(B, C, D) and cytokine levels were measured by ELISA (A  n=13; B, C, D n=11).* indicates a significance 
of p<0.05, **indicates a significance of p<0.01, *** indicates a significance of p<0.001 (student’s t-test), 
mean values + SEM mean (A.) or mean values ± SEM (B., C, .D.) are shown.    
 
A.
B. C. D.
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As presented in Fig. 2 A., IFN- production in MLCs was significantly inhibited after 8 days of 
MLC culture in cells pretreated with 50 µM zinc for 15 min prior to PBMC mixing. Hence, the 
results of Campo et al., were successfully reproduced. Fig. 2 B shows that IFN- levels in MLC 
supernatants of cells supplemented with zinc were decreased compared with the control as early 
as 3 days (72 h) following MLC initiation. At day 8 (192 h) the zinc-dependent inhibition of IFN-
 production was most prominent. Usage of the immunosuppressive drug cyclosporine A (CsA) 
demonstrated that IFN- production can be completely abrogated in MLCs. Thus, IFN- 
production was not entirely suppressed by zinc proposing different strategies of immune-
modulation. 
In contrast to IFN-, IL-10 levels were significantly increased in zinc-supplemented MLCs after 3 
days of MLC incubation (Fig. 2 C). Notably, IL-10 production rose continuously in MLCs until 
day 6 regardless of treatment, revealing that Th2 cells contribute to the allogeneic reaction. 
Hence, a significantly reduced Th1/Th2 ratio in zinc-supplemented MLCs compared to control 
MLCs at each stated time point was observed starting from day 3 (Fig. 12 D). Accordingly, a shift 
from a mainly Th1-driven response in the direction of a Th2 response underlines the 
immunomodulating zinc effect. 
Th1-cytokine production also comprises IL-2. In contrast to IFN-, IL-2 production of allogeneic 
activated lymphocytes was not inhibited by zinc supplementation (Fig. 3 A). Remarkably, IL-2 
levels in the supernatant of MLCs were significantly elevated after 48 h of MLC incubation.  
 
 
Fig. 3. Impact of zinc on IL-2 cytokine levels. 2x10
6
/ml PBMCs were preincubated with or without 50µM 
zinc for 15 min before mixing of MLCs. Supernatants were collected at indicated time points of incubation 
and cytokine levels were measured by ELISA (A n=14).  Murine V T cells were preincubated with or 
without 50µM zinc for 15 min before stimulation with or without 250ng/ml TSST in the presence of MHC 
II expressing cells. Supernatants were collected after 48h of incubation and mIL-2 levels were detected by 
ELISA (B n=3). * indicates a significance of p<0.05 (student’s t-test) between with and without zinc 
treatment, different letters indicate significant differences of p<0.05 (ANOVA, post test: Tukey), mean 
values ± SEM (A) or mean values + SEM (B) are shown.   
 
A. B.
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Since both cytokines belong to the group of Th1 cytokines, a similar regulation was expected. 
Therefore, the impact of zinc on activation-induced IL-2 expression was further validated by 
measuring IL-2 expression in response to zinc-supplementation in murine V T cell clones 
overexpressing the TCR Vchain. Significantly enhanced IL-2 production, following zinc 
preincubation, was observed in Vcells stimulated with toxic shock syndrome toxin (TSST) 
superantigen for 48 h in the presence of APCs (Fig. 3 B).  
4.1.2 Attenuated Proliferation in Zinc-Supplemented MLCs 
Lymphocyte proliferation reflects the severity of alloresponsiveness and is therefore one of the 
key parameter characterizing the MLC. In the following experimental series the cell proliferation 
rate was measured as an indicator of the impact of zinc on MLC severity. Cell proliferation was 
assessed by addition of 
3
H-thymidine for the last 16 h of the 8 days lasting MLC incubation, since 
after 8 days IFN- production was prominently reduced. As a control proliferation of untreated 
and zinc-supplemented PBMCs was assessed, and MLC proliferation values were normalized to 
the proliferation of control PBMCs to gain normalized results. Furthermore, 1 µg/ml of CsA was 
used as an internal control as well as for a direct comparison between the zinc-impact and the 
well-known CsA-impact regarding MLC proliferation. 
 
Fig. 4. Zinc inhibits MLC proliferation. 2x10
6
/ml PBMCs were preincubated with or without 50µM zinc 
for 15 min or 1µg/ml CsA before mixing of MLCs. After 7 days of incubation cells were pulsed for the last 
16 hrs with 
3
H-thymidinde prior to washing and measuring of 
3
H-thymidine incorporation by detection of 
radioactivity in the -counter as counts per minute (cpm). Results are presented as proliferation index 
(cpm/cpm untreated control PBMC) (n=10). Diverse letters indicate significant differences of p<0.05 
(ANOVA, post test: Tukey); mean values + SEM are shown. 
 
As displayed in Fig. 4, the proliferation rate of unstimulated PBMCs was not affected by zinc 
supplementation. As expected, mixing of PBMCs into MLCs resulted in profound proliferation 
due to allogeneic stimulation. Concomitantly to IFN- production, zinc-supplementation 
significantly reduced MLC proliferation rates, albeit not to the level of unactivated PBMCs. CsA-
52 
 
treated MLCs, on the other hand, showed completely abrogated proliferation levels, comparable 
to those of the untreated PBMCs. Incubation of MLCs with zinc consequently demonstrates an 
immunomodulatory capacity which is indicated in reduced, yet not completely suppressed 
proliferation. Zinc-induced Tregs were suggested to play a role in the modulation of MLCs by 
inhibiting the immune response, since IL-2 and IL-10 levels, in contrast to IFN-levels, were not 
reduced by zinc despite reduced cell proliferation. Notably, IL-2 serves as Treg survival factor 
and IL-10 is reported to be produced by Tregs (Barrat et al. 2002). Therefore, the amount of 
Tregs in MLCs was investigated. 
4.2 Zinc-Induced Treg Upregulation in the MLC 
4.2.1 Zinc Upregulates Expression of the Treg-Associated Molecules Foxp3 and 
CTLA-4 
Detection of Foxp3 protein levels in MLCs by western blot analysis at different time points (72h, 
120h, 192h) revealed the capacity of zinc to induce Tregs. -actin protein levels served as a 
loading control. MLCs were generated from allogeneic PBMCs preincubated with or without 
50µM zinc, respectively, prior to mixing. Foxp3 protein levels intensified significantly at day 3 
(72 h) and day 8 (192 h) in zinc-supplemented MLCs compared to controls (Fig. 5 A, B). 
 
Fig. 5. Zinc-enhanced Foxp3 expression in the MLC. 2x10
6
/ml PBMCs were preincubated with or 
without 50µM zinc for 15 min before mixing of MLCs. Cells were harvested after 72, 120, and 192 h of 
MLC culture and cell lysates were generated. Foxp3 and -actin protein levels were detected by western-
blot analysis, one representative blot out of n=6 is presented in A. Quantification by optical density 
determination was performed and Foxp3 values were normalized to -actin values (B.) (n=6). ** indicates 
a significance of p<0.01 (student’s t-test), mean values ± SEM are shown.   
 
Surprisingly, after 5 days (120 h) no significant difference was found in expressed Foxp3 protein 
levels between control and zinc-treated cells. Additionally, Fig. 5 B. reveals increasing Foxp3 
levels after 5 days compared to 3 days of incubation in both control and zinc-supplemented cells, 
MLC72 h        120 h         192 h
A. B.
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followed by a decline in the control cells, but stabilization in zinc supplemented cells at day 8. 
Thus, zinc may play a role in prolonging Foxp3 protein levels resulting in elevated iTreg levels.  
A further Treg marker is the co-inhibitory molecule CTLA-4 (see Introduction), which is 
constitutively expressed by nTregs and upregulated along with Foxp3 in iTregs following T cell 
activation (Takahashi et al. 2000). CTLA-4 expression was detected at 3, 5, and 8 days of MLC 
incubation by measuring CTLA-4 mRNA levels (Fig. 6). Concomitantly, mRNA levels of the 
housekeeping-gene PBGD were assessed for relative quantification. Relative CTLA-4 expression 
levels were normalized to the relative expression levels of the untreated control after 72 h of 
MLC incubation in an effort to detect expression changes during the MLC course. Similar to the 
Foxp3 protein level CTLA-4 mRNA of zinc-supplemented MLCs was significantly enhanced 
compared to their controls at day 3 (Fig. 6). At day 5 the expression level increased in both 
control cells and zinc-treated cells, but Fig 6 reveals a significant higher CTLA-4 expression level 
in zinc-supplemented cells after 8 days of incubation compared to the control. Due to the 
correlation between Foxp3 protein levels and CTLA-4 expression there is evidence for zinc-
induced upregulation of iTregs in MLCs. 
 
Fig. 6. Zinc-enhanced CTLA-4 mRNA expression in the MLC. 2x10
6
/ml PBMCs were preincubated 
with or without 50µM zinc for 15 min before mixing of MLCs. mRNA was isolated after 72, 120, and 192 
hrs of MLC culture. CTLA-4 expression levels were quantified by RT-PCR and were normalized to PBGD. 
Results were standardized to CTLA-4 expression levels of MLCs without zinc at 72 hrs (n=7).* indicates a 
significance of p<0.05 (student’s t-test), mean values ± SEM are shown. 
 
4.2.2 Zinc-Induced Upregulation of Tregs Occurs in Allogene-Activated Blasts 
Western blot analysis and mRNA detection examine over-all Foxp3 and CTLA-4 expression of 
complete cell lysates. Therefore, the cellular source of Foxp3 and CTLA-4 in MLCs was not 
revealed. In order to confirm that zinc-upregulated Foxp3 and CTLA-4 expression derive from 
induced allogen-activated iTregs, 2-color and 3-color flow-cytometric analyses were performed. 
The amount of Tregs was assessed after 8 days of MLC incubation as this time point revealed 
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significantly enhanced CTLA-4 and Foxp3 levels (Fig. 5 and Fig. 6). Detection of CD4
+
Foxp3
+
 
cells was used to measure the amount of Tregs in the MLC by flow cytometry. Alloactivated T 
cells occurred in the form of T cell blasts displaying greater side scatter (SSC) and forward scatter 
(FSC) values than naïve CD4
+
 T cells, which enables gating of alloreactive CD4 blasts to obtain 
the amount of Tregs among all T cells. This gating-strategy as presented in Fig. 7A comprises 
activated blasts, as confirmed by measuring the specific expression of the activation marker 
CD69 on those cells. Gating on CD4
+
SSC
hi
 blasts revealed a significant increase in the amount of 
Foxp3 expressing cells following zinc supplementation compared to the control (Fig. 7 B). 
Hence, elevated amounts of Foxp3-expressing cells among the alloactivated T cell blasts manifest 
an enhancing effect of zinc on the amount of iTregs.      
 
Fig. 7. Elevated Foxp3 expression among CD4+ blasts. 2x10
6
/ml PBMCs were preincubated with or 
without 50µM zinc for 15 min before mixing of MLCs. Cells were harvested after 8 days of incubation and 
analyzed for CD4
+
Foxp3
+
 expression by flow cytometry. Gating was performed on CD4
+
 blasts. A. 
displays one representative flow cytometric analysis out of n=16. B. The amount of Foxp3 expressing CD4 
blasts was measured (n=16). ** indicates a significance of p<0.01 (student’s t-test), mean values + SEM are 
shown. 
 
4.2.3 Zinc Upregulates the Expression of Foxp3-Associated Molecules CD25 
and CTLA-4 
The transcription-factor Foxp3 induces the expression of its target genes including cd25 and ctla-
4, both contributing to the suppressive effects of Tregs (see Introduction). CD25, the IL-2 
receptor alpha chain, is expressed on activated T cells and Tregs and associates with CD122 to 
form the heterodimeric IL-2 high-affinity receptor (Tsudo et al. 1987). Foxp3 drives Tregs to 
express strongly increased levels of CD25 (further referred to as CD25
hi
), whereas activated T 
cells reveal medium CD25-expression levels (CD25
mid
). Naïve T cells do not show CD25 
expression. It was therefore of great interest to investigate whether the enhanced Foxp3 
expression was reflected in an enhanced expression of CD25. Flow cytometric analysis of 
 A.
B.
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CD4
+
CD25
hi
 expressing cells was performed 8 days after MLC incubation and by gating on CD4
+
 
blasts (Fig. 8 A) the percentage and CD25 MFI (geometrical mean fluorescence intensity) of 
CD25
hi
 expressing activated blasts was determined. Fig. 8 demonstrates an increased amount of 
CD25
hi
 expressing cells among the alloactivated blasts in the MLC in zinc-treated versus control 
cells. This held true not only for the relative amount of CD25
hi
 expressing cells among the 
activated cells (Fig. 8 B), but also the CD25 expression level per cell was enhanced as observed 
in the significantly elevated MFI levels (Fig. 8 C). These finding support the idea that zinc-
upregulated iTregs are the cellular source of increased Foxp3 protein levels and, more 
importantly, increased Foxp3 levels result in increased CD25 expression, which is involved in 
downregulation of T effector cell (Teff) activity due to outcompeting these cells for IL-2.    
 
Fig. 8. Elevated CD25 expression among CD4
+ 
and Foxp3
+
 blasts. 2x10
6
/ml PBMCs were preincubated 
with or without 50µM zinc, respectively, for 15 min before mixing of MLCs. Cells were harvested after 8 
days of incubation and analyzed for CD4 and CD25 expression by flow cytometry. Gating was performed 
on CD4
+
 blasts (A. displays one representative flow cytometric analysis out of n=10) and the amount of 
CD25 expressing CD4 blasts (B.) and CD25 MFI (geo mean) (C.) among CD4 blasts (n=10) was measured. 
D. Cells were analyzed for Foxp3 and CD25 expression by flow cytometry. Gating was performed on 
CD25
+
 blasts (D. displays one representative flow cytometric analysis out of n=8) and the amount of 
Foxp3
+
CD25
hi
 expressing CD25
+
 blasts (E.) and CD25 MFI (geo mean) of CD25
hi
Foxp3
+
 cells (F.) was 
measured (n=8). * indicates a significance of p<0.05, ** indicates a significance of p<0.01, *** indicates a 
significance of p<0.001 (student’s t-test), mean values + SEM are shown. 
A. B.
C.
D. E.
F.
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In order to confirm that the zinc-upregulated CD25 expression is related to the enhanced Foxp3 
expression the amount of simultaneously Foxp3 and CD25
hi
 expressing cells was assessed by 
flow cytometry.  Zinc-treated and control cells were analyzed after 8 days of MLC incubation. 
Gating was performed on CD25 expressing blasts as displayed in Fig. 8 D, comprising 
alloactivated Teffs and Tregs (CD25
mid
 and CD25
hi
 expressing blasts). Among the CD25
+
 blasts, 
the amount of CD25
hi
 Foxp3
+
 expressing cells was measured. Additionally, CD25-MFI of 
CD25
hi
Foxp3
+
 cells was determined to reveal an association between Foxp3 and CD25 expression 
on the single cell level. 
Among CD25 expressing blasts, the amount of CD25
hi
Foxp3
+
 expressing cells was significantly 
elevated in the zinc-supplemented group compared to the control (Fig. 8 E). In addition, the 
CD25 MFI among the CD25
hi
 Foxp3 expressing cells showed significantly higher CD25 levels 
per Foxp3
+
 cell in zinc-treated MLCs (Fig. 8 F). This result uncovers a link between Foxp3
+
 and 
CD25
hi
 expressing cells, underlining the evidence for zinc-upregulated iTregs in the MLC. In 
particular, enhanced CD25 expression per cell in the zinc-treated MLCs suggests elevated Foxp3-
induced gene expression.  
CTLA-4, a negative regulator of TCR signaling, also underlies the regulation of the transcription 
factor Foxp3. Therefore, to confirm the idea of zinc-upregulated iTregs the amount of 
CD4
+
CTLA-4
+
 expressing cells was assessed. Tregs were recently associated with enhanced 
intracellular CTLA-4 expression and increased capacity to traffic CTLA-4 to the cell surface 
following stimulation (Wang et al. 2011). In order to gain a better understanding of zinc-induced 
modulation of Tregs surface (sCTLA-4) and intracellular (icCTLA-4) CTLA-4 the expression of 
both was analyzed in CD4
+
 blasts after eight days of MLC. Both, their percentage and CTLA-4 
MFI in CD4
+
CTLA-4
+
 blasts were determined (Fig. 9 A and D). Fig. 9 B reveals an increased 
amount of sCTLA-4 expressing cells among the CD4 expressing blasts in the zinc-treated cells 
compared to the control. Additionally, sCTLA-4 MFI was increased considerably (Fig. 9 C). The 
amount of icCTLA-4 expressing CD4
+
 blasts was slightly enhanced by zinc supplementation 
(Fig. 9 E), but this increase was not statistically significant. The same was true for the icCTLA-4 
MFI in alloreactive CD4
+
blasts (Fig. 9 F).   
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Fig. 9. Elevated CTLA-4 expression among CD4
+
 blasts. 2x10
6
/ml PBMCs were preincubated with or 
without 50µM zinc, respectively, for 15 min before mixing of MLCs. Cells were harvested after 8 days of 
incubation and analyzed for CD4 and surface CTLA-4 (sCTLA-4) expression (A.-C.) or CD4 and 
intracellular CTLA-4 (icCTL-4) expression (D.-F.) by flow cytometry. Gating was performed on CD4
+
 
blasts (A. and D. displays one representative flow cytometric analysis out of n=12) and the amount of 
surface CTLA-4 and intracellular CTLA-4 expressing CD4 blasts (B., E.; n=12) and surface and 
intracellular CTLA-4 MFI (geo mean) (C., F.; n=12) among CD4 blasts was measured. *** indicates a 
significance of p<0.001 (student’s t-test), mean values + SEM are shown. 
 
Similar to CD25 expression, sCTLA-4 expression was enhanced with regard to the amount of 
sCTLA-4 expressing cells as well as the sCTLA-4 MFI per CD4 blast in zinc supplemented 
MLCs. These results support the finding that zinc supplementation increases Foxp3 expressing 
iTregs. Notably, increased amounts of sCTLA-4 molecules exert elevated suppressive function on 
Teffs. The results presented in Fig. 9 are in accordance with the observed increased CTLA-4 
mRNA levels in zinc-treated MLCs (Fig. 6). Changes in icCTLA-4 levels, which might also have 
been explained by increased CTLA-4 mRNA expression, were not as prominent as the increase in 
sCTLA-4 expression. This may be explained with immediate trafficking of newly expressed 
CTLA-4 molecules to the cell membrane leading to increasing sCTLA-4 expression with no 
detectable alteration in the icCTLA-4 level. 
Not only do Tregs express CTLA-4, but also activated Teffs upregulate sCTLA-4 expression 
following TCR stimulation to regulate the strength of current immune responses. Resultantly,the 
enhanced CTLA-4 expression reported in Fig. 9 needs further analysis to confirm simultaneous 
CTLA-4 and Foxp3 expression in CD4
+
 blasts and hence to identify Tregs. For this purpose, 
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MLCs were incubated with or without 50µM zinc, respectively, for 8 days and analyzed for their 
CD4 and simultaneous sCTLA-4 and Foxp3 expression by flow cytometry. Gating of CD4
+
 cells 
is shown in Fig. 10 A. As displayed in Fig. 10 B, the amount of sCTLA-4
+
Foxp3
+
 expressing 
CD4
+
 blasts was significantly elevated in zinc-supplemented MLCs compared to the control, 
confirming that the increased CTLA-4 levels were allocated to enhanced Foxp3
+
 Tregs. 
 
Fig. 10. Elevated amounts of sCTLA-4
+
Foxp3
+
 cells among CD4
+
 blasts. 2x10
6
/ml PBMCs were 
preincubated with or without 50µM zinc, respectively, for 15 min before mixing of MLCs. Cells were 
harvested after 8 days of incubation and analyzed for CD4, surface CTLA-4 (sCTLA-4) and Foxp3 
expression by flow cytometry. Gating was performed on CD4
+
 blasts (A. displays one representative flow 
cytometric analysis out of n=10) and the amount of sCTLA-4
+
Foxp3
+
 (B.) among CD4
+
 blasts (n=10) was 
measured. ** indicates a significance of p<0.01 (student’s t-test), mean values + SEM are shown. 
 
Last of all, it was important to confirm co-occurrence of both enhanced CD25 expression and 
increased CTLA-4 levels in zinc-supplemented MLCs, both associated with increased amounts of 
Foxp3-expressing cells. For this reason, MLCs were incubated with or without 50µM zinc, 
respectively, for 8 days. Subsequently, cells were stained for CD25 and sCTLA-4 or CD25 and 
icCTLA-4, respectively, and analyzed by flow cytometry. Gating was performed on CD25
+
 (Fig. 
11 A, D) cells to allow for analysis of the entire amount of alloreactive blasts (compare to Fig. 8 
D.).  
In zinc-supplemented MLCs the amount of CD25
hi 
sCTLA-4
+
 blasts increased significantly, as 
displayed in Fig. 11 B. In addition, with regard to the surface CTLA-4 MFI in CD25
hi
CTLA-4
+
 
blasts, a significant enhancement of sCTLA-4 expression per cell was observed. Similar to the 
results of CD4
+
icCTLA-4
+
 cells shown in Fig. 6 E. and F., the amount of CD25
hi
icCTLA-4 
expressing cells was not significantly altered by zinc supplementation. The icCTLA-4 MFI, on 
the other hand, was significantly increased in CD25
hi
CTLA-4
+
 blasts (Fig. 11 F.).  
 
 A.
B.
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Fig. 11. Elevated CD25
hi
CTLA-4 expression among C25
+
 blasts by zinc. 2x10
6
/ml PBMCs were 
preincubated with or without 50µM zinc, respectively, for 15 min before mixing of MLCs. Cells were 
harvested after 8 days of incubation and analyzed for CD25 and sCTLA-4 expression (A.-C.) or CD25 and 
icCTLA-4 expression (D.-F.) by flow cytometry. Gating was performed on C25
+
 blasts (A. and D. A. 
display one representative flow cytometric analysis out of n=5) and the amount of sCTLA-4 and icCTLA-4 
expressing CD25 blasts (B., E.; n=5) and surface and intracellular CTLA-4 MFI (geo mean) (C., F.; n=5) of 
CD25
hi
CTLA-4
+
 blasts was measured. * indicates a significance of p<0.05, ** indicates a significance of 
p<0.01, *** indicates a significance of p<0.001 (student’s t-test), mean values + SEM are shown. 
 
These results confirm that the amount of concomitantly CD25
hi
 and sCTLA-4
+
 expressing cells 
grew in zinc supplemented blasts, supporting the finding that iTregs become upregulated in 
MLCs by zinc supplementation. Increasing Foxp3-levels, which upregulate cd25 and ctla-4 gene-
expression, presumably were the reason for elevated CD25 and sCTLA-4 expression. sCTLA-4 
as well as CD25 expression are important for the downregulation of immune responses and 
belong to the group of Treg markers. 
4.2.4 Zinc Upregulates Expression of Activation-Marker CD69 in T Cells 
The C-type lectin receptor CD69, a member of the type II C-lectin natural killer membrane 
receptor family, is highly upregulated following T cell activation and is postulated to be an early 
activation marker (Testi et al. 1989). For a more in-depth investigation of the immunomodulating 
effect of zinc in the MLC the amount of CD69 expressing alloactivated blasts was analyzed.  
In CD4
+
 blasts, gated as displayed in Fig. 9 A., the amount of CD69 expressing cells was 
significantly elevated in zinc-incubated MLCs after 8 days of MLC culture. In addition, gating on 
CD25
+
 blasts, shown in Fig. 9 B., revealed increasing CD69 levels in CD25
hi
 expressing cells in 
zinc-treated MLCs. These results support the idea that zinc upregulates activation-induced Tregs, 
A.
B. C.
D.
E. F.
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since the greater amount of CD25
hi
 expressing cells in the zinc supplemented MLCs are CD69 
positive, characterizing them as recently activated cells. 
Lately, mounting evidence linked CD69 to the Treg subset, as mice lacking CD69 developed 
allergies and autoimmune diseases (Martin and Sanchez-Madrid 2011). Taking these findings into 
account, upregulation of CD4
+
CD69
+
 blasts and CD25
hi
CD69
+
 blasts seems to contribute to the 
idea of zinc as a modulator of the allogeneic immune response and an inducer of allogen-specific 
iTregs. 
 
Fig. 12. Zinc elevates CD69 expression in alloactivated blasts. 2x10
6
/ml PBMCs were preincubated with 
or without 50µM zinc for 15 min before mixing of MLCs. Cells were harvested after 8 days of incubation 
and analyzed for CD4
+
CD69
+
 (A) and CD25
hi
CD69
+
 (B) expression by flow cytometry. Gating was 
performed on CD4
+
 blasts (A displays one representative flow cytometric analysis out of n=6) or CD25
+
 
blasts (B. displays one representative flow cytometric analysis out of n=4) and the amount of CD4
+
CD69
+
 
and CD25
hi
CD69
+
 blasts was measured (A n=6, B n=4). * indicates a significance of p<0.05, *** indicates 
a significance of p<0.001 (student’s t-test), mean values ± SEM are shown. 
 
4.2.5 Zinc Enhances PPAR- mRNA Expression 
Recently, the peroxisome proliferator-activated receptor (PPAR)- was reported to have 
immunoregulatory function and has been proposed to prevent immunoinflammatory disorders 
(Hontecillas et al. 2011). In addition, PPAR is upregulated in activated T cells and therefore 
serves as an additional marker of T cell activation. Consequently, it was of interest to investigate 
whether PPARis modulated by zinc in MLCs.  
MLC mRNA was isolated from zinc-supplemented and control MLCs, respectively, after 72 h, 
120 h, and 192 h. PPAR -expression was detected by real-time PCR. PBDG expression served as 
B.A.
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housekeeping gene. The relative PPAR expression levels were normalized to the relative 
expression levels of the control at 72 h of MLC incubation to gain the changes in 
PPARexpression during the MLC course.  
 
Fig. 13. Zinc-enhanced PPAR mRNA expression in the MLC. 2x106/ml PBMCs were preincubated 
with or without 50µM zinc for 15 min before mixing of MLCs. mRNA was isolated after 72, 120, and 192 
hrs of MLC culture. PPAR- expression levels were quantified by RT-PCR and were normalized to PBGD. 
Results are compared to PPAR- expression levels of MLCs without zinc at 72 h (n=7).* indicates a 
significance of p<0.05 (student’s t-test), mean values ± SEM are shown.   
 
Fig. 13 displays higher increases of PPAR mRNA levels in the zinc supplemented MLCs 
compared to the untreated control after 8 days of incubation. This finding indicates a potential 
role for PPAR in zinc-induced allogeneic response modulation. Yet, the role of PPARin Tregs 
has to be further elucidated. Zinc-induced upregulation of PPARmight also, similar to CD69 
expression, suggest that the amount of activated T cells increases in the MLC, supporting the idea 
of iTreg induction. 
Overall, the above presented data together with the finding that zinc enhances the amount of 
CD25
hi
 Foxp3
+
 and CTLA-4
+
Foxp3
+
 expressing cells among the alloactivated CD4 blasts, 
confirm the hypothesis that zinc is capable of upregulating CD4
+
 Foxp3
+
CTLA-4
+
 CD25
hi 
iTregs. 
Consecutively, molecular zinc targets responsible for elevated Tregs and immunomodulation of 
the MLC were investigated in a further experimental series described in the following. 
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4.3 Investigation of Molecular Zinc-targets in Tregs 
4.3.1 Analysis of Foxp3 Promoter Methylation Pattern  
Interestingly, zinc was shown to be associated with the modulation of epigenetic mechanisms 
(Wessels et al. 2013). Moreover, a role for DNA methylation patterns in the Foxp3 locus was 
identified, which discriminates Tregs from activated Foxp3-expressing effector T cells by 
affecting stability of Foxp3 expression (Lal et al. 2009). Increasing methylation of the foxp3 locus 
is associated with decreasing stability of Foxp3 expression. Since zinc is capable of Foxp3-
upregulation in activated T cells, as presented above, zinc may be capable of enhancing Foxp3-
locus demethylation. This way, transient Foxp3 expression in activated T cells would be 
stabilized and Foxp3 protein expression would be prolonged. DNA methylation patterns were 
analyzed using the MethylScreen assay, which involves DNA ingestion by methylation-sensitive 
restriction enzymes (HhaI) and methylation-dependent restriction enzymes (McrBC) followed by 
quantitative real-time PCR of restriction-refractory template. Primers were designed to amplify a 
CpG rich template located within the human foxp3 promoter region (first intron, containing 9 
CpGs) to assess the Foxp3 methylation pattern. PBMCs derived from healthy male donors were 
used to measure methylation changes in the X-chromosomal directed foxp3 locus. Zinc-
supplemented PBMCs and MLCs were analyzed for the detection of Foxp3 CpG methylation 
pattern after 8 days of incubation. 
 
 
Fig. 14. Zinc does not affect the Foxp3 methylation pattern. 2x10
6
/ml PBMCs were incubated with or 
without 50µM zinc for 8 days (A.). MLCs were generated comprising cells preincubated with or without 
50µM zinc for 15 min (B.). After eight days of incubation DNA was isolated and ingested by 60U HhaI, 
and 30U McrBC or both for 6 h at 37°C followed by quantitative real-time PCR of restriction-refractory 
template. Primers were used for a CpG-containing Foxp3 intron. Shown are the mean values+SEM of n=7 
experiments.   
 
In PBMCs no difference was detected in the accessibility of the DNA in both, methylation-
sensitive and methylation-dependent restricted Foxp3 DNA between zinc-supplemented and 
A. B.
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control cells (Fig. 16 A). In MLCs, a slight yet not significant increase in the amount of 
demethylated Foxp3 CpG islands in the promoter region by zinc supplementation was detected 
(Fig. 16 B). This effect underlined the above described upregulation of Foxp3 expression by zinc, 
but did not actually reveal the underlying mechanism. Therefore, further potential zinc targets 
were investigated. 
 
4.3.2 Zinc-Associated Inhibition of the HDAC Sirt-1 
Recent research demonstrated the capacity of zinc ions to inhibit the activity of various enzymes 
including the histone-deactylase Sirt-1 (Chen et al. 2010). Chen et al. observed that exogenous 
zinc strongly inhibits Sirt-1 deacetylase activity (IC50 of 0.82µM for Zn(Gly)). As Sirt-1 can 
deacetylate various histone and non-histone substrates, including Foxp3, a potential role for zinc-
associated Sirt-1 inhibition in MLC modulation may exist, as decreased Sirt-1 activity was 
observed to stabilize Foxp3 protein levels (van Loosdregt et al. 2011). 
In order to verify the ability of zinc to inhibit the HDAC Sirt-1, a Sirt-1 enzyme activity assay 
was performed. Purified Sirt-1 enzyme was incubated with various amounts of zinc, and the 
deacetylase-activity was obtained by detection of released fluorescence from deacetylated 
substrates. Furthermore, the general deacetylase inhibitor nicotinamide was used as control for 
assay functionality and for a comparison between the capacity of zinc and nicotinamide to inhibit 
Sirt-1. The IC50 of nicotinamide for Sirt-1 inhibition is reported to be 88 µM (Lavu et al. 2008).  
 
Fig. 15. Zinc inhibits Sirt-1 activity. Impact of zinc and nictotinamide on the activity of purified Sirt-1 
enzyme was assessed using a Sirt-1 activity assay. A. 10, 100, and 1000 µM zinc or nicotinamide was 
added and Sirt-1 activity is shown as percentage of activity in the untreated control (n=3). B. Zinc was 
added ranging from 0.1 – 5 µM. Sirt-1 activity is shown as percentage of enzyme activity in the untreated 
control (n=3). * indicates a significance of p<0.05 (student’s t-test), different letters indicate significant 
differences (ANOVA, post test: Tukey); mean values + SEM (A) or mean values ± SEM (B) are shown. 
 
Fig.15 A. shows that zinc was capable of inhibiting Sirt-1 activity significantly when added in 
concentrations of 10, 100, and 1000µM, suppressing Sirt-1 activity down to approximately 15%. 
A. B.
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Since equal concentrations of nicotinamide reduced Sirt-1 activity to a much smaller amount, it 
was assumed that zinc inhibits Sirt-1 more effectively. Therefore, the IC50 of zinc was further 
narrowed down by addition of zinc concentrations ranging from 0.1 – 5µM zinc. Fig. 15 B. 
displays that Sirt-1 was significantly inhibited by applying zinc concentrations of 1µM and more. 
Although zinc in these more physiological concentrations was not capable of inhibiting Sirt-1 
completely, zinc reduced Sirt-1 activity to about 60%.  
Due to the reaction-buffer composition used in the activity assay added zinc was buffered to a 
certain amount. Therefore, the actual amount of free zinc in the buffer was assessed to reveal the 
absolute amount of zinc required to obtain 50% Sirt-1 activity. Furthermore, 10µM of the zinc-
chelator TPEN was used to access Sirt-1 activity in very low zinc-levels. 50µM TPEN and 50µM 
zinc were added to reach minimal and maximal zinc levels needed for the quantification of free 
zinc, which was detected by usage of 1µM of the zinc-specific probe Fluozin3-A. The obtained 
IC50 value lies at 12.9nM (with a confidence interval ranging between 5.36 and 31.31nM), 
shown in Fig. 16. 
 
Fig. 16. IC50 determination of zinc-related Sirt-1 inhibition. IC50 was assessed by using a Sirt-1 
activity assay (B). Zinc concentrations ranging from 0.1 to 5 µM zinc were added and Sirt-1 activity was 
measured. In addition, 10 µM TPEN was added and Sirt-1 activity was detected. Results are presented as 
percentage of the untreated control (n=3). The amount of definite free zinc in the assay was determined by 
1 µM Fluozin-3 (A). Addition of 50 µM TPEN and 50 µM zinc were added to reach minimal and maximal 
zinc levels needed for quantification of free zinc (n=3). The IC50 was calculated by searching the zinc 
concentration with inducing 50% Sirt-1 inhibition.* indicates a significance of p<0.05 (student’s t-test); 
mean values ± SEM are shown. 
 
Based on the above findings, it was of interest to measure the amount of free zinc in T cells 
treated with and without zinc in order to clarify if the intracellular zinc concentration reached a 
relevant level capable of intracellular Sirt-1 inhibition. In order to determine the free intracellular 
zinc levels of T cells, PBMCs were isolated and incubated with or without 50µM zinc, 
A. B.
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respectively, for 15 min prior to zinc-probe incubation and subsequent flow-cytometric analysis 
of intracellular zinc in CD3-labeled cells was performed. The time span of 15 min of zinc-
incubation was chosen in accordance with the MLC experiments involving 15 min of zinc pre-
incubation prior to MLC mixture. 
The zinc probes ZinPyr-1 and Fluozin3-AM were used for this purpose. Whereas Fluozin-3 
measures the zinc content in T cell vesicles, Zinpyr-1 detects the amount of T cell cytosolic free 
zinc. Preincubation with zinc elevated cytosolic free zinc levels significantly up to around 0.1nM 
(Fig. 17 A). Vesicular zinc, on the other hand, did not increase following 15 min zinc 
preincubation. However, elevation of vesicular zinc was detected after 15 min of zinc 
preincubation with subsequent T cell activation via cells of the B cell-line Raji for 60 min 
compared to non-preincubated B cell-activated T cells, which were not preincubated with zinc. 
The increased vesicular zinc reached concentrations of around 0.9nM zinc (Fig. 17 B). 
 
Fig. 17. Zinc-supplementation increases intracellular zinc levels in T cells. 2x10
6
/ml PBMCs were 
incubated with or without 50µM zinc for 15 min. (A.) Intracellular free zinc was detected in 1x10
6
 cells by 
using 10 µM of the zinc probe ZinPyr-1 (n=6). In addition, by gating on CD3
+
 cells the zinc content of T 
cells was analyzed specifically. Minimum and maximum values were obtained by addition of 50 µM TPEN 
or 100 µM zinc and 50 µM pyrithione, respectively, to enable calculation of free zinc. B. The zinc probe 
Fluozin-3 (1 µM) was used to detect vesicular zinc in CD3
+
 PBMCs. In addition, after preincubation with 
or without 50µM zinc, cells were activated by the addition of 5x10
5
/ml Raji cells for 15 or 30 min prior to 
flow cytometry (n=6). * indicates a significance of p<0.05 (student’s t-test) and different letters indicate 
significant changes (ANOVA, post test: Tukey). Mean + SEM are shown.   
 
4.3.3 Sirt-1 Inhibition Enhances Foxp3-Acetylation 
Since the detected intracellular zinc levels in T cells comes below the determined Sirt-1 IC50 of 
13nM the relevance of the elevated zinc contents with regard to cellular Sirt-1 activity and its 
Foxp3 deacetylase capacity was assessed by immunoprecipitation/westernblot. It has been 
described earlier that Sirt-1 can function as protein deacetylase using Foxp3 as substrate (Kwon et 
al. 2012). The level of acetylated Foxp3 was assessed by immunoprecipitation of Foxp3 prior to 
western blotting using antibodies against Foxp3 and K31-acetylated Foxp3.  
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Although the results of the zinc-related IC50 for Sirt-1 inhibition and the intracellular zinc 
concentration obtained in zinc supplemented T cells were somewhat inconsistent, Fig. 18 
demonstrates an increasing effect on Foxp3-acetylation by zinc. Even if this effect was not 
statistically significant, it hints at zinc-inhibition of Sirt-1 and subsequent Foxp3-acetylation, 
leading to reduced Foxp3 protein degradation, as shown in Fig. 5. 
 
Fig. 18. Zinc-supplementation increases Foxp3 acetylation. 2x10
6
/ml PBMCs were incubated with or 
without 50µM zinc for 15 min prior to mixing of MLCs. After 5 days and 8 days of incubation cell lysates 
were generated and Foxp3 protein was enriched by immunoprecipitation followed by western blotting. 
Protein levels of Ack31-acetylated and total Foxp3 were obtained. A. Representative blot out of n=10 is 
shown. B. Quantification by optical density determination was performed and AcK31-Foxp3 values were 
normalized to total Foxp3 values and presented as fold of untreated MLC. Mean values + SEM are shown. 
 
4.3.4 Sirt-1 Inhibitor Ex-527 Mirrors Zinc Effects in MLCs 
To validate the capacity of zinc to enhance Tregs by Sirt-1 inhibition, Ex-527 was used to 
investigate whether a Sirt-1-specific inhibitor was able to mimic the demonstrated zinc-effect. 
MLCs were generated and CD4
+
Foxp3
+
 expression was analyzed by flow cytometry. Gating of 
CD4
+
 blasts was performed as described before (Fig. 4 A).  
Indeed, the addition of 50µM Ex-527 enhanced the amount of CD4
+
Foxp3
+
 expressing blasts 
significantly compared to the control (Fig. 19 B.), leading to abrogated IFN- expression in the 
MLC (Fig. 19 C). Concomitantly, addition of 5µM Ex-527 caused the same effect to some extent, 
yet not significantly. Moreover, the effect of Ex-527 on cell viability was measured, revealing an 
increasing effect of Ex-527 on cell viability in the MLC (Fig. 19 D). These findings support the 
idea that Ex-527 attenuates the allogeneic immune reaction. In fact, the Sirt-1 inhibitor Ex-527 
was capable of imitating the zinc effects observed in the allogeneic reaction, supporting the idea 
of zinc-inhibition of Sirt-1 being the molecular mechanism involved in Treg upregulation. 
A. B.
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Fig. 19. Sirt-1 inhibitor Ex-527 imitates zinc-induced MLC modulation. 2x10
6
/ml PBMCs were 
incubated with or without 5µM or 50µM Ex-527 zinc for 15 min prior to MLC generation. After 8 days the 
cells were analyzed for CD4
+
Foxp3
+
 and supernatant was collected for IFN- ELISA. A. One 
representative flow-cytometric analysis out of n=6 is shown. B. The percentage of CD4
+
Foxp3
+
 cells is 
revealed. C. IFN- cytokine levels are presented. D. Cell viability was detected by PI staining of cells and 
results are displayed. * indicates a significance of p<0.05, ** indicates a significance of p<0.01 (student’s t-
test), and mean + SEM is shown.  
 
Regarding the potential use of zinc or Ex-527 as therapeutic agents, the toxicity of both reagents 
in PBMCs was compared. Concentrations of 50µM zinc, which were applied in MLC 
experiments did not affect PBMC viability after 3 days of incubation (Fig. 20). Even increasing 
zinc concentrations did not prove to be toxic. In contrast, increasing concentrations of Ex-527 
decreased the PBMC viability significantly. Therefore, while showing similar effects as Ex-527, 
zinc displays less toxicity and is hence more beneficial than Ex-527. Notably, Ex-527 treatment 
of MLCs increased total cell viability due to decreased allogeneic reaction, which overlays the 
toxic effect of Ex-527 on PBMCs (Fig.19). Yet, incubation of non-activated PBMC with Ex-527 
reveals its potential harm, which was not achieved by zinc-incubation.     
A.
B.
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Fig. 20. Effects of zinc and Ex-527 on viability of PBMCs. 2x10
6
/ml PBMCs were incubated for 3 days 
with or without 50, 75, and 100 µM zinc or Ex-527. Cell toxicity was obtained by PI staining (1µg/ml) 
prior to flow-cytometric analysis and is displayed as percentage of viable cells. Shown are the mean values 
+ SEM of n=3 experiments. Different letters indicate significant differences (ANOVA, post test: Tukey).   
 
4.4 In Vivo Zinc-Supplementation Upregulates Tregs in In Vitro 
Generated MLCs 
In the previous section, MLC supplementation with zinc was shown to upregulate Tregs in vitro, 
leading to diminished allogeneic immune reaction. The relevance of these findings for a potential 
therapeutic application of zinc to modulate the allogeneic response in vivo was investigated in this 
study by measuring the effect of physiological relevant zinc doses supplemented to immune-
competent subjects. For this purpose healthy male subjects were administered either 10 mg 
zinc/day supplemented as Zn-Aspartate (n=9) or placebo (n=7) over a time period of 10 days. 
Blood samples were taken before administration (t=0d) and again after 10 days of intake (t=10d). 
Serum zinc levels were also measured at these time points to assess the subject’s zinc status. 
Furthermore, PBMCs were isolated and MLCs were generated at day 0 and 10. The combination 
of different donor PBMCs in the MLC resulted in n=9 MLCs in the placebo group and n=16 
MLCs in the zinc group. Uneven amounts of MLCs in the placebo and zinc group was due to a 
drop out of volunteers. After 8 days of in vitro MLC incubation, the amount of CD4
+
Foxp3
+
 
expressing cells within the CD4
+
 blasts was analyzed by flow cytometry (Fig. 21 A, B). 
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Fig. 21. Impact of in vivo zinc supplementation on ex vivo generated MLCs. 7 healthy, male subjects 
were supplemented with placebo (10 mg/day) for 10 days; 9 healthy, male subjects were supplemented with 
10mg/day zinc supplied as Zn-Aspartate for 10 days. Blood was collected at day 0 and day 10 and serum 
zinc levels were detected by atomic absorption (C. placebo n=7, Zn-Aspartate n=9.). At time points t=0 and 
t=10 MLCs were generated. After 8 days supernatants were collected and IFN- levels were measured (E. 
placebo n=9, Zn-Aspartate n=16) and CD4
+
Foxp3
+
 expression was analyzed by flow cytometry (D. placebo 
n=9, Zn-Aspartate n=16). Gating on CD4
+
 blasts was performed as presented in A. and B. (A. and D. 
display one representative flow cytometric analysis of n=9 or n=16, respectively). Values of MLC 
generated at t=10 were normalized to values of MLC generated at t=0. * indicates a significance of p<0.05, 
** indicates a significance of p<0.01 (student’s t-test), mean values + SEM are shown. 
 
Other than in vivo placebo supplementation, in vivo supplementation with Zn-Aspartate 
significantly increased the amount of CD4
+
Foxp3
+ 
blasts in ex vivo generated MLCs (Fig.21 D). 
Concomitantly, MLC supernatants were collected after 8 days of MLC incubation and analyzed 
for IFN- expression in MLCs generated at t=0 and t=10. IFN- levels were significantly reduced 
in the MLCs generated at t=10 compared to MLCs generated at t=0 in the zinc-group compared to 
the placebo group (Fig.21 E). Verification of serum-zinc levels revealed increased zinc levels 
after 10 days of zinc administration in the zinc-supplemented volunteers, which were not detected 
after 10 days of placebo administration (Fig. 14 C). 
These findings indicate an increased amount of Tregs in MLCs generated of PBMCs derived 
from in vivo zinc-supplemented individuals, mirroring the results observed in in vitro zinc 
A. B.
C. D. E.
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supplementation experiments and thus emphasizing the relevance of zinc supplementation in 
pharmacological doses for modulation of the allogeneic immune reaction. 
4.5 Zinc-Induced Tregs Attenuate the Allergen-Induced Immune 
Response 
Besides the Graft-versus-Host disease, allergic diseases belong to the group of adverse immune 
overreactions. Allergies are an abundant health problem, affecting a copious number of people 
worldwide. As such, the development of therapeutic agents to ameliorate allergic immune 
reactions remains thus a primary research goal. Notably, allergies are frequently accompanied by 
zinc-deficiency (Di Toro et al. 1987). Subsequently, another important aim of this study was to 
verify zinc capabilities, if any, of upregulating Tregs in the allergic immune reaction, to lead to an 
improvement of the disease.  
 
Fig. 22. Timothy grass allergen extract induces PBMC proliferation. Different allergen concentrations 
ranging from 1-10 µg/ml were used to detect the most potent allergen concentration for PBMC proliferation 
in further experiments. Shown are data from one experiment using PBMC of an allergic individual. 
Proliferation was measured by 
3
H-thymidine assay.   
 
The allergic immune reaction was investigated using extracted timothy grass pollen, known to 
trigger hay fever in allergic individuals. With the aim of establishing the most effective in vitro 
allergen concentration, PBMCs were isolated from one individual suffering from seasonal hay 
fever. The cells were subsequently stimulated with various concentrations of the timothy grass 
allergen extract. After five days of stimulation, proliferation of the cells was assessed, revealing 
the most potent allergen concentration to activate allergenic immune reactions in vitro. Based on 
this result, further experiments were performed using 2.5 µg/ml (Fig. 22). 
Subsequently, the capacity of zinc to attenuate the allergic immune reaction was investigated by 
measuring various immune parameters, including proliferation and cytokine production. The 
allergen-induced proliferation of responder derived PBMCs was compared to non-responder 
PBMCs, with the aim of confirming that the allergen-extract activates PBMCs of allergic 
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individuals specifically. Furthermore, the effect of zinc on the allergen-induced proliferation was 
assessed. Proliferation was measured by the 
3
H-thymidine assay. The results were normalized to 
the respective control (PBMC without zinc and without allergen treatment) for a sound 
comparison. 
 
Fig. 23. Impact of zinc on proliferation levels in timothy-grass treated cells. PBMCs from non-allergic 
(A) and allergic (B) subjects were preincubated with or without 50µM zinc before stimulation with or 
without 2.5µg/ml timothy-grass allergen for 5 days. Proliferation was assessed by 
3
H-thyidine assay (A: 
n=8; B: n=12). Non-identical letters indicate a significance of p<0.05 (ANOVA, post test: Tukey), mean 
values ± SEM are shown.   
 
As shown in Fig. 23, five days of allergen-incubation significantly enhanced proliferation in 
PBMCs derived from allergic individuals (B), in contrast to PBMCs of control individuals (A). 
Pre-incubation with zinc abolished the allergen-induced proliferation of allergic PBMCs, reaching 
a proliferation level comparable to those obtained by treatment with zinc only. These results 
confirm a beneficial impact of zinc in the allergic immune reaction.  
As the measurement of PBMC proliferation serves as a potent parameter for the detection of 
proceeding immune reactions, whilst lacking detailed information about the immune response, 
additional immune parameters were investigated. These involved the detection of cytokine levels 
in the supernatant of PBMCs incubated with allergen extract following pretreatment with or 
without zinc. The cytokine production of the Th1 cytokines IFN- and TNF- as well as levels of 
the Th2 cytokine IL-10 were verified by ELISA. Following 24 h of incubation with 2.5 µg/ml 
allergen of PBMCs pretreated with or without zinc revealed that PBMC did express TNF- only 
when stimulated with allergen (Fig. 24 A), confirming the results provided by the proliferation 
assay (Fig. 24 B). Pre-incubation with zinc further increased the amount of released TNF-
significantlyAfter 5 days of allergen exposure the expression of the determining Th1 cytokine 
IFN- was slightly elevated following zinc preincubation (Fig. 24 B). In contrast, the Th2 
cytokine IL-10 showed decreased levels after 5 days of allergen exposure when pre-treated with 
zinc (Fig. 24 C).  
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Fig. 24. Altered Th1 and Th2 cytokine levels in allergen-activated zinc-supplemented PBMCs. 
2x10
6
/ml PBMCs of allergic subjects were pre-incubated with or without 50µM zinc for 15 min prior to 
activation with 2.5µg/ml timothy-grass allergen. Supernatants were collected after 24hrs for TNF- 
(A.n=6), and 5 days for IFN-n=6 and IL-10 (C; n=6) and cytokine levels were analyzed by ELISA. 
D. ratio of IFN-to IL-10 is shown. * indicates a significant difference with p<0.05 (student’s t-test), and 
mean values + SEM are shown.      
 
Information on the ratio of Th1 to Th2 cytokines was obtained by calculating the ratio of IFN-/ 
IL-10 levels. This ratio revealed a significant zinc-induced shift towards Th1 cytokines, which 
was further underlined by the finding that the Th1 cytokine TNF- showed enhanced levels in 
zinc-preincubated cells after 24 h of allergen exposure compared to allergen-activated cells 
without zinc (Fig. 24 A). Considering the type-I allergic reaction as a Th2 driven immune 
response, a shift towards Th1 cytokines by zinc promotes allergy attenuation. 
Moreover, the levels of Th1 and Th2 cytokines were obtained by measuring IFN- and IL-4 
mRNA expression by real-time PCR since IL-4 detection by ELISA is not feasible in human 
PBMC. The cytokine’s mRNA levels were detected of zinc-pretreated and control PBMCs 
derived from allergic volunteers activated with 2.5 µg/ml allergen after 4 h and 3 days. The 
cytokine expression levels were normalized to the expression levels of the housekeeping gene 
PBGD and standardized to the values of 4 h allergen-treated PBMCs. Fig. 25 A displays 
increasing IFN- production by cells preincubated with zinc in response to allergen compared 
with the control. The increase was only marginal after 4h of incubation and increased slightly, yet 
not significantly, after 3 days of incubation. In contrast, the Th2 cytokine IL-4 mRNA levels 
A.
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decreased after 4 h of allergen-incubation in the zinc-treated samples, which was not statistically 
significant (Fig. 25 B). After 3 days of incubation IL-4 levels were almost abolished.  
 
Fig. 25. Zinc-induced shift of Th1/Th2 ratio towards Th1 cytokines in allergen-activated PBMCs. 
2x10
6
/ml responder-derived PBMCs were preincubated with or without 50µM zinc and activated with 2.5 
µg/ml allergen extract. RNA was isolated after 4h and 3 days of incubation and IFN- (A; n=6) and IL-4 
(B; n=6) mRNA expression levels were quantified by RT-PCR and normalized to PBGD. Results were 
standardized to expression levels without zinc at 4 hrs of allergen incubation. Mean values + SEM are 
shown. 
 
The reason for non-significant differences between the control and zinc-treated cells may be due 
to the fact that only a considerably small amount of T cells are activated by allergen-exposure. 
However, these results are in accordance with the cytokine levels detected by ELISA and support 
the idea that zinc modulates the allergic immune reaction as mirrored in decreased proliferation 
and modified cytokine expression. As zinc was shown to upregulate Tregs in the MLC the 
capacity of zinc to upregulate Tregs among the allergen-activated cells was assessed. PBMCs 
from individuals suffering from seasonal hay fever were isolated and preincubated with or 
without 50µM zinc for 15 min followed by incubation with 2.5 µg/ml of timothy grass allergen 
extract. After 5 days of incubation CD4
+
Foxp
+
 allergen-activated blasts were analyzed by flow-
cytometry. Gating was performed on CD4
+
 blasts as displayed in Fig. 26 A, analogous to flow 
cytometric analyses in MLCs (Fig. 4 A). Indeed, zinc supplemented cells revealed a significant 
increase in CD4
+
Foxp3
+
 blasts compared to control cells (Fig. 26 B). 
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Fig. 26. Zinc induces the upregulation of Foxp3 expression in allergen-activated CD4
+
 blasts. 
2x10
6
/ml PBMCs derived from allergic individuals were preincubated with or without 50µM zinc for 15 
min followed by stimulation with 2.5µg/ml timothy-grass allergen for 5 days. The amount of Foxp3
+
 
allergen-activated CD4
+ 
blasts within 50µM zinc-pretreated PBMCs was analyzed by flow-cytometry 
(n=5). Fig. A displays one representative flow cytometric analysis out of n=5.* indicates a significance of 
p<0.05 (student’s t-test), and mean values + SEM are shown. 
 
Additionally, PBMCs derived from hay-fever affected individuals (responder) and control 
PBMCs derived from donors lacking immune sensitivity towards this allergen (non-responder) 
were preincubated either with or without 50µM zinc for 15 min prior to stimulation either with or 
without timothy grass allergen extract. After 5 days of incubation, the cells underwent flow-
cytometric analysis for the detection of CD4
+
CD25
hi
 expressing cells among CD4
+
 activated 
blasts. CD4
+
 blasts were gated as described above (Fig. 26). Within the non-responder group, zinc 
supplementation enhanced the amount of CD4
+
CD25
hi
 expressing blasts significantly compared 
to the control (Fig. 27 C). Stimulation with the allergen alone did not affect Treg levels; yet, 
slightly increasing Treg amounts were observed in zinc-preincubated PBMCs stimulated with 
allergen (Fig. 27 C). This result confirmed the insensitivity of non-responders to the allergen and 
approves the induction of iTregs in otherwise activated CD4
+
 cells by zinc. Within the responder 
group zinc alone also increased the Treg level, though not significantly (Fig. 27 D). This may be 
related to the declined Treg response found in allergic patients. Incubation with the allergen only, 
caused an insignificant increase in Tregs as well, due to allergen-induced Tregs, whereas 
preincubation with zinc prior to allergen exposure showed a significant upregulation of 
CD4
+
CD25
hi
 Tregs (Fig. 27 D). These results confirm the idea that zinc is capable of upregulating 
Tregs in activated T cell populations, including allergen-activated T cells. Again, upregulation of 
the transcription factor Foxp3 is likely to be associated with the increased CD25 expression. 
 For further verification an additional Treg marker, CTLA-4, was measured in the CD4
+
 blasts of 
cultured responder PBMCs. The flow cytometric analysis of the CD4
+
 blasts was performed as 
described before (Fig. 4 A). Since the non-responder cells did not exhibit elevated Treg levels 
after allergen treatment, thereby excluding the detection of unspecific allergen effects, further 
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analysis was conducted with PBMCs from allergic subjects only. Moreover, as a declared aim of 
this experiment was the investigation of zinc-related modulation of Tregs in an allergy model, the 
effect of zinc pretreatment was assessed only in allergen-exposed PBMC, omitting the effect of 
zinc in allergen-untreated PBMC.  
 
Fig. 27. Zinc upregulates the amount of CD25hi expressing Tregs in allergen-activated blasts. 
2x10
6
/ml PBMCs were preincubated with or without 50µM zinc and subsequently stimulated with or 
without 2.5µg/ml allergen for 5 days. A. and B. show one representative flow cytometric analysis out of 
n=6 for non-responder or one out of n=6 for responder respectively. In Fig. C the amount of CD25
hi
 
expressing CD4
+ 
blasts is shown including PBMCs of non-timothy grass allergic subjects (n=6). Fig. D 
displays results for responder-derived PBMCs (n=6). * indicates a significance of p<0.05 (student’s t-test), 
and mean values ± SEM are shown.  
 
In this experiment the expression of surface CTLA-4 was detected only, because no significant 
impact of zinc on the intracellular expression was observed in MLCs (Fig. 9 E, F). The 
percentage of CD4
+
sCTLA-4
+
 expressing cells and the MFI of sCTLA-4 among CD4
+
sCTLA-4
+
 
cells was analyzed. In addition, CTLA-4 mRNA expression was measured to gain information 
about zinc-induced changes in the amount of total CTLA-4 expression. CTLA-4 mRNA 
expression was normalized to PBGD mRNA levels and standardized to respective values of the 
control. Zinc-supplemented responder PBMCs showed an increased amount of CTLA-4
+
 cells 
among the CD4
+
 blasts compared to the control, as provided in Fig. 28 A, which was nearly 
statistically significant (p=0.06). Whereas CTLA-4 MFI did not show a zinc-related association 
non-
responder
responder
A.
2.91% 9.07% 3.77% 9.82%
4.7% 16.27% 4.03% 9.98%
B.
respondernon-responderC. D.
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(Fig. 28 B), CTLA-4 mRNA expression was significantly increased in the zinc-preincubated 
samples compared to the control (Fig. 28 C). Hence, these experiments confirmed an upregulation 
of iTregs, although not as sound as in the MLC. Still, enhanced CTLA-4 mRNA expression 
points to the fact that zinc influences the expression of this Treg marker. 
 
Fig. 28. Zinc affects CTLA-4 expression in allergen-activated PBMC. 2x106/ml PBMCs of allergen-
responder were preincubated with or without 50µM zinc and subsequently stimulated with 2.5µg/ml 
allergen for 5 days. In Fig. A the amount of CTLA-4
+
 expressing CD4
+ 
blasts is shown (n=5). In Fig. B 
CTLA-4 MFI of CTLA-4
+
CD4
+ 
blasts is displayed (n=5). (C.) CTLA-4 expression levels were quantified 
by RT-PCR and were normalized to PBGD. Results were standardized to CTLA-4 expression levels of 
PBMCs stimulated with allergen (n=6). * indicates a significance of p<0.05 (student’s t-test), and mean 
values ± SEM are shown. 
 
In conclusion, the results sustain the finding that zinc has the capacity to enhance immune-
modulating Tregs upon T cell activation, inducing the attenuation of the allergic reaction. That 
way, a potent therapeutic role for zinc supplementation for the alleviation allergic diseases could 
be assumed. 
4.6  Zinc Ameliorates Murine EAE Disease Course 
4.6.1 Zinc Upregulates Tregs in Murine MLCs 
A prerequisite for the usage of zinc in murine disease models for further investigations of the 
immunomodulating role of zinc is its verification in murine MLCs in vitro. Murine splenocytes 
were isolated from C57BL/6 mice and cultured in MLCs with cells of the murine macrophage cell 
line RAW264.7 (BALB/c-derived). The disparate H-2 haplotypes (H-2
b
 in C57BL/6 and H-2
d
 in 
BALB/c) triggered the allogeneic response. After 5 and 8 days of incubation either with or 
without 50µM zinc, cell lysates were generated and Foxp3 expression was analyzed by western 
blot. Additionally, expression of the housekeeping gene -actin was assessed and Foxp3 levels 
were normalized to -actin (Fig. 29 A). Quantification of western blot results displayed elevated, 
albeit statistically insignificantly, enhanced Foxp3 protein levels in zinc-supplemented cells (Fig. 
29 B). Moreover, cells were used for the measurement of CD4
+
Foxp3
+
 expressing blasts by flow-
cytometry after 5 and 8 days. Gating of CD4
+
 blasts was performed as described for human 
A. B. C.
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MLCs above (Fig. 4 A). Notably, flow cytometric analysis of CD4
+
 blasts revealed significantly 
increased amounts of CD4
+
Foxp3
+
 cells after 5 and 8 days of MLC incubation (Fig 29 C).  
 
Fig. 29. Zinc upregulates Tregs in murine MLCs. 2x10
6
/ml splenocytes derived from C57BL/6 mice 
were cultured with 1x10
6
/ml RAW264.7 cells after preincubation with or without 50 µM zinc. Cell lysates 
were generated after 8 days of incubation and Foxp3 and -actin protein levels were detected by western 
blotting, one representative blot out of n=3 is displayed in A. Western blot results were quantified by 
optical density determination and Foxp3 values were normalized to -actin values (B.). Flow cytometric 
analysis was performed to detect Foxp3
 
expression in gated CD4
+
 blasts (C.). n=3, * indicates a 
significance of p<0.05 (student’s t-test), mean values + SEM are shown.   
 
This data suggests that zinc is capable of inducing Tregs not only in human alloactivated cells but 
also in murine MLCs, which gives way for further analysis of zinc on the modulation of immune 
responses in in vivo animal studies. This study used the murine experimental autoimmune 
encephalomyelitis (EAE) model to gain insight into the potential impact of zinc in autoimmune 
diseases. 
4.6.2 Zinc-Supplementation Affects Treg-Levels In Vivo 
Before performing the EAE experiment it was of interest to verify if zinc affects the amount of 
Tregs in mice in vivo. Therefore, 2 groups each consisting of 4 animals were injected daily with 
either 30 µg zinc/day supplied as Zn-Aspartate, or the same volume of NaCl, respectively. After 
21 days, the animals were sacrificed and blood cells as well as splenocytes were analyzed for 
their amount of Foxp3-expressing Tregs and RORt-expressing Th17 cells. Flow-cytometric 
analysis of CD4
+
 blasts (Fig. 30 A) revealed increased Foxp3 expression in splenocytes derived 
from zinc-treated animals compared to the placebo group (Fig. 30 B). Due to the low case number 
of 4 animals per group this result was not statistically significant. In contrast to Foxp3
+ 
cells, the 
A.
B.
C.
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amount of the Th17 lineage-specific transcription factor RORt expressing cells showed a slight 
decrease among splenocytes, which may be associated with increased Foxp3
+
 cells. These results 
were more obvious when presented as the ratio of Th17 cells/Tregs as zinc decreases this ratio in 
splenocytes. Additionally, blood cells of the control animals did not differ in their amount of 
Foxp3 expressing CD4
+
 blasts, as well as in their amount of RORt+ cells, between placebo-
treated and zinc-treated animals (Fig. 30 B).  
 
Fig. 30. Impact of zinc treatment on the amount of peripheral Tregs and Th17 cells in control 
animals. Mice were injected daily with NaCl (n=4) or 30 µg/day (n=4) zinc supplied as Zn-Aspartate. 
After 21 days, animals were sacrificed and blood and splenocytes were obtained for flow cytometric 
analysis. Gating was performed on CD4
+
 blasts (A. shows one representative flow cytometric analysis for 
blood and splenocytes) and the percentages of CD4
+
Foxp3
+
 and CD4
+
RORt+ blasts were assessed (B). The 
ratio of CD4
+
RORt+/ CD4+Foxp3+ blasts was determined (C). Mean values + SEM are shown. 
 
CD4
+
 blasts in control animals were most likely to originate from marginal inflammatory 
processes due to daily i.p. zinc injections. Since these animals were not further antigen-
challenged and revealed only slight immune T cell activation, a substantial increase in iTregs by 
zinc was not expected. Nonetheless, the increasing Treg percentage in zinc-treated animals 
supports the idea of zinc to affect Treg upregulating agent in vivo. The fact that splenocytes 
constitute a larger amount of T cells compared to peripheral blood may contribute to the different 
results in splenocytes and blood. The impact of zinc seen on the induction of Tregs in the spleen 
A.
B.
C.
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is promising for an ameliorating effect of zinc on EAE and encourages the investigation of zinc 
on EAE-induced mice. 
4.6.3 Zinc-Induced Tregs Attenuate EAE Disease 
Similar to allergic diseases, autoimmune disorders arise from inappropriate immune responses 
and affects multitude patients worldwide. Since a general immune suppression increases the 
susceptibility towards perilous pathogens, strategies to control specifically autoimmune responses 
without serious adverse effects need to be developed. Regarding the immunomodulating effects 
of zinc on allergic- and alloimmune responses (see above), application of zinc in autoimmune 
diseases is a promising approach.  
The investigation of zinc-immunomodulary effects on autoimmune diseases was performed using 
the induction of experimental autoimmune encephalomyelitis (EAE). EAE serves as a murine 
model of multiple sclerosis and is characterized by CNS-inflammation, demyelination, and 
paralysis, mediated by myelin-specific CD4
+
 T cells. In our experimental setting the animals were 
injected daily with either low-dose (6 µg/day; 0.3 mg/kg body weight) or high-dose (30 µg/day; 
1.5 mg/kg body weight) zinc supplied as Zn-Aspartate starting 2 days prior to EAE immunization 
(Fig. 31). A placebo group received the same volume of NaCl instead. EAE progression was 
monitored on a daily basis by disease-staging, conducted under blinded conditions.  
 
Fig. 31. Schematic of the experimental setting. Mice were injected i.p. with NaCl or high (30 µg/ml) or 
low (6 µg/ml) doses of zinc supplied as Zn-Aspartate daily for 21 days, starting 2 days prior to EAE 
induction. Disease progression was obtained daily beginning 6 days after MOG injection, when disease 
symptoms start to emerge. 19 days following EAE induction all mice were sacrificed. 
 
This experimental setting inquired the effect of prophylactic zinc administration on the EAE 
disease course. Furthermore, this experiment dealt with the question of whether Treg upregulation 
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owes to a potential beneficial zinc effect. Remarkably, zinc was capable of modulating the 
amount of Foxp3 expressing Tregs among activated murine MLCs in vitro (Fig. 29) and in vivo, 
which suggests its contribution to EAE attenuation.  
Fig. 32 displays the attenuating effect of prophylactic zinc on the EAE disease incidence. Indeed, 
both low dose and high dose zinc applications, decreased the EAE disease incidence in a zinc 
concentration-dependant way. About 70% of the high-zinc treated animals and about 82% of the 
low zinc treated animals developed EAE, whereas in the placebo group the disease incidence 
reached about 91%. Therefore, injection of zinc exerted a protective impact regarding the 
development of EAE. Furthermore, this figure validates the effectiveness of the EAE-induction 
procedure as nearly 100% of the placebo animals developed EAE symptoms. 
 
Fig. 32. EAE-disease incidence in differently-treated groups. Mice were injected daily with placebo 
(n=11), 6 µg/day (n=11) or 30 µg/day (n=10) zinc supplied as Zn-Aspartate, starting 2 days prior to EAE 
induction. The disease incidents among the different groups are shown.  
 
Not only was the disease incidence affected by zinc treatment, but also disease intensity and 
disease course as presented in Fig. 32. The placebo animals severely suffered from EAE, reaching 
a mean scoring of 3 out of 5, with 5 corresponding to death (see chapter 3.2.12), whereas animals 
receiving zinc injections showed a decelerated EAE onset, which reached a mean score of 2 in the 
low-zinc group (Fig. 33 A), or even 1.5 in the high zinc group (Fig. 33 B), respectively. The 
changes in disease severity were statistically significant on days 16 and 17 following EAE 
induction in low-zinc treated mice and at days 16, 17, and 18 in the high-zinc treated animals. 
Thus, prophylactic zinc effect was demonstrated to attenuate the disease course in addition to 
disease incidences in a dose-dependent manner. 
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Fig. 33. EAE-disease course in differently-treated groups. Mice were injected daily with placebo (n=11), 
6 µg/day (n=11) or 30 µg/day (n=10) zinc supplied as Zn-Aspartate, starting 2 days prior to EAE induction. 
The disease course was obtained by daily staging of the animals starting from day 6 following EAE 
induction. * indicates a significant difference with p<0.05 (student’s t-test), and mean values ± SEM are 
shown. 
 
In addition, the animals’ body weight is a crucial indicator of their well-being and was thus 
measured daily or at least every two days. The results are presented in Fig. 34. The animals’ body 
weight slightly decreased in the first five days after EAE induction in all groups due to the 
antigen challenge, and increased as soon as the first disease symptoms occurred. With disease 
progression the body weights in all groups sharply decreased, but to distinct extents comparing 
placebo and zinc-treated animals.  
The high zinc group revealed a significantly higher mean body weight compared to the placebo 
group coincidently with lower EAE symptom scores (Fig. 34 A). The difference in body weight 
between both groups started as early as 9 days after EAE induction. Interestingly, significant 
differences in disease severity were not detected before day 16 (Fig. 33 B). The low-zinc group’s 
mean body weight was significantly lower at day -2 compared to the control group (Fig. 34 B). 
Hence, the mean body weights were normalized to the mean body weight at day -2 in order to 
display differences between placebo and low-zinc groups’ changes in body weight during the 
disease course (Fig. 34 C, D). Using this analysis a difference was also obtained between the 
placebo and low zinc group depicting a better well-being in the low zinc-treated mice. 
Standardization of body weights to the body weights at the starting day revealed for the high zinc 
treated group a reduction in body weight before disease onset compared to the placebo group. 
Yet, with increasing disease progression the body weight increases to levels similar to those the 
beginning whereas the placebo-treated animals’ body weight decreases correspondingly to 
disease severity. In conclusion, zinc attenuated the autoimmune disease EAE, which is reflected 
in disease incidence, disease symptoms, and body weight. 
 
A. B.
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Fig. 34. Weight-course in differently-treated animal groups. Mice were injected daily with placebo 
(n=11), 6 µg/day (n=11) or 30 µg/day (n=10) zinc supplied as Zn-Aspartate, starting 2 days prior to EAE 
induction. The weight was obtained daily or at least every second day. A. shows weight of placebo and 
low-zinc animals, B. displays weight course of placebo and high-zinc animals. In C and D weight 
normalized to weight obtained at day -2 is shown (n=4). * indicates a significance difference with p<0.05 
(student’s t-test) comparing placebo and zinc-treated groups, and mean values ± SEM are shown. 
 
As soon as the EAE disease course reached a plateau phase within the placebo group all mice 
were sacrificed and prepared for further investigations. Splenocytes together with peripheral 
blood cells were isolated and analyzed for RORt and Foxp3 expression among CD4+ blasts to 
assess the amount of peripheral Th17 cells and the amount of counteracting Tregs to investigate if 
increasing Treg counts owe to the attenuating zinc effect. For flow cytometric analysis, the same 
gating strategy was applied as demonstrated before (Fig. 4 A) comprising SSC versus CD4 
dotblots to obtain CD4
+
 blasts (Fig. 35 A). The measurements revealed no significant alterations 
in Treg levels in the periphery, including splenocytes as well as blood cells (Fig. 35 B, D). 
Nevertheless, the amount of RORt expressing Th17 cells among the peripheral blood cells was 
significantly reduced in the high zinc group compared to the placebo treated animals (Fig. 35 C). 
Alongside, a slightly diminished amount of CD4
+
RORt blasts among splenocytes was detected 
(Fig. 35 D) supporting the finding that zinc attenuates the basically Th17 driven EAE disease. 
A. B.
C. D.
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The divergent Treg and Th17 levels in EAE-derived cells from results observed in EAE-free 
animals (Fig. 30) arise from the vigorous inflammation in EAE-induced animals. 
 
 
Fig. 35. Impact of zinc treatment on the amount of peripheral Tregs and Th17 cells in EAE-induced 
animals. Mice were injected daily with placebo (n=11), 6 µg/day (n=11) or 30 µg/day (n=10) zinc supplied 
as Zn-Aspartate, starting 2 days prior to EAE induction. At day 19, animals were sacrificed and blood and 
splenocytes were obtained for flow cytometric analysis. Gating was performed on CD4
+
 blasts (A. shows 
one representative flow cytometric analysis for blood and splenocytes) and the percentages of CD4
+
Foxp3
+
 
(B., D.) and CD4
+
RORt+ (C., D.) cells were measured. * indicates a significance difference with p<0.05 
(student’s t-test), and mean values + SEM are shown. 
  
All in all, flow cytometric analysis did not convincingly affirm that zinc-induced Tregs are 
responsible for EAE attenuation. Therefore, immunohistochemical staining of spinal cord 
sections for Foxp3 and CD3 was performed to measure the amount of infiltrated Tregs. As EAE 
provokes inflammatory immune reactions at the spinal cord, infiltration of activated Tregs at the 
site of inflammation is feasible. This might also explain the decreasing Treg levels in the 
periphery (Fig. 35). CD3 and Foxp3 staining was not doable on the same slide but was done on 
consecutive slides derived from the same lumbal spinal cord region. Furthermore, counting of 
stained cells was performed by 3 blinded individuals to rule out biased values. As the zinc effect 
was most prominent in the high zinc treated group compared to the control group histological 
analysis was conducted in these groups only. In addition, this analysis solely included animals 
which developed EAE since healthy animals did not exhibit perivascular infiltration due to intact 
blood-brain barriers and restricted immune cell entry.  
Concomitantly to CD3 or Foxp3 staining, cells were counterstained with haematoxylin to 
visualize cell nuclei. Thus, CD3
+
 and Foxp3
+
 cells appeared as brown events; cell nuclei emerged 
as blue events. Whereas the amount of CD3
+
 cells mirrors the degree of the infiltration of 
B. C.
D. E.
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immunoreactive T-cells, Foxp3
+
 cells represent the amount of Tregs. The percentage of Foxp3
+
 
cells of CD3
+
 cells was calculated to reveal the relative amount of Tregs compared to CD3
+
 cells. 
 
Fig. 36. Impact of zinc treatment on the amount of infiltrated Tregs in EAE-induced animals. Mice 
were injected daily with placebo (n=11) or 30 µg/day (n=10) zinc supplied as Zn-Aspartate, starting 2 days 
prior to EAE induction. At day 19, animals were sacrificed, perfused, and spinal cords were isolated. Spinal 
cord slides were stained for CD3 or Foxp3 and concomitantly with haematoxylin for cell nuclei 
visualization (A). CD3
+
 stained cells were counted independently by 3 different individuals (B) and the 
percentage of Foxp3
+
 cells of CD3
+
 cells (C) was calculated. Mean values + SEM are shown for n=9 EAE-
developing placebo animals and n=7 EAE-developing Zn-treated animals (B). * indicates a significance 
difference with p<0.05 (Mann-Whitney test). 
 
Notably, the percentage of Foxp3
+
 cells relative to CD3
+
 cell infiltration was significantly higher 
in the high zinc treated animals compared to the placebo group (Fig. 36 B). This result indicates 
that the amount of Foxp3-expressing Tregs increases on the basis of zinc-treatment, which is 
associated with amelioration of EAE severity. Since in the periphery no considerable alterations 
of Treg amounts were found zinc seemed to mainly affect Foxp3-stabilization in activated 
infiltrating T cells. These results support the idea of zinc-induced activated Tregs as presented 
above.   
A.
C.B.
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To conclude, the results of this thesis indicate that zinc has modulating effect on immune 
responses by enhancing Treg levels within activated T cells due to deceleration of Foxp3 
degradation. Zinc-based modulation of immune responses was shown in MLCs (Th1-reactive), 
the allergic immune reaction (Th2-reactive), and the autoimmune reaction (Th17-reactive). 
Moreover, the impact of zinc was evaluated in vitro, ex vivo, and in vivo, emphasizing the 
relevance of the presented results for a future treatment of adverse immune reactions with zinc.  
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V. Discussion 
The aim of this thesis was to investigate the immunomodulating capacity of zinc in diverse T cell-
dominated immune reactions. The study has expanded on previous work that revealed the 
capability of zinc to inhibit IFN- production in the allogeneic mixed lymphocyte culture. In fact, 
Faber et al. observed that zinc in pharmacological doses of 50µM suppresses IFN- production in 
the MLC without affecting immune responses triggered by superantigens (Faber et al. 2004). 
Importantly, levels of the Th1 cell-derived cytokine IFN- are an important indicator for the 
allogeneic immune reaction in MLCs, since the MLC comprises prominent T cell activation 
(Danzer et al. 1994). In accordance, IFN- levels in MLCs between organ donors and recipients 
correlate with the severity of the acute GVHD (van der Meer et al. 1999). Reduced IFN- 
production by zinc hence mirrors attenuated T cell responses and the inhibition of the allogeneic 
immune reaction. Potential relevance for a therapeutic use of zinc in acute GVHD is therefore 
anticipated. 
This thesis confirms that IFN- production in MLCs supplemented with zinc is significantly 
reduced after eight days compared to untreated control MLCs (Fig. 2). Indeed, IFN- production 
was slightly, yet significantly, inhibited from as early as 3 days after MLC incubation, showing 
the most prominent effect after 8 days. Moreover, not only was an ameliorating effect of zinc on 
the allogeneic immune reaction confirmed, but even fortified by finding decreased lymphocyte 
proliferation in zinc-treated MLCs after 8 days of incubation (Fig.4). Similar to IFN- production, 
cell proliferation indicates lymphocyte activation mediated by foreign histocompatibility antigens 
(mostly MHC class II molecules) expressed on the allogeneic cells (Kruisbeek et al. 2004). 
In contrast to the complete abrogation of IFN- production and proliferation achieved by 1 µg/ml 
Cyclosporine A (CsA), inhibition triggered by pharmacological zinc doses of 50µM was 
incomplete. Hence, this finding suggests that pharmacological doses of zinc induce immune 
tolerance by modulating allogeneic immune cells rather than by eliciting complete 
immunosuppression. Nevertheless, a direct comparison between the presented effects mediated 
by zinc and CsA on the MLC is not feasible, as the herein used high CsA concentration 
functioned as a control to demonstrate that the MLC reaction can be completely abrogated in 
vitro. Therapeutic doses of CsA lie in the range of 40 ng/ml (Miroux et al. 2009). Surprisingly, 
Faber et al., found that 50µM zinc inhibited the IFN- production in MLCs as effectively as 20 
µg/ml CsA when measured after 5 days of incubation (Faber et al. 2004). Moreover, 20 µg/ml 
CsA did not abrogate IFN- production completely in their study, which stands in contrast to the 
result found in this thesis, which described complete IFN- suppression by 1 µg/ml CsA. It is 
likely that a dose-dependent effect of CsA on the MLC exists, which reveals a most potent 
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inhibition at a concentration of 1 µg/ml. The impact of increasing CsA dosages was not within the 
scope of this thesis and as such, further investigation was not undertaken. 
Modulation of the allogeneic immune reaction by zinc was further characterized by determining 
the ratio of Th1 to Th2 cytokines. Th2-derived IL-10 levels steadily increased in both, zinc-
treated and control, MLCs until day 6 of incubation, reaching levels of ~150 pg/ml (Fig. 2). This 
result implies that both Th1 and Th2 cells are involved in the allogeneic immune reaction, which 
is consistent with previously published observations in patients with GVHD (Yeh et al. 2012). 
Notably, IL-10 levels were not as prominently elevated as IFN- levels (~40 ng/ml in the 
untreated control MLC), which verifies that the MLC is a mainly Th1-driven response. Three 
days following MLC incubation IL-10 levels were significantly, yet moderately, elevated in the 
zinc-treated MLC compared to the untreated control. This trend, prolonged by zinc supply, 
seemed to extend to after 8 days in contrast to the control MLCs. In accordance, the IFN-/IL-10 
ratio showed a significant shift of IFN- (Th1) towards IL-10 (Th2) cytokines starting at day 3 of 
incubation and increasing until day 8. Remarkably, the IFN-/IL-10 ratio has previously been 
reported as an important measure of immune reactivity in transplantations (van den Boogaardt et 
al. 2006).  
However, it has to be taken into account that the reduced zinc-mediated proliferation rates and 
hence decreased amounts of cytokine-producing cells affect the cytokine levels. Therefore, 
reduced IFN- levels may be due to restricted proliferation of IFN- producing cells in addition to 
limited T cell activity. With regard to IL-10 levels, reduced cell proliferation of IL-10-producing 
cells may conceal elevated IL-10 release per cell. Interestingly, exogenous addition of the Th2 
cytokines rhIL-4 and rhIL-10 was demonstrated to reduce IFN- production in MLCs (Danzer et 
al. 1994), stressing the ameliorating effect of zinc-altered Th2 cytokine levels. Consistent with 
this finding, Th2 cells have been demonstrated to improve treatment outcome in clinical 
allogeneic stem cell transplantation (SCT). Studies by Fowler and colleagues, demonstrated that 
donor Th2 cells did not initiate acute GVHD, and that they can regulate GVHD mediated by 
unmanipulated donor T cells without impairing alloengrafment (Fowler and Gress 2000). 
Surprisingly, IL-2 levels were not reduced after zinc treatment of MLCs (Fig. 3). Since both IFN-
 and IL-2 belong to the Th1 cytokine family additional to promoting both the allogeneic immune 
response, this result was striking. In fact, IL-2 levels were even slightly but significantly 
increased after 48 h in zinc-treated MLCs. Increased IL-2 levels after 48 h were also confirmed in 
zinc-pretreated V T cells stimulated with superantigens in the presence of APCs. Consistently, a 
recent publication demonstrated elevated IL-2 production after IL-1 stimulation associated with 
increasing intracellular zinc levels in murine EL-4 T cells (Daaboul et al. 2012). Increased IL-2 
production by activated T cells may also arise because extracellular zinc levels can control TCR-
88 
 
signal strength and calibrate the TCR-activation threshold, thereby allowing T cell responses 
already with suboptimal stimuli (Yu et al. 2011). As a consequence, T cells get activated more 
rapidly by zinc, which results in higher IL-2 production. In contrast, decreased IFN- levels in 
zinc-treated MLCs imply a divergent effect of zinc on IFN- and IL-2 production in the MLC.  
It has to be emphasized that IL-2 is a survival factor for Tregs and increasing IL-2 levels are 
capable of inducing proliferation of otherwise non-proliferative Tregs (Zheng et al. 2007). 
Increased Treg activity by zinc might explain reduced overall proliferation and IFN- production, 
because Treg-mediated suppression not only affects Th1 cells but also effector cells such as IFN- 
-producing CD8
+
 T cells and B cells (Lim et al. 2005; Mempel et al. 2006).      
Accordingly, IL-10, in addition to being a Th2 cytokine, is secreted by Tregs in order to exert 
immunosuppressive function (Maynard et al. 2007). Remarkably, IL-10 was slightly enhanced by 
zinc after 3 days of MLC culture whereas IFN- was slightly decreased at this time point, 
possibly due to Treg-mediated inhibition. Moreover, Th2 cells were proposed to be less 
susceptible to the suppressive activity of Tregs than Th1 cells (Cosmi et al., 2004), which might 
account for the distinctive impact of zinc on Th1-derived IFN- production and Th2-derived IL-
10 production. 
In addition, Foxp3 levels were enhanced by zinc after 3 days and after 8 days of MLC incubation 
(Fig. 5), further substantiating the idea of increased Treg amounts, as Foxp3 is generally accepted 
as lineage-specific Treg marker (Fontenot et al. 2005). The fact that 5 days of MLC culture did 
not lead to altered Foxp3 levels in neither control nor zinc-treated cells suggests that zinc 
modulates Tregs in two different phases: Firstly, an early effect arising after 48-72 h of MLC 
incubation, indicated by slightly increased Foxp3, IL-2, and IL-10 levels, and a later effect 
starting after roughly 6 days of MLC incubation, characterized by increased iTregs leading to 
decreased IFN- expression and proliferation. Since the effect of zinc on the allogeneic immune 
reaction was more prominent after 8 days than after 3 days, the second phase is likely to play a 
stronger role in immune-tolerance induction. To test this hypothesis, Tregs induced upon zinc 
supply after 8 days of MLC were further analyzed. The analysis revealed increased amounts of 
CD4, CD25
hi
, Foxp3, and CTLA-4 expressing cells after 8 days in zinc-treated MLCs, all 
belonging to the group of Treg marker molecules (Akimova et al. 2011). 
The fact that CD25, Foxp3 and CTLA-4 are proteins that are also transiently expressed by 
activated T cells (Walker et al. 2003) indicates an accumulation of iTregs rather than nTregs after 
8 days of MLC incubation. More precisely, the presented data suggest increased stability of 
iTregs, which developed from activated antigen-specific Teffs upon zinc supply. Taken together, 
this clearly demonstrates for the first time that zinc inhibits the allogeneic immune response by 
inducing immune-tolerance mediated by increasing antigen-specific iTreg levels.  
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This phenomenon is important for transplantation medicine, for which inhibition of the allogeneic 
immune reaction is crucial to ensure graft functionality. Immunosuppressive strategies completely 
suppress the allogeneic immune reaction and thereby prevent graft rejection, but they are also 
hazardous for the patient because antigeneic immune reactions are also suppressed (Dunn 1990). 
The apparent ability of zinc to induce tolerance in the allogeneic immune response without acting 
completely immunosuppressive is therefore a promising approach. The idea of enriching 
allogeneic-specific Tregs is one proposed strategy to treat GVHD, comprising methods to 
converse or expand Tregs in vivo or ex vivo (d'Hennezel and Piccirillo 2012). But this labor- and 
cost-intensive process of generating the product may preclude their wide application. 
The results illustrating that zinc reduces the allogeneic immune reaction are consistent with 
conducted studies by Kown et al., which show that the systemic application of 1 and 5 mg/kg 
ZnCl2 dose-dependently reduced acute allograft rejection in a rat model of transplantation (Kown 
et al. 2000; Kown et al. 2002). The authors explain the observed prolongation of graft survival by 
a zinc-induced inhibition of apoptosis during the acute allogeneic immune reaction via inhibition 
of the proapoptotic enzyme caspase-3. Reduced apoptosis of graft-tissue cells would thus 
contribute to allograft survival. However, reduced apoptosis in allografts may be a secondary 
effect related to the attenuating impact of zinc on the immune reaction. Inhibition of effector cells 
by Tregs, as presented in this thesis might account for reduced graft cell apoptosis. Therefore, 
measuring the amount of Foxp3-expressing Tregs within the allografts would have been of great 
interest. The finding that zinc inhibits caspase-3 might be advantageous for Treg survival, but this 
idea was not further pursued in this study. However, the observations of Kown et al. indicate that 
the impact of zinc seen in in vitro MLCs might also prove relevant in vivo. This idea is supported 
by findings of Okamoto and co-workers, who concluded that zinc supplementation maintains 
functional grafts in intraportal islet transplanted rat recipients (Okamoto et al. 2011). 
To further elucidate the relevance of zinc administration for therapeutic purposes, this study 
verified the bioavailability of physiological amounts of orally administered zinc and its impact on 
ex vivo-generated MLCs. It is encouraging that a daily oral supplementation with physiological 
amounts of zinc-aspartate (10mg) for 10 days significantly increased the amount of Tregs in ex 
vivo generated MLCs when comparing before and after supplementation (Fig. 21). As this effect 
was only observed in MLCs generated with PBMCs derived from zinc-supplemented volunteers, 
in contrast to MLCs generated from PBMCs derived from placebo-supplemented volunteers, it 
can be concluded that supplementation of 10mg zinc per day over a time period of 10 days or less 
is sufficient to modulate immune cells towards attenuating MLCs by upregulating Tregs. Notably, 
a recent study revealed that 10mg elemental zinc/day has no adverse effects (Bobat et al. 2005).   
It has to be mentioned that IFN- levels were not much decreased comparing MLCs before and 
after zinc-supplementation, respectively. But this can be explained by the fact that MLCs were 
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generated at two different time points, which may result in a slightly diverging cell composition 
or other parameters influencing cytokine levels in the MLC. Importantly, Faber et al., who 
supplemented individuals with 80 mg zinc/day for 1 week, observed prominent IFN- suppression 
in ex vivo generated MLCs when comparing before and after supplementation time points (Faber 
et al. 2004). This finding verifies the herein presented inhibition of IFN- expression in ex vivo 
generated MLCs from zinc-supplemented volunteers. In addition, data from this thesis suggests 
that increased amounts of Tregs are responsible for this result. However, it has to be kept in mind 
that the volunteers’ nutritional status was not assessed in either study so it may be that nutritional 
zinc and phytic acid intake varied among the individuals. However, serum zinc levels were 
significantly increased after 10 days of zinc intake proving that zinc supplementation was not 
only effective in attenuating the allogeneic immune reaction in ex vivo generated MLCs but also 
in raising the volunteers’ zinc-status.  
Chronic disorders including allergies are often accompanied by zinc deficiency (Richter et al. 
2003; Rink 2011). Allergies, which belong to the Th2-driven diseases, may be caused by the shift 
of Th1 to Th2 cytokine occurring during zinc-deficiency (Prasad 2000). Therefore, allergies are 
likely to be susceptible to zinc-induced modulation of the allergic immune reaction. This 
suggestion was followed-up in this thesis in in vitro allergy experiments. Most importantly, zinc 
was able to enhance Tregs in allergen-activated PBMCs resulting in decreased PBMC 
proliferation (Fig. 26, 23). Tregs can indeed inhibit T cell activation following allergen exposure 
and this process may be deficient in atopic subjects (Ling et al. 2004). The suggestion that 
allergic subjects show decreased Treg-mediated suppression is interesting as it might correlate 
with decreased zinc levels in allergic subjects.  
However, increased amounts of Tregs were less prominent compared to the MLC. This can be 
explained by the relatively small pool of activated T cells and resulting iTregs levels, which are 
subsequently stabilized by zinc. Changes in Treg levels in this small pool are not as obvious and 
may be masked by present naive cells and activated effector cells. Consistently, cytokine levels 
show rather marginal changes after zinc supplementation (Fig. 24). Still, the measured cytokine 
changes indicate a shift of Th2 to Th1 cytokines since IFN- increased relative to IL-10. Allergies 
are Th2-dominated immune responses as indicated by the fivefold diminished IFN- production 
compared to its levels in the MLC. IL-10 levels, in contrast, were nearly 5 times higher than in 
the MLC. Thus, the shift towards Th1 cytokine suggests that zinc ameliorates the allergic 
reaction. In accordance, it was reported that the IL-4 production in short-term, allergen-stimulated 
pollen-reactive cells of individuals with seasonal allergic rhinitis was higher increased than the 
IFN- production (Imada et al. 1995). 
91 
 
The relatively limited suppression of Th2 cytokine production, also confirmed for IL-4 mRNA 
expression, might be further explained by the fact that Th2 cells are less susceptible to Treg 
suppression. Moreover, potentially reduced IL-10 levels are likely to be hidden by increased 
Treg-derived IL-10 expression.  
Taken together, the Th1-reactive allogeneic and the Th2-directed allergic reaction follow 
different courses and mechanisms, but are both modulated by zinc. In this study, experiments 
were performed using the timothy-grass allergen that causes hay fever. As 400 people worldwide 
suffer from this form of allergic rhinitis, with high prevalence recorded in industrialised nations, 
these results are of great interest (Bousquet et al. 2001). The zinc-effect remains to be confirmed 
in vivo. In addition to this, further research on the impact of zinc on immune responses induced 
by various other forms of allergies is required.  
The effect of zinc on autoimmune diseases, especially a Th17-dominated autoimmune disease, 
was investigated in a mouse model for multiple sclerosis (MS). This EAE model enables research 
not only on the immunomodulating capacity of zinc in Th17 driven immune responses, but also 
on zinc-mediated effects in in vivo immune reactions. A daily injection of zinc, starting 2 days 
prior to EAE induction, diminished the incidence of EAE development in zinc-treated groups 
(Fig. 32). This supports the existence of an early moderate impact of zinc on immunomodulation 
as seen in the MLC. Most notably, EAE course was significantly milder in zinc-treated animals. 
This dose dependent effect was reflected in the animals’ body weight (Fig. 34). In contrast to the 
placebo group, the zinc-treated animals did not suffer from weight loss following EAE onset, 
thoroughly indicating improved health status. However, no changes in peripheral Treg levels 
were found when analysing blood cells and splenocytes (Fig. 35). The EAE-induced immune 
reaction allows immune cells to cross the blood-brain-barrier and infiltrate the otherwise immune-
privileged CNS (Bartholomaus et al. 2009). The amount of perivascularly recruited autoreactive 
CD3
+
 T cells was slightly reduced in zinc-treated animals. In contrast, the percentage of iTregs 
among these CD3
+
 cells that infiltrate into the spinal cord was significantly increased in zinc-
treated mice (Fig. 36). Significantly enhanced Treg levels in the infiltrates of zinc-treated animals 
support the proposed model of zinc-stabilized Tregs, which develop in the course of T cell 
activation. These induced Tregs can exert immunosuppressive function on other immune cells 
and inhibit disease progression. The relevance of Tregs in EAE amelioration and MS is well 
established (McGeachy et al. 2005; Liu et al. 2006; Zozulya and Wiendl 2008).  
The presented results are consistent with the results of other groups who published reduced EAE 
severity in zinc-treated mice (Kitabayashi et al. 2010; Stoye et al. 2012). Stoye et al. reported an 
ameliorating zinc effect however not until after the first peak of disease. Contrastingly, in this 
study the ameliorating effect of zinc was already evident before the first peak of disease occurred. 
Although the same zinc concentrations were used, several differences between both studies must 
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be acknowledged. Stoye et al. performed preventive zinc application from day 1 to day 10, 
whereas in this study, zinc application started 2 days before EAE induction and was continued 
until day 19, the end of the study. Moreover, we chose to investigate MOG35-55/CFA-induced 
EAE in C57BL/6 mice, being the mouse model of EAE with the fastest disease progression and 
with predictive value for the efficacy of a chosen compound in MS. In contrast, Stoye et al., used 
the PLP139-151/CFA-induced, remitting-relapsing EAE in SJL mice, which is recommended for 
testing the effect of compounds on the development of EAE relapses (therapeutic treatment) 
(Zhang et al. 2004). Yet, the work of Stoye et al. bears the advantage of observing both the 
therapeutic and preventive value of zinc by additionally starting zinc application 11 days after 
EAE induction for 10 days resulting in decreased EAE severity in the relapsing phase. Based on 
the fact that the MLC and allergy experiments involved preincubation with zinc for 15 min prior 
to T cell activation in the present study, we chose pretreatement with zinc for the EAE 
experiment. Of course, based on the study by Stoye et al., investigation of the therapeutic value of 
zinc and its underlying mechanisms are of great interest for further studies.  
Interestingly, the zinc-mediated ameliorating effect of EAE was also seen in mice, which 
consumed zinc-enriched drinking water starting 1 month before EAE induction (Kitabayashi et al. 
2010). EAE severity was greatly reduced in zinc-treated animals compared to control animals 
proving the protective effect of zinc on EAE disease. Certainly, one has to bear in mind the 
divergent bioavailability of the zinc supplements and the different application protocols used. 
Especially the approach from Kitsbayashi et al. has to be interpreted with caution as the used zinc 
dosage of 3000 ppm in the animals’ drinking water (equivalent to 480-1200 mg zinc/kg) is within 
the range of the oral LD50 of zinc sulphate heptahydrate (500 mg zinc/kg). Consequently, the 
observed effects are most likely due to high dose zinc toxicology. 
Still, the protective value of zinc for autoimmune diseases was also shown in a model of collagen-
induced arthritis (CIA) in the aforementioned study. Consistent with our results, analysis of 
peripheral cells in that study revealed decreased Th17 but unaltered Treg levels. Unfortunately, 
levels of tissue-infiltrated Tregs were not assessed. Furthermore, Kitabayashi et al. showed that 
following Th17 cell injection, zinc-treated mice developed EAE severity comparable to control 
mice. This finding suggests that zinc attenuates EAE by inhibiting Th17 cell development. Tregs 
are known to counteract Th17 development (Chaudhry et al. 2009) and increased amounts of 
Tregs may well explain decreased Th17 levels in zinc-treated animals. Overall, this data indicates 
that zinc ameliorates autoimmune responses. This may be of considerable interest as each year 
about 150 per 100,000 individuals worldwide are affected by the chronic and disabling disease 
MS, for which no cure is yet available. MS is mainly treated with immunosuppressive drugs that 
often exhibit toxic side effects (Rosati 2001). 
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Interestingly, the zinc-mediated increased Treg levels assessed in in vitro experiments were 
confirmed in vivo in mice, demonstrating physiological relevance. In a follow-up, the molecular 
mechanism behind the increase in Tregs by zinc was further investigated. As mentioned earlier 
the modulation of IL-2 production in activated T cells might play an important role. This 
hypothesis is further supported by results of Rouse et al. stating that pretreatment with moderate 
IL-2 concentrations caused significant amelioration of EAE (Rouse et al. 2012). Expanded Tregs 
and concomitant inhibition of Th17 induction were hypothesized to be the reason for IL-2-
mediated EAE suppression. Notably, post-treatment with IL-2 failed to inhibit EAE despite an 
induction of Tregs. This data shows that IL-2 can expand Tregs at disease onset, which 
suppresses the disease. But once the antigen-specific response is triggered, IL-2 induced Tregs 
only play a limited role in controlling the immune response. According to these results the timing 
of enhanced IL-2 levels is critical for its impact on immune suppression. IL-2 supplementation to 
an already started immune reaction presumably expands Tregs but also stimulates Teff 
proliferation thus preventing tolerance induction. Hence, the importance of IL-2-elevation timing 
exacerbates the investigation of the potential impact of zinc-mediated IL-2 production on immune 
reaction. Moreover, it was demonstrated that zinc can improve the IL-2 signaling in T cells. 
Kaltenberg et al., published that the addition of zinc increases IL-2-induced ERK signaling and 
proliferation of T cells (Kaltenberg et al. 2010). Follow-up studies showed that zinc also increases 
IL-2-induced Akt signaling, which is partly due to a decreased PTEN (phosphatase and tensin 
homolog) activity by zinc (Plum et al. submitted). As a result IL-2-activated PIP3/Akt signaling is 
increased and influences cellular downstream processes. Improved IL-2-signaling in T cells by 
zinc may therefore be another factor involved in Treg upregulation and immune regulation. Yet, 
this idea was not further investigated in this thesis.  
Instead, a different mechanism was revealed. Interestingly, a role for HDAC Sirt-1 inhibition by 
zinc in modulating Tregs was found. Sirt-1 modifies Foxp3 stability by promoting proteasomal 
degradation of Foxp3 protein (van Loosdregt et al. 2010; van Loosdregt et al. 2011). 
Deacetylation of specific lysine residues favours Foxp3 ubiquitinylation at these sites, 
subsequently inducing protein degradation. Abolished Sirt-1 activity supports prolonged Foxp3 
stability along with Foxp3 function resulting in the presented immune modulations. The in vitro 
IC50 of zinc-inhibition of Sirt-1 deacetylase activity in this study was determined to be ~13 nM 
(Fig. 16). Inhibition of Sirt-1 by zinc has been demonstrated previously (Chen et al. 2010). Yet, 
Chen and colleagues postulated an IC value of 820 nM. Different approaches account for the 
diverging results. Whereas Chen et al. used Zn(Gly)2 consisting of zinc chloride and glycine with 
a molar ratio of 1:2, this study used ZnSO4 without any addition. In this thesis, actual free zinc 
levels of the added zinc concentrations in the assay buffer were determined. This approach allows 
for a specific analysis of the IC50 value. Yet, it is interesting that Chen et al., characterized zinc 
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as a non-competitive inhibitor for NAD
+
 and the acetyl peptide, suggesting that zinc binds at a 
different site compared to the activators NAD
+
 and the acetyl peptide (Chen et al. 2010). 
The ability of zinc to inhibit Sirt-1 activity was underlined by the fact that the HDAC inhibitor 
nicotinamide showed a weaker inhibition of Sirt-1 than zinc when added in equimolar 
concentrations (Fig. 15). The physiological intracellular concentration of nicotinamide ranges 
between 40 and 50μM for human cells, which is suggested to be just below the threshold for 
significant inhibition of intracellular Sirt-1 activity (Revollo et al. 2004). 
In order to evaluate the physiological relevance of the measured IC50 in activated T cells 
intracellular zinc levels in T cells were determined with the zinc probes Fluozin-3 and Zinpyr-1 
(Fig. 17). Fluozin-3 labels lysosomal zinc compartments in T cells whereas Zinpyr-1 detects 
cytosolic zinc. Zinc concentrations detected with either probe were below 1nM in activated T 
cells. This result stands in contrast to results from other publications, which consider 
concentrations of 17nM to be likely in vivo (Yu et al. 2011).Thus, although zinc concentrations in 
activated zinc-treated T cells were increased compared to the activated control intracellular zinc 
levels in activated T cells either with or without zinc supplementation fell below concentrations 
required for Sirt-1 inhibition in this work.  
Nonetheless, a zinc-mediated inhibition of Sirt-1 function cannot completely be ruled out for 
several reasons: Intracellular zinc levels were obtained in CD3
+
 cells comprising CD4
+
 Teffs and 
Tregs as well as CD8
+
 cells. Further analysis of specific cell subtypes may indicate that CD4 T 
cells have higher intracellular zinc levels than CD8 T cells. On the other hand, zinc affects the 
acetylation status of Foxp3 in MLCs as detected by Foxp3 immunoprecipitation. Subsequent 
western blot analysis revealed increased Foxp3 K31 acetylation by zinc (Fig. 18), which as per a 
recent publication established is crucial for human Foxp3 stabilization (Kwon et al. 2012). This 
increase was not statistically significant, which may be due to high variances between the 
subjects’ responses. Further, in this thesis Foxp3 levels were upregulated after 5 days in both 
untreated and zinc-treated MLCs (Fig. 5). After 8 days Foxp3 expression in zinc-treated MLCs 
was sustained, whereas in control MLCs Foxp3 levels receded. These findings definitely support 
the idea that zinc prevents Foxp3 degradation by reducing Sirt-1 activity and consequently that 
stabilized Foxp3 expression is responsible for the immunomodulating effect of zinc. Furthermore, 
the Sirt-1inhibitor EX-527 (6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide, IC50 = 
~38 nM) was capable of mimicking the results obtained in zinc-treated MLCs (Fig. 19). In a 
consistent manner, a study by Beier et al. indicates that Sirt-1 targeting promotes Foxp3
+
 Treg 
cell function and prolongs allograft survival (Beier et al. 2011). Although these results were 
found in Sirt-1-deleted mice this does not alleviate their importance as mice and human MLCs 
reacted in similar ways to the zinc-treatment in the present thesis (Fig. 29). In addition, wild-type 
allograft recipients treated with EX-527 exhibited similar reactions as Sirt-1 deleted mice. 
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Interestingly, Sirt-1 deletion promotes the expression of Treg-associated genes as Foxp3, CD25 
and CTLA-4, consistent with what we observed with zinc. Furthermore, the reduction of Teff 
cell-associated genes including the gene coding for IFN- was downregulated, which is in 
accordance with decreased IFN- expression mediated by zinc. 
In contrast, complete Sirt-1 deletion was shown to promote susceptibility to EAE (Zhang et al. 
2009). However, the difference in Sirt-1-deleted mice between transplantation model and EAE 
model are likely to be a result of different disease courses involving diverse T cells, mainly Th1 
cells in allografts and Th17 cells in EAE. Complete Sirt-1 inhibition, which is not likely to be 
achieved by the used zinc concentrations, thus seems to have an adverse effect on EAE 
attenuation. Indeed, application of high zinc levels (120 µg/day), which may inhibit Sirt-1 to a 
greater extent, consistently had no influence on EAE severity (Stoye et al. 2012). Therapeutic 
application of 120 µg zinc/day applied from day 11 to 19 even aggravate the clinical disease.  
Supplementation of zinc in high concentrations therefore has to be considered carefully in Th-17-
driven diseases.  
Effects of zinc on Sirt-1 action may also be explained by higher intracellular zinc levels in the 
range of 13nM due to local cellular zinc gradients following T cell activation as suggested by Yu 
et al. (Yu et al. 2011). Moreover, zinc might promote translocation of the predominantly nuclear-
located protein to the cytoplasm losing spatial proximity to the nuclear-located Foxp3 protein. 
The Sirt-1 inhibitors Sirtinol and EX-527 were shown to block translocation of Sirt-1 to the 
nucleus in endothelial cells (Kozako et al. 2012). In fact, translocation of Sirt-1 to the nucleus is 
important for cell survival (Hou et al. 2010), and EX-527-mediated modulation of Sirt-1 location 
presumably accounts for decreased PBMC viability (Fig. 20). Furthermore, a zinc-mediated 
inhibition of Sirt-1 expression is possible and would result in decreased Sirt-1 levels and hence 
Sirt-1 action. Consistently, IL-2 signaling was proposed to inhibit Sirt-1 expression in T cells 
(Gao et al. 2012). Although this was suggested to lead to a breakdown of T-cell tolerance in the 
referenced publication, it might also account for inhibited Sirt-1 expression in MLCs due to 
increased IL-2 production and IL-2 signaling by zinc. Unfortunately, until now no adequate Sirt-1 
antibody that enables the measurement of CD4
+
Foxp3
+
 Sirt-1
+
 cells by flow cytometry is 
available to investigate Sirt-1 levels specifically in Tregs.  
Regarding the similar effects of zinc and the Sirt-1 inhibitor EX-527, zinc could be a reasonable 
substitute in Sirt-1 inhibitor-treated diseases. For example, the Sirt-1 inhibitor Sirtinol induces 
apoptosis in cells of ATM (adult T cell leukemia-lymphoma) patients (Kozako et al. 2012). 
However, increasing amounts of Tregs in cancer patients aggravates their condition as tumor-
specific effector cells become inhibited. Careful consideration is therefore advisable before using 
zinc as treatment in cancer. The complex impact of zinc-induced Sirt-1 inhibition on various cell 
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types provides an interesting future research topic. Apart from being an important factor for Treg 
differentiation, Sirt-1 was demonstrated to affect several signal transduction molecules, as for 
example NFB (Salminen et al. 2008). Sirt-1 can negatively regulate the transcriptional activity 
of p65, which leads to reduced production of proinflammatory cytokines in macrophages 
(Yoshizaki et al. 2010; Zhang et al. 2010). Therefore, zinc treatment has to be considered 
cautiously in inflammatory diseases with vast macrophage involvement. The complexity of Sirt-1 
modulation is also obvious in that its biological function involves the control of gene expression, 
metabolism, and senescence (Haigis and Guarente 2006; Michan and Sinclair 2007). However, 
consistent with the presented results, Sirt-1 is highly expressed in activated T cells (Gao et al. 
2012), which also express Foxp3 and allow for its modulation by increasing zinc levels. 
It is in this context interesting that Sirt-1 was shown to inhibit PPAR- (Picard et al. 2004). In 
fact, cells in which Sirt1 had been downregulated showed higher levels of PPAR-γ mRNA and 
PPAR- protein. Although these results were observed in adipocytes, they support the proposed 
model of zinc-mediated Sirt-1 inhibition since zinc upregulated PPAR- mRNA in MLCs (Fig. 
13). Interestingly, PPAR- was proposed previously to play an important role in both 
immunoregulation (Hontecillas et al. 2011) and in Tregs (Wohlfert et al. 2007; Hamaguchi and 
Sakaguchi 2012), a finding consistent with our results. 
Collectively, the research presented in this thesis shows that zinc upregulates Tregs in Th1, Th2, 
and Th17 driven immune responses. This may prove zinc to be a substantial therapeutic agent for 
a vast number of common T cell-related disorders such as transplanted grafts, allergies, and 
autoimmune diseases. The results support earlier postulates of a beneficial effect of zinc 
supplementation and for the first time show that the inhibition of Sirt-1 is involved in zinc-
mediated Foxp3 stability. Increased Foxp3 stability induces enhanced levels of specific iTregs, 
which are capable of promoting tolerance in adverse immune reactions and consequential 
diseases. The presented findings are summarized in Fig. 37. 
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Fig. 37. A schematic overview of zinc-mediated induction of iTregs. CD4
+
 T cells activated by allergens, 
autoantigens, or alloantigens transiently express the transcription-factor Foxp3. Acetylation of Foxp3 
protein by histone-acetyltransferases alleviates transcription of Foxp3-controlled genes including cd25 and 
ctla-4 and represses expression of ifn-. Foxp3-deacetylation of K263, K31, and K268 by the histone-
deacetylase Sirt-1 allows for ubiquitination and subsequent proteosomal degradation. Zinc inhibits Sirt-1 
activity thereby augmenting Foxp3 stability and function. Sustained CTLA-4, CD25 and Foxp3 expression 
characterize iTregs and contribute to effector immune cell inhibition and modulation of Th1, Th2, and 
Th17-controlled immune responses. 
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VI. Conclusion 
The trace element zinc is essential for immune cell function as documented by impaired immune 
activity in zinc-deficient patients. But also supplementation of physiological zinc doses modulates 
immune responses. It was demonstrated before that zinc-treated MLCs are inhibited relative to 
control MLCs as indicated by decreased IFN- production. In addition, zinc was used 
successfully to ameliorate autoimmune diseases in mice. Therefore, an immunomodulatory effect 
of zinc was anticipated in this study, offering the opportunity to elaborate zinc application as a 
useful tool in controlling diseases, which involve excessive T cell activation. 
This thesis confirms the ability of zinc to modulate Th1, Th2, and Th17 driven immune 
responses. More precisely, zinc was capable of inducing immune tolerance in in vitro MLCs, of 
inhibiting in vitro allergic immune responses towards timothy grass allergen, and of attenuating 
the in vivo EAE disease, an animal model of multiple sclerosis. Furthermore, this work expands 
on known zinc effects and reveals that the induction of Tregs by zinc is responsible for the 
presented immunomodulation. In fact, zinc prolonged levels of specific CD4
+
CD25
hi
CTLA-4
+
 
iTrges derived from activated T cells thereby accumulating antigen-specific Tregs with 
immunosuppressive capacity. This zinc-mediated effect was observed in alloantigen-, allergen-, 
and autoantigen-activated T cells. The molecular mechanism underlying zinc-mediated induction 
of Tregs involves increased K31-Foxp3 acetylation, which prevents Foxp3 degradation and 
stabilizes Foxp3 activity. In accordance, deacetylation of Foxp3 by the histone deacetylase Sirt-1 
promotes ubiquitination of the vacant lysine residues leading to Foxp3 removal by the 
proteasome. One important finding of this work is that zinc inhibits Sirt-1 and thereby stabilizes 
Foxp3. The Sirt-1 inhibitor EX-527 mirrored the impact of zinc in the MLC, supporting the idea 
of zinc-mediated Sirt-1 inhibition. Experimental preincubation with zinc in the above mentioned 
scenarios reinforced the potential use of zinc as a preventive molecule. Further evidence for this 
powerful capacity is provided by the finding that orally administered zinc for 10 days enhanced 
Foxp3 expression in ex vivo generated MLCs. 
Altogether, this work illustrates that zinc may modulate adverse T cell-driven immune responses 
by upregulating Tregs and Treg-mediated immune cell alleviation. Advancing our understanding 
of how zinc modulates immune responses can help to establish zinc as a new therapeutic tool for 
the fields of transplantation, allergy, and autoimmunity. The advantage of a zinc-based therapy as 
compared to immunosuppressive strategies becomes obvious in its lack of toxicity and its ability 
to induce immune tolerance without completely abrogating antigenic immune defence. This is an 
important aspect of the immune system’s ability to fight infectious diseases, and hence a topic of 
broad interest which warrants further studies.  
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VIII. List of Abbreviations 
AAS  atomic absorption spectrophotometry 
APC antigen presenting cell 
APS  ammonium persulfate 
ATM  adult T cell leukemia-lymphoma 
BSA bovine derum albumin 
CFA  complete freuds adjuvant 
CNS central nervous system  
CPM  counts per minute 
CsA cyclosporine A 
CTL cytotoxic T cell 
CTLA-4 cytotoxic T lymphocyte antigen 4 
DSMZ deutsche Sammlung fuer Microorganismen und Zellkulturen 
ELISA enzyme-linked immunosorbent assay 
FACS fluorescence activated cell sorting 
FCS fetal calf serum 
FSC  forward side scatter 
GITR glucocorticoid-induced tumor necrosis factor receptor family related gene 
GVHD graft-versus-host disease 
HAT histone-acetyltransferase 
HCT hematopoietic stem cell transplantation 
HDAC histone deacetylase 
HLA human leukocyte antigen 
HRP horseradish peroxidas 
IBD inflammatory bowel disease 
IDDM insulin-dependent diabetes mellitus 
IDO indoleamine 2,3 dioxygenase 
IFN interferon 
IHC immunohistochemistry 
IL interleukine 
IPEX Immunodysregulation, Polyendocrinopathy, and Enteropathy, X-linked 
iTregs induced regulatory T cells 
MDRE  methylation-dependent restriction enzymes 
MFI mean fluorescence intensity 
MHC major histocompatibility complex 
MLC mixed lymphocyte culture 
MOG  myelin oligodendrocyte glycoprotein 
MS multiple sclerosis 
MSRE  methylation-sensitive restriction enzyme 
MT metallothionein 
MTF metal-responsive transcription factor  
NAD+ nicotinamide adenine dinucleotide 
NK natural killer cells 
nTregs natural regulatory T cells 
O-AADPr 2'-O-acetyl-ADP-ribose  
PAMP pathogen-associated molecular pattern 
PBGD   porphobilinogen deaminase 
PBMC peripheral blood mononuclear cells 
PCR polymerase chain reaction 
PI propidium iodide 
PMSF phenylmethylsulfonylfluorid 
PPAR- peroxisome proliferator activated receptor  
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PTEN phosphatase and tensin homolog 
PRR pattern recognition receptor 
RDA recommended daily allowance 
RORt RAR-related orphan receptor gamma 
ROS reactive oxygen species 
RmT room temperature 
SCT  stem cell transplantation 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEA Staphylococcus-Enterotoxine A 
Sirt Sirtuin 1 
SLE systemic lupus erythematodes 
SSC side scatter 
TCR T cell receptor 
Teffs effector T cells 
TEMED N,N,N’,N’-tetramethylethylenediamine 
TGF transforming growth factor 
Th T helper cell 
TMB 3,3′,5,5′-tetramethylbenzidine  
Tregs regulatory T cells 
TSDR Treg-specific demethylated region 
TSST  toxic shock syndrome toxine 
WHO World Health organisation 
Zip Zrt- and Irt-like proteins 
ZnT zinc transporter 
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Zusammenfassung 
Die Bedeutung des Spurenelements Zink für das Immunsystem wurde in den letzten Jahren 
intensiv untersucht. Neben der Wichtigkeit von Zink für eine funktionierende Immunaktivität 
wurde außerdem die Wirkung von Zinksupplementierung auf Immunreaktionen getestet. Dabei 
wurde gezeigt, dass Zink in der Lage ist, die allogene Immunreaktion zu mildern. Aufbauend auf 
diesem Ergebnis wurde im Rahmen der vorliegenden Doktorarbeit die beschriebene 
Immunmodulation durch Zink genauer erforscht und seine Wirkung auf weitere ungewollte 
Immunreaktionen untersucht.  
Es konnte bestätigt werden, dass Zink die allogene Immunreaktion vermindert. Des Weiteren 
wurde der verantwortliche Mechanismus für diesen immunmodulierenden Zink-Effekt 
erschlossen. Dabei wurde festgestellt, dass Zink in der Lage ist den Anteil der regulatorischen T 
Zellen in der allogenen Immunreaktion zu erhöhen. Da regulatorische T Zellen eine 
immunsupprimierende Wirkung ausüben, kann die Supplementierung mit Zink zu einer 
Hemmung der aktivierten T Zellen führen und insgesamt die allogene Immunaktivität 
herunterregulieren. Als mögliche Ursache für diesen Effekt wurde auf molekularer Ebene die 
Inhibierung der Histondeacetylase Sirt-1durch Zink beobachtet. Eine reduzierte Aktivität dieses 
Enzyms führt in aktivierten T Zellen zu einer erhöhten Foxp3 Stabilität, da der Abbau dieses 
Moleküls verhindert wird. Da Zink die Aktivität der Sirt-1 hemmt, liegt Foxp3 vermehrt in 
acetylierter Form vor und erhöht auf diese Weise die Stabilität dieses Transkriptionsfaktors. Ein 
Anstieg an regulatorischen T Zellen durch Zink während der allogenen Immunantwort ist das 
Ergebnis. 
Bei der allogenen Immunantwort handelt es sich um eine Th1-gesteuerte Immunantwort. Zink 
war außerdem in der Lage die Th2-spezifische allergische Immunreaktion zu modulieren. Dieses 
wurde in Immunzellen von Individuen mit Heuschnupfen gezeigt, die in vitro mit dem 
Lieschgrasallergen stimuliert wurden. Auch in diesem System war ein Anstieg an regulatorischen 
T Zellen zu verzeichnen. Des Weiteren wurde die Wirkung von Zink auf die Th17-dominierte 
Autoimmunreaktion in einem in vivo Tiermodell untersucht. Die Tiere, die täglich mit Zink 
behandelt wurden zeigten einen deutlich abgemilderteren Verlauf der Autoimmunereaktion im 
Vergleich zu den Kontrolltieren. Auch in diesem Fall war das Ergebnis auf einen erhöhten Anteil 
an induzierten regulatorischen T Zellen zu beobachten. Diese Ergebnisse bestätigen die Idee, dass 
Zink unerwünschte Immunantworten ummodulieren kann, indem es regulatorische T Zellen 
heraufreguliert. Aufgrund seiner fehlenden Toxizität, geringen Nebenwirkungen und den 
niedrigen Kosten ist die klinische Anwendung von Zink in der Transplantationsmedizin und in 
der Behandlung von Allergien und Autoimmunkrankheiten daher von großem Interesse. 
 
